



New Ray Medicine International Holding Limited
新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

Stock Code : 6108

2024
ANNUAL REPORT



CONTENTS

Corporate Information	2
Financial Summary	3
Chairman's Statement	4
Management Discussion and Analysis	6
Biographical Details of the Directors and Senior Management	24
Report of the Directors	26
Corporate Governance Report	34
Environmental, Social and Governance Report	46
Independent Auditor's Report	60
Consolidated Statement of Profit or Loss and Other Comprehensive Income	66
Consolidated Statement of Financial Position	67
Consolidated Statement of Changes in Equity	69
Consolidated Statement of Cash Flows	70
Notes to the Consolidated Financial Statements	72



CORPORATE INFORMATION

Board of Directors

Executive Directors

Ms. Wang Qiuqin (*Chairman and Chief Executive Officer*)
Mr. Huo Zhihong (resigned on 16 October 2024)
Mr. Chu Xueping
Ms. Zhou Wan

Independent Non-executive Directors

Mr. Leung Chi Kin
Ms. Li Sin Ming, Ivy
Mr. Sy Lai Yin, Sunny

Board Committees

Audit Committee

Ms. Li Sin Ming, Ivy (*Chairman*)
Mr. Leung Chi Kin
Mr. Sy Lai Yin, Sunny

Remuneration Committee

Mr. Leung Chi Kin (*Chairman*)
Ms. Li Sin Ming, Ivy
Mr. Sy Lai Yin, Sunny

Nomination Committee

Mr. Leung Chi Kin (*Chairman*)
Ms. Li Sin Ming, Ivy
Mr. Sy Lai Yin, Sunny

Corporate Governance Committee

Ms. Wang Qiuqin (*Chairman*)
Mr. Huo Zhihong (resigned on 16 October 2024)
Mr. Sy Lai Yin, Sunny
Ms. Zhou Wan (appointed on 16 October 2024)

Company Secretary

Mr. Ng Yat Sing, HKICPA

Auditor

Moore CPA Limited
Certified Public Accountants
Registered Public Interest Entity Auditor

Stock Code

6108

Registered Office

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Headquarters

B–C, 37/F
Dikai International Center
19 Dangui Road
Hangzhou, the People's Republic of China

Principal Place of Business in Hong Kong

Room 911B, 9th Floor
Tower 1, Silvercord
No. 30 Canton Road
Kowloon, Hong Kong

Principal Banker

Agricultural Bank of China

Principal Share Registrar and Transfer Office

Conyers Corporate Services (Bermuda) Limited
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Hong Kong Branch Share Registrar and Transfer Office

Tricor Investor Services Limited
17/F
Far East Finance Centre
16 Harcourt Road
Hong Kong

Website

www.newraymedicine.com

FINANCIAL SUMMARY

2024 Financial Highlights

- The Group recorded a revenue of approximately HK\$93.9 million for the year ended 31 December 2024 (2023: approximately HK\$50.2 million), representing an increase of approximately 87.1% as compared to 2023.
- The Group's gross profit was approximately HK\$11.5 million for the year ended 31 December 2024 (2023: approximately HK\$12.9 million), representing a decrease of approximately 10.9% as compared to 2023.
- Net loss attributable to owners of the Company was approximately HK\$31.0 million for the year ended 31 December 2024 (2023: loss of approximately HK\$22.2 million), representing an increase of approximately 39.6% as compared to 2023.
- The Board does not recommend the payment of a final dividend for the year ended 31 December 2024 (2023: Nil).
- The Group had a gearing ratio (defined as total bank and other borrowings divided by total equity) of zero as at 31 December 2024 (2023: zero).

	2020 HK\$'000	2021 HK\$'000	2022 HK\$'000	2023 HK\$'000	2024 HK\$'000
Operating results					
Revenue	133,214	335,380	89,771	50,154	93,945
Gross profit	16,456	34,274	13,248	12,941	11,492
Loss before tax	(69,901)	(3,608)	(80,286)	(22,342)	(32,060)
Loss for the year	(69,731)	(2,824)	(77,947)	(22,170)	(31,013)
Profitability					
Gross profit margin	12.4%	10.2%	14.8%	25.8%	12.2%
Net profit margin	N/A	N/A	N/A	N/A	N/A
Assets and liabilities					
Total assets	650,120	662,047	539,849	491,603	505,235
Equity attributable to owners of the Company	605,924	632,572	525,657	480,253	470,956
Total liabilities	44,196	29,475	14,192	11,350	34,279
Bank balances and cash	65,755	150,153	154,413	103,954	64,255
Quick ratio (times)	8.7	18.4	47.0	62.5	11.3
Current ratio (times)	10.6	24.8	51.5	68.1	12.0

CHAIRMAN'S STATEMENT

On behalf of the board (the “**Board**”) of directors (the “**Directors**”) of New Ray Medicine International Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), I am pleased to present the annual results of the Group for the year ended 31 December 2024 (the “**Year**”). The Chinese government has implemented a series of policies to reform its healthcare system, such as the volume-based procurement (帶量採購), which was officially initiated in 11 cities in the People's Republic of China (“**PRC**”) in 2018, and the expansion of the volume-based procurement nationwide since 2019. The first, second and third batches of the national volume-based procurement were successfully implemented during the years 2019 to 2020. The fourth, fifth, sixth and seventh batches were completed in February 2021, June 2021, November 2021 and July 2022, respectively. The fourth batch of the volume-based procurement involved 45 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 52% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 96% as compared to its original bidding price. The fifth batch of the volume-based procurement involved 62 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 56% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 98% as compared to its original bidding price. The sixth batch of the volume-based procurement involved 42 varieties of insulin products, and the average price of the shortlisted varieties was reduced by approximately 49% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 74% as compared to its original bidding price. The seventh batch of the volume-based procurement involved 60 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 48% as compared to the average original bidding prices. The eighth batch of the volume-based procurement (“**8th Batch**”) was completed in March 2023. The 8th Batch involved 39 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 56% as compared to the average original bidding prices. The ninth batch of the volume-based procurement (“**9th Batch**”) was completed in November 2023. The 9th Batch involved 41 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 58% as compared to the average original bidding prices.

The renewal batch of the volume-based procurement for insulin products was completed in April 2024. This renewal batch involved 6 varieties of insulin products, with the average price being 3.8% lower than that of the sixth batch of the volume-based procurement for insulin products. Moreover, the tenth batch of the volume-based procurement (“**10th Batch**”) was completed in December 2024. The 10th Batch involved 385 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced over 60% as compared to the average original bidding prices.

Facing the market challenges, the Group has been actively tightening the cooperation with suppliers and end customers (e.g. hospitals) to improve our sales and marketing capabilities and make efforts to expand its distribution network in the PRC so as to minimise the impact of unfavourable external factors on the Group.

For the Year, the total revenue of the Group was approximately HK\$93.9 million, representing an increase of approximately 87.1% as compared to the year ended 31 December 2023 (“**FY2023**”). The increase in revenue was mainly attributable to (i) the Group having launched a product of chemical reagents for pharmaceutical in the PRC in 2024, which generated a slightly lower gross profit due to the Group being in its initial phase of launching this product and (ii) partially offset by the decrease in the demand for the Group's major product under the second generation of Cephalosporins (二代頭孢產品) (1.0g) (“**Product**”) during the Year due to the continuously adverse impact from the further strengthened policy on the adoption of stratified and categorised management of antibacterial drugs in various regions in mainland China. As a result, the demand for the Product has declined during the Year.

CHAIRMAN'S STATEMENT

During the Year, the Group recorded a net loss of approximately HK\$31.0 million for the Year (2023: loss of approximately HK\$22.2 million), representing an increase of approximately 39.6% as compared to FY 2023. The increase was primarily due to (i) the impairment loss on inventories of approximately HK\$13.1 million due to the slow-moving inventories that were close to their expiry date (FY 2023: impairment loss of approximately HK\$1.6 million); and (ii) partially offset by the fair value gain on financial assets at fair value through profit or loss of approximately HK\$3.9 million provided for the Year (FY 2023: fair value gain of approximately HK\$0.4 million).

The Group remains prudently optimistic in spite of the headwind that the industry will face in the future. The aging population, urbanisation, increase in chronic diseases and household income, and wider coverage of medical insurance in the PRC will drive the demand for medical treatments and use of drugs. The Group believes that the pharmaceutical industry will be fueled with new opportunities and momentum for growth in the long term. The policies will bring challenges for many pharmaceutical enterprises, in particular the small and medium-sized ones, which will accelerate the consolidation and concentration of the market players in the industry. The Group will closely monitor the guidelines of the national policy and adapt to the market changes. The Group will endeavour to maximise return for shareholders by focusing on proprietary drugs with promising marketing and sales performance and looking for new opportunity to acquire new distribution rights, with the aforesaid the Group is poised to benefit from this development.

Meanwhile, in order to strengthen the competitive advantages of the Group over its competitors in the PRC, the Group will continue to enhance its local distribution network, sales and marketing capabilities in the future. In addition, the Group has been exploring various opportunities to enhance its distribution capabilities.

Finally, on behalf of the Board, I would like to express my sincere gratitude to our shareholders, investors, suppliers, distributor customers and business partners for their strong support to the Group. I would also like to express my heartfelt appreciation to our Directors and all staff for their diligence and contribution throughout the Year.

Wang Qiuqin

Chairman and Executive Director

Hong Kong
25 March 2025

MANAGEMENT DISCUSSION AND ANALYSIS

The Group is principally engaged in the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services in the PRC. The Group will continue to participate in the distribution of the prescription drug market in the PRC with its unremitting efforts in business development.

Business Review

During the Year, the revenue of the Group was contributed by (i) the distribution and trading of pharmaceutical and related products; and (ii) the provision of marketing and promotion services, in the PRC. The major category of pharmaceutical products distributed by the Group is injection drugs.

The table below sets out the revenue and gross profit margin of the Group (by segment) for the Year and FY 2023 respectively.

	Revenue contributed from each business segment				Gross profit margin	
	2023 HK\$'000	%	2024 HK\$'000	%	2023 %	2024 %
(1) <i>Distribution and trading of pharmaceutical and related products</i>	42,852	85.4	88,708	94.4	14.0	7.4
(2) <i>Provision of marketing and promotion services</i>	7,302	14.6	5,237	5.6	N/A	N/A
Total	50,154	100.0	93,945	100.0		

(1) Distribution and Trading of Pharmaceutical and related Products

This segment generated revenue of approximately HK\$88.7 million for the Year (FY 2023: approximately HK\$42.9 million), representing an increase of approximately 106.8% as compared to FY 2023. The increase in revenue in this segment was primarily attributable to (i) the Group having launched a product of chemical reagents for pharmaceutical in the PRC in 2024, which generated a slightly lower gross profit due to the Group being in its initial phase of launching this product and (ii) partially offset by the decrease in the demand for the Product during the Year due to the continuously adverse impact from the further strengthened policy on the adoption of stratified and categorised management of antibacterial drugs in various regions in mainland China. As a result, the demand for the Product has declined during the Year.

(2) Provision of Marketing and Promotion Services

This segment generated revenue of approximately HK\$5.2 million for the Year (FY 2023: approximately HK\$7.3 million), representing a decrease of approximately 28.8% as compared to FY 2023. Under the implementation of the “Two-Invoice” System (兩票制) in the PRC since 2017, the Group has started to develop its business of the provision of marketing and promotion services in respect of pharmaceutical products in the PRC. The Group’s marketing and promotion model involves formulating marketing and promotion strategies and conducting academic promotion programs of the Group’s products in return for service income from the suppliers. The revenue generated by this segment was decreased for the Year as compared to that for FY 2023.

MANAGEMENT DISCUSSION AND ANALYSIS

Future Prospects

(i) Industry Outlook

The PRC pharmaceutical industry is facing many challenges as a result of the release of a series of policies by the Chinese government to reform its healthcare system, such as the volume-based procurement (帶量採購), which was officially initiated in 11 cities in the PRC in 2018, and the expansion of the volume-based procurement nationwide since 2019. The first, second and third batches of the national volume-based procurement were successfully implemented during the years 2019 to 2020. The fourth, fifth, sixth, seventh, eighth and ninth batches were completed in February 2021, June 2021, November 2021, July 2022, March 2023 and November 2023, respectively. The fourth batch of the volume-based procurement involved 45 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 52% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 96% as compared to its original bidding price. The fifth batch of the volume-based procurement involved 62 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 56% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 98% as compared to its original bidding price. The sixth batch of the volume-based procurement involved 42 varieties of insulin products, and the average price of the shortlisted varieties was reduced by approximately 49% as compared to the average original bidding prices, with the biggest price reduction of one variety being approximately 74% as compared to its original bidding price. The seventh batch of the volume-based procurement involved 60 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 48% as compared to the average original bidding prices. The 8th Batch was completed in March 2023. The 8th Batch involved 39 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 56% as compared to the average original bidding prices. The 9th Batch was completed in November 2023. The 9th Batch involved 41 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced by approximately 58% as compared to the average original bidding prices.

The renewal batch of the volume-based procurement for insulin products was completed in April 2024. This renewal batch involved 6 varieties of insulin products, with the average price being 3.8% lower than that of the sixth batch of the volume-base procurement for insulin products. Moreover, the 10th Batch was completed in December 2024. The 10th Batch involved 385 varieties of pharmaceutical products, and the average price of the shortlisted varieties was reduced over 60% as compared to the average original bidding prices.

It is expected that the national volume-based procurement will continue in the future, and the scope of drugs under such procurement scheme will become wider and the downward pressure of the price of drugs is anticipated. The above-mentioned policies may put the pharmaceutical distribution and trading enterprises in the PRC, including the Group, in a challenging position and may affect the profitability of these companies in the future.

(ii) Growth Strategies

(a) *Continue to diversify the existing product portfolio*

The Group intends to seek to acquire distribution rights of new products to enhance its product portfolio. Looking ahead to 2025, the Group will continue to enhance its product portfolio, distribution channels, marketing, and promotion strategy in order to achieve a better and sustainable long-term development.

MANAGEMENT DISCUSSION AND ANALYSIS

Future Prospects *(Continued)*

(ii) Growth Strategies *(Continued)*

(b) Continue to enhance and expand the sales and marketing capabilities

In order to strengthen its competitive advantages over its competitors in the PRC, the Group will continue to enhance its local distribution network and sales and marketing capabilities. In addition, the Group has been exploring different opportunities to enhance its distribution capabilities.

(c) Focus on long term growth

As a long-term business strategy, the Group intends to focus on its core businesses of the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services in respect of pharmaceutical products in the PRC by reallocating its resources to the future development of these businesses. Besides, the Group will continue to seek potential merger and acquisition opportunities to bring higher return for its shareholders.

Environmental Policies and Performance

The Group recognises the importance of environmental protection. The Group has introduced various steps and procedures to ensure all resources are efficiently utilised. The Group has well-established practices in reducing electricity consumption, recycling ink cartridges and toner cartridges. In addition, it encourages its employees to participate in environmental protection activities which benefit the community as a whole. Further discussions on the Group's environmental policies and performance are set out in the Environmental, Social and Governance ("**ESG**") report in this report.

Relationships with Stakeholders

The Group maintains good partnership with its employees, has close cooperation with its suppliers and provides reliable products and services to its customers so as to operate in a sustainable manner.

The Group cooperates with suppliers and customers in order to improve its effectiveness and efficiency in the supply chain and to reduce the relevant costs by capitalising on the distributors' functions including formulating marketing and promotion strategies tailored for local markets; speeding up product delivery and payment collection process; improving efficiencies of customers by allowing them to keep fewer inventories on hand and ensuring timely replenishment of inventories.

The Group's employees have accumulated extensive experience in the PRC pharmaceutical industry. The Group believes that with their industry expertise and strong execution capability, the employees will be able to successfully implement the Group's strategies in the growing pharmaceutical distribution industry in the PRC.

Compliance with Applicable Laws and Regulations which have a Significant Impact on the Group

The pharmaceutical industry in the PRC is highly regulated by the PRC government. The Law on the Administration of Pharmaceuticals of the PRC (《中華人民共和國藥品管理法》) provides the basic legal framework in respect of the administration of pharmaceutical products in the PRC and covers a number of aspects such as manufacturing, distributing, packaging, pricing and advertising with respect to pharmaceutical products. The regulations made under the Law on the Administration of Pharmaceuticals contain the detailed rules for the administration of pharmaceuticals in the PRC.

The Group is a reputable drug distributor in Zhejiang province, the PRC. In the PRC, a drug distributor must obtain various permits and licences, including the Business Licence, the Pharmaceutical Operation Permit, the Good Supply Practice Certificate before it starts business in relation to the distribution of pharmaceutical products.

MANAGEMENT DISCUSSION AND ANALYSIS

Compliance with Applicable Laws and Regulations which have a Significant Impact on the Group *(Continued)*

Pharmaceutical Operation Permit and Business Licence

An approval must be obtained from the China Food and Drug Administration of the PRC (中華人民共和國國家食品藥品監督管理總局) (“**CFDA**”) at the provincial level before a company starts its business in relation to wholesale of pharmaceutical products. After the approval has been obtained, the relevant department will issue a Pharmaceutical Operation Permit. According to the Measures on the Administration of the Pharmaceutical Operation Permit (《藥品經營許可證管理辦法》), a Pharmaceutical Operation Permit is valid for 5 years. The enterprise which holds such permit should apply to the original issuing authority for a new Pharmaceutical Operation Permit 6 months prior to the expiry for the extension of its permit. In addition, before commencing a business, a wholesale or retail pharmaceutical distribution company must also obtain a Business Licence from the relevant Municipal Administration for Market Regulation.

In this connection, the Group has obtained the Pharmaceutical Operation Permit granted by Zhejiang Food and Drug Administration (浙江食品藥品監督管理局) (“**ZFDA**”), which is the competent drug administrative authority of Zhejiang province, the province in the PRC where the Group registers for its pharmaceutical distribution operation. The Group has also obtained the Business Licence granted by and registered with the relevant Municipal Administration for Market Regulation in accordance with applicable PRC laws and regulations. The Pharmaceutical Operation Permit is valid till 8 August 2029.

During the Year, no material breach of laws and regulations that have a significant impact on the Group’s business and operations was noted by the Group.

Principal Risks and Uncertainties

There are certain principal risks and uncertainties related to the business of the Group in the PRC pharmaceutical industry. The principal risks and uncertainties are:

- the reliance on the Group’s suppliers and distributor customers – the Group’s business relies on the pharmaceutical products provided by its suppliers which are in turn distributed through the distributor customers of the Group to ultimate customers such as hospitals and medical institutions in the PRC. However, the Group does not have long-term commitments with these suppliers and distributor customers. In order to minimise the risk, the Group will continue to diversify the existing product portfolio and expand the distribution networks; and
- the government policies of the pharmaceutical industry in the PRC – the pharmaceutical industry in the PRC is highly regulated, a substantial amount of the pharmaceutical products distributed by the Group are subject to the government price controls or other price controls in the PRC. To mitigate the impact of the government policies on the pharmaceutical industry in the PRC, the Group will continue to diversify the portfolio of products distributed by it.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review

Revenue

The total revenue for the Year was approximately HK\$93.9 million, representing an increase of approximately 87.1% from approximately HK\$50.2 million for FY 2023. The increase in revenue was primarily attributable to (i) the Group having launched a product of chemical reagents for pharmaceutical in the PRC in 2024, which generated a slightly lower gross profit due to the Group being in its initial phase of launching this product and (ii) partially offset by the decrease in the demand for the Product during the Year due to the continuously adverse impact from the further strengthened policy on the adoption of stratified and categorised management of antibacterial drugs in various regions in mainland China. As a result, the demand for the Product has declined during the Year.

Cost of Sales

The cost of sales for the Year was approximately HK\$82.5 million, representing an increase of approximately 121.8% from approximately HK\$37.2 million for FY 2023. The increase in cost of sales was in line with the increase in sales volume of the chemical reagents product for pharmaceutical during the Year.

Gross Profit and Gross Profit Margin

Gross profit decreased by approximately HK\$1.4 million, or approximately 10.9%, from approximately HK\$12.9 million for FY 2023 to approximately HK\$11.5 million for the Year. The decrease in gross profit of the Group for the Year was mainly attributable to (i) the Group having launched a product of chemical reagents for pharmaceutical in the PRC in 2024, which generated a slightly lower gross profit due to the Group being in its initial phase of launching this product and (ii) the decrease in sales volume of the Product when compared to FY 2023. The Group's gross profit margin for the Year was approximately 12.2%, which has decreased by 13.6 percentage points when compared to that for FY 2023.

Other Income, Gains and Losses, Net

The net other gain for the Year were approximately HK\$2.1 million (2023: loss of approximately HK\$1.3 million). Such change was primarily attributable to the absence of the impairment loss on intangible asset (2023: impairment loss of approximately HK\$2.8 million) and the impairment loss on prepayments for a distribution right during the Year (2023: approximately HK\$1.0 million).

Selling and Distribution Expenses

Selling and distribution expenses for the Year were approximately HK\$15.9 million, representing an increase of 12.8% from approximately HK\$14.1 million for FY 2023. The increase in selling and distribution expenses was primarily attributable to the increase in the marketing service fee and delivery expenses in line with the increase in distribution and trading of pharmaceutical and related products.

Administrative Expenses

Administrative expenses for the Year were approximately HK\$14.7 million, representing a slight increase of approximately 0.7% from approximately HK\$14.6 million for FY 2023. The administrative expenses was relatively stable for the Year as compared to that for FY 2023.

Impairment Loss on Trade and Other Receivables

The Group has provided for impairment loss on trade and other receivables of approximately HK\$5.7 million (2023: impairment loss of HK\$4.1 million) during the Year based on the provision matrix.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Impairment Loss on Inventories

The Group has provided for impairment loss on inventories of approximately HK\$13.1 million (2023: approximately HK\$1.6 million) in respect of the slow-moving inventories which were close to their expiry date.

Impairment Loss on Intangible Asset and Prepayment for a Distribution Right

The Group has not provided for impairment losses on intangible asset and prepayment for a distribution right during the Year. For FY 2023, the Group has provided for impairment losses on intangible asset and prepayment for a distribution right of approximately HK\$2.8 million and HK\$1.0 million respectively in respect of the decrease of the value based on the management's assessment.

Income Tax Credit

Income tax credit for the Year was approximately HK\$1.0 million (2023: approximately HK\$0.2 million). The increase in income tax credit was primarily due to the decrease in deferred tax for tax purposes.

Loss for the Year

Loss for the Year was approximately HK\$31.0 million, representing an increase of approximately 39.6% from approximately HK\$22.2 million for FY 2023.

The Group recorded an increase in net loss for the Year of approximately 39.6% as compared to FY 2023 primarily due to (i) the impairment loss on inventories of approximately HK\$13.1 million due to the slow-moving inventories that were close to their expiry date (FY 2023: impairment loss of approximately HK\$1.6 million); and (ii) partially offset by the fair value gain on financial assets at fair value through profit or loss of approximately HK\$3.9 million provided for the Year (FY 2023: fair value gain of approximately HK\$0.4 million).

Equity Instruments at Fair Value through Other Comprehensive income

The Group's equity instruments at fair value through other comprehensive income ("FVTOCI") comprise (i) equity instruments at FVTOCI listed in Hong Kong which have been determined based on the quoted market prices available on The Stock Exchange of Hong Kong Limited ("**Stock Exchange**") and (ii) equity instruments at FVTOCI for unlisted investments in companies incorporated in Hong Kong with limited liability and stated at fair value based on valuations prepared by independent valuers.

(i) Equity instruments at FVTOCI listed in Hong Kong

Town Health International Medical Group Limited

As at 31 December 2024, the Group's securities investment in the shares ("**TH Shares**") of Town Health International Medical Group Limited ("**Town Health**") (a company whose shares being listed on the Main Board of the Stock Exchange with stock code: 3886) had a fair value of approximately HK\$28.8 million and an investment amount of approximately HK\$142.0 million. As at 31 December 2024, the fair value of the Group's investment in Town Health accounted for approximately 5.7% of the Group's total assets. The Group recognised a fair value loss of approximately HK\$9.4 million on its investment in the TH Shares for the Year. The Group received dividend income from Town Health of approximately HK\$141,000 for the Year (2023: approximately HK\$141,000). During the Year, the Group did not dispose of any of its holding in TH Shares.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Equity Instruments at Fair Value through Other Comprehensive income *(Continued)*

(i) **Equity instruments at FVTOCI listed in Hong Kong** *(Continued)*

Town Health International Medical Group Limited (Continued)

As at 31 December 2024 and the date of this report, the Group held 117,602,000 TH Shares, representing approximately 1.74% of the total issued share capital of Town Health. Town Health and its subsidiaries are principally engaged in the provision of medical and dental services in Hong Kong, managing healthcare networks and the provision of third party medical network administrator services in Hong Kong, the provision of medical and dental services in the PRC, the provision of hospital management services and related services, and leasing properties. According to the announcement of interim results of Town Health for the six months ended 30 June 2024, in 1989, Town Health established its first medical centre in Sha Tin to serve residents in the community. In 2024, Town Health reached an important milestone of its 35th anniversary. At the important milestone, Town Health has adopted a new logo that better highlights the core values and corporate commitment, demonstrating Town Health's original intention and enthusiasm to provide quality healthcare services. The new logo is based on the design concept of caring and sense of responsibility. It presents a simple "house" shape. The house is constructed from the initial "T" and "h" of the English name "Town Health", and "T" and "h" also form the Chinese character "仁 (benevolence)", implying doctors' benevolence and excellent medical skills. The new corporate colours, i.e. blue and lake green, are fresh and calm, and inject vitality into Town Health's corporate image. Town Health has expanded from a community medical centre to the present industry leader with its business extending into multiple areas of healthcare, which is all due to the trust and support of every shareholder, customer and business partner. With a new image, Town Health will provide high-quality healthcare services from primary care to high-end cross-specialty services, to meet a full range of needs of customers from prevention, outpatient, diagnosis and surgery to rehabilitation and nursing. Looking ahead, Town Health will continue to support the government's primary healthcare development strategy and proactively participate in government-funded and public-private partnership programmes for primary healthcare. Meanwhile, Town Health seeks to integrate the healthcare resources of various business segments in Hong Kong and the Mainland China to establish a full-cycle, integrated and one-stop healthcare service ecosystem in the Guangdong-Hong Kong-Macao Greater Bay Area.

Jiangxi Rimag Group Co., Ltd.

As at 31 December 2024, the Group's securities investment listed in Hong Kong (other than the TH Shares) had a fair value of approximately HK\$60.6 million. During the Year, the Group acquired shares of Jiangxi Rimag Group Co., Ltd. ("**Jiangxi Rimag Group**") (a company whose shares are listed on the Main Board of the Stock Exchange with stock code: 2522) as a cornerstone investor. These shares are classified as equity securities listed in Hong Kong and were acquired at a cost of approximately HK\$12.0 million as disclosed in the sub-section headed "Material Acquisitions or Disposals and Significant Investments" in the section headed "Management Discussion and Analysis" in this report. Jiangxi Rimag Group and its subsidiaries are principally engaged in providing medical imaging services, imaging solution services and Rimag Cloud services in the PRC. As at 31 December 2024, the Group held 801,000 shares of Jiangxi Rimag Group, representing approximately 0.32% of the total issued share capital of Jiangxi Rimag Group with a fair value of approximately HK\$56.9 million. As at 31 December 2024, the fair value of the Group's investment in Jiangxi Rimag Group accounted for approximately 11.3% of the Group's total assets. The Group recognised a fair value gain of approximately HK\$44.9 million on its investment in Jiangxi Rimag Group for the Year. This fair value gain was recognised in other comprehensive income or loss for the Year as part of the Group's investment in Jiangxi Rimag Group. No dividend income was received from Jiangxi Rimag Group during the Year, and the Group did not dispose of any of its holdings in Jiangxi Rimag Group.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Equity Instruments at Fair Value through Other Comprehensive Income *(Continued)*

(i) **Equity instruments at FVTOCI listed in Hong Kong** *(Continued)*

Jiangxi Rimag Group Co., Ltd. (Continued)

According to the announcement of annual results of Jiangxi Rimag Group for the year ended 31 December 2024, Jiangxi Rimag Group's goal is to become a leading medical group in China and worldwide that focuses on developing medical imaging capabilities. Jiangxi Rimag Group aims to establish a medical imaging solution service platform with industrial ecological organizational capabilities, which can effectively integrate value chain resources across the industry, empower the medical imaging industry, and continuously consolidate Jiangxi Rimag Group's leading position in the industry. To achieve this goal, Jiangxi Rimag Group plans to implement the following strategies: (1) Jiangxi Rimag Group will further expand its medical imaging center network and enrich the offerings of its imaging solution services to strengthen Jiangxi Rimag Group's industry-leading position. Jiangxi Rimag Group actively takes diversified measures to promote cooperation and exploration with high-quality medical institutions with social capital, expand the layout and implementation of imaging centers through various means such as mergers and acquisitions, industrial fund incubation, etc., so as to realize the continuous expansion and layout of the medical imaging center network and consolidate Jiangxi Rimag Group's leading position in the industry; (2) Jiangxi Rimag Group will strengthen ecological collaboration with upstream and downstream industries and deeply integrate industry chain resources for the building of an open and collaborative medical imaging industry ecosystem. Jiangxi Rimag Group plans to deepen ecological collaboration with upstream and downstream companies in the medical imaging industry (including equipment providers and equipment maintenance companies, medical imaging AI service providers, medical supply chain service providers, industry associations, etc.) and carry out strategic ecological incubation, in order to deeply integrate industry value chain resources and build an open and collaborative medical imaging industry ecosystem. It is expected that the above efforts will further help us enhance Jiangxi Rimag Group's professional capabilities and operational efficiency and consolidate Jiangxi Rimag Group's position in the industry; (3) Jiangxi Rimag Group will strengthen its operational management capabilities, cultivate and attract highly skilled medical imaging and management talents, and continuously improve Jiangxi Rimag Group's professional level and brand capabilities. Jiangxi Rimag Group targets to continuously enhance its operation and management strength, and through the improvement of professional standards, operational management mechanisms and talent training systems to achieve the enhancement of "imaging services capacity" in the whole imaging process of "radiologists, radiologic technologists, managers and clinicians"; (4) Jiangxi Rimag Group will deeply explore the value of image data and its AI applications, create an innovative ecosystem of "data + service model", and provide comprehensive regional smart imaging solutions. The deep integration of AI and big data technologies has accelerated the emergence of a more efficient and fairer smart medical ecosystem. Jiangxi Rimag Group plans to continue exploring the deep integration of data and medical services, deepen Rimag's strategic layout in the AI medical field and enhance Rimag's ability to deliver comprehensive regional smart imaging solutions. Jiangxi Rimag Group plans to continue to build the smart healthcare ecosystem by strengthening Jiangxi Rimag Group's own capabilities or cooperating with third parties, and continuously expand Jiangxi Rimag Group's service capabilities and scope; and (5) Jiangxi Rimag Group will continue to improve the internal control system and strengthen the risk management and corporate governance system. As Jiangxi Rimag Group attaches great importance to the construction of internal control system, Jiangxi Rimag Group continues to establish a scientific, standardized and effective governance structure, and continuously improve risk management mechanisms and risk response strategies.

The Group did not dispose of any equity securities listed in Hong Kong during the Year. Due to an increase in the fair value of certain listed securities investments, a fair value gain (partially offset by the fair value loss on the TH Shares) of approximately HK\$34.3 million was recognised under the FVTOCI (non-recycling reserve) during the Year. The Group will continue to monitor its investments cautiously in view of recent uncertain market conditions.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Equity Instruments at Fair Value through Other Comprehensive income *(Continued)*

(ii) **Equity instruments at FVTOCI for unlisted investments**

China Nvwa Pharmaceutical Group Limited

During the Year, the Group acquired 16% of the issued share capital of China Nvwa Pharmaceutical Group Limited ("**Target Company**"). These shares are classified as equity instruments at FVTOCI for unlisted investments and were acquired at a cost of approximately HK\$17.3 million as disclosed in the sub-section headed "Material Acquisitions or Disposals and Significant Investments" in the section headed "Management Discussion and Analysis" in this report. The Target Company and its subsidiaries are principally engaged in the manufacture, sales and distribution of pharmaceutical products in the PRC. As at 31 December 2024 and the date of this report, the Group held 16 shares of Target Company, representing approximately 16% of the total issued share capital of the Target Company with a fair value of approximately HK\$12.9 million. As at 31 December 2024, the fair value of the Group's investment in the Target Company accounted for approximately 2.6% of the Group's total assets. The Group recognised a fair value loss of approximately HK\$4.4 million on its investment in the Target Company for the Year. This fair value loss was recognised in other comprehensive income or loss for the Year as part of the Group's investment in the Target Company. No dividend income was received from the Target Company during the Year, and the Group did not dispose of any of its holdings in the Target Company.

Financial Asset At FVTPL

The Group's financial assets at FVTPL include investment in 嵊州新銳萬馬實業有限公司 (in English, for identification purpose only, Shengzhou Xin Rui Wan Ma Enterprises Co., Ltd.) ("**Shengzhou Xin Rui Wan Ma**") and investment in 嵊州新銳萬霖企業管理有限公司 (in English, for identification purpose only, Shengzhou Xinrui Wanlin Enterprise Management Co., Ltd.) ("**Shengzhou Xinrui Wanlin**"). The costs of these investments are HK\$36.2 million and HK\$14.3 million, respectively.

As at 31 December 2024 and the date of this report, the Group held approximately 39% equity interest in Shengzhou Xin Rui Wan Ma with a fair value of approximately HK\$29.9 million. As at 31 December 2024, the fair value of the Group's investment in Shengzhou Xin Rui Wan Ma accounted for approximately 5.9% of the Group's total assets. During the Year, Shengzhou Xin Rui Wan Ma repaid shareholder loans to its shareholders as repayment of by way of capital distribution, and the Group received the shareholder loan repayment as capital distribution refund of approximately HK\$10.7 million. The Group recognised a fair value gain of approximately HK\$4.0 million on its investment in the Shengzhou Xin Rui Wan Ma for the Year. This fair value gain or loss was recognised in profit or loss for the Year as part of the Group's investment in Shengzhou Xin Rui Wan Ma. No dividend income was received from Shengzhou Xin Rui Wan Ma during the Year, and the Group did not dispose of any of its holdings in Shengzhou Xin Rui Wan Ma.

The purpose of Shengzhou Xin Rui Wan Ma is to engage in a project which involves the investment and construction of a healthcare industrial park in Shengzhou, Zhejiang Province, the PRC ("**Project**"). The Project includes the acquisition of the land use right of a project land by public tender and the construction, development and operation of the related facilities and buildings thereon. During the Year, Shengzhou Xin Rui Wan Ma was constructing and developing a healthcare industrial park in Shengzhou, Zhejiang Province, PRC.

As at 31 December 2024, in Phase 1, the construction area covers 58,297.28 square meters and includes 16 buildings with a total of 28 units. Meanwhile, in Phase 2, the construction area covers 68,275.12 square meters, consisting of 13 buildings with a total of 32 units. All units in Phase 1 had been sold. For Phase 2, Shengzhou Xin Rui Wan Ma has contracted to sell 17 units, with a total contract sum of RMB 116 million. Shengzhou Xin Rui Wan Ma has received RMB 34 million, representing 29% of the total, as deposits for the sales of units.

The Group considered that the investment of Shengzhou Xin Rui Wan Ma undertaking the Project presents a good opportunity for the Group to utilise its available funds for a return and to expand investment portfolio with quality assets and to broaden the Group's strategic cooperation opportunities with other stakeholders in the PRC healthcare industry.

Please refer to the announcements of the Company dated 11 July 2022, 26 July 2022 and 16 January 2023 for further details of the cooperation agreement and the supplemental cooperation agreement in relation to Shengzhou Xin Rui Wan Ma.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Financial Asset At FVTPL *(Continued)*

During the Year, the Group has an investment in Shengzhou Xinrui Wanlin of approximately RMB13.26 million as disclosed in the sub-section headed “Material Acquisitions or Disposals and Significant Investments” in the section headed “Management Discussion and Analysis” in this report. As at 31 December 2024, the fair value of the Group’s investment in Shengzhou Xinrui Wanlin was approximately HK\$14.3 million, accounting for approximately 2.8% of the Group’s total assets. The Group recognised a fair value loss of approximately HK\$0.1 million on its investment in Shengzhou Xinrui Wanlin for the Year. No dividend income was received from Shengzhou Xinrui Wanlin during the Year, and the Group did not dispose of any of its holdings in Shengzhou Xinrui Wanlin.

The Group will continue to monitor its investments cautiously in view of recent uncertain market conditions.

Liquidity, Financial Resources and Capital Structure

The capital structure of the Group consists of cash and cash equivalents and equity attributable to owners of the Company, comprising share capital, various reserves and retained profits.

During the Year, the long-term funding and working capital required by the Group were primarily derived from the income generated from its core business operations. The Group’s liquidity position was well-managed in the Year.

The Group’s cash and cash equivalents amounted to approximately HK\$64.3 million in total as at 31 December 2024 (2023: approximately HK\$104.0 million), among which approximately 13.6% (2023: approximately 6.3%) were denominated in Hong Kong dollars, approximately 86.4% (2023: approximately 93.7%) were denominated in Renminbi. The Group did not have any bank loan nor any other borrowing as at 31 December 2024 (31 December 2023: nil).

The Group’s gearing ratio (defined as total bank and other borrowings divided by total equity) was zero as at 31 December 2024 (2023: zero).

The Group’s financial resources are sufficient to support its business operations. The Group will also consider other financing activities when appropriate business opportunities arise under favourable market conditions.

Foreign Currency Risk

The Group carries out its business in the PRC and most of the transactions are denominated in Renminbi. However, the Group has foreign currency bank balances in Hong Kong dollars which expose the Group to foreign currency risk. To mitigate the foreign currency risk, the Group continuously assesses and monitors the exposure of the exchange rate fluctuations. During the Year, the Directors did not consider it necessary to adopt a foreign currency hedging policy as the potential impact on the profit or loss of the Group due to the exchange rate fluctuations was immaterial.

Employee Information

As at 31 December 2024, the Group had 29 employees (2023: 23) with staff costs for the Year including Directors’ emolument, amounting to approximately HK\$8.7 million (2023: approximately HK\$8.1 million). The Group’s remuneration policy is based on the positions, duties and performance of the employees. The employees’ remunerations vary according to their positions, which include salaries, overtime allowances, bonuses and/or various subsidies. The Group offers comprehensive and competitive remuneration and benefits packages to all its employees. In addition, the Group has adopted a share option scheme for the purpose of providing incentives and rewards to eligible persons who contribute to the success of the Group’s operations.

The Group also provides other employee benefits including a provident fund scheme for its employees in Hong Kong as required under the Mandatory Provident Fund Schemes Ordinance (Chapter 485, the Laws of Hong Kong), and participates in employee pension schemes organised and governed by the relevant local governments for its employees in the PRC.

Contingent Liabilities

As at 31 December 2024, the Group did not have any significant contingent liabilities.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Material Acquisitions or Disposals and Significant Investments

Acquisition of 16% of the issued share capital of China Nvwa Pharmaceutical Group Limited ("Target Company")

On 16 May 2024, Major Bright Holdings Limited ("**Major Bright**"), an indirect wholly-owned subsidiary of the Company, as the purchaser, and Mr. U Man long ("**Vendor**"), a third party independent of the Company and its connected persons, as the vendor, entered into the sale and purchase agreement in relation to the acquisition of 16 ordinary shares ("**Sale Shares**") of the Target Company at the consideration of HK\$17,280,000. The Sale Shares represent 16% of the issued share capital of the Target Company. The Target Company and its subsidiaries (collectively, the "**Target Group**") are principally engaged in the manufacture, sales and distribution of pharmaceutical products in the PRC.

Immediately after completion of the acquisition, the Group holds 16% equity interest in the Target Company. The Directors consider that the Group does not have control nor significant influence over the Target Company since the Group does not have the right to appoint any director of the board of the Target Company. The Directors have elected to designate this investment in equity instrument at fair value through other comprehensive income as they believe that this investment is held for long-term purpose and realising the performance potential in the long-run.

The acquisition was approved by the shareholders of the Company at a special general meeting held on 16 July 2024. All the conditions precedent set out in the sale and purchase agreement were fulfilled and completion of the acquisition took place on 31 July 2024.

Details of the acquisition are disclosed in the Company's announcements dated 16 May 2024 and 16 July 2024, and the Company's circular dated 21 June 2024.

Cooperation agreement and increase in capital contribution of Shengzhou Xinrui Wanlin

On 24 May 2024, 浙江新銳生物藥業有限公司 (in English, for identification purpose only, Zhejiang Xinrui Biopharmaceutical Co., Ltd.) ("**Zhejiang Xinrui Biopharmaceutical**"), an indirect wholly-owned subsidiary of the Company, 浙江萬馬產業發展集團有限公司 (in English, for identification purpose only, Zhejiang Wanma Industrial Development Group Co., Ltd.) ("**Partner A**") and 杭州觀聖管理諮詢有限公司 (in English, for identification purpose only, Hangzhou Guansheng Management Consulting Co., Ltd.) ("**Partner B**") entered into the cooperation agreement ("**Cooperation Agreement**") in respect of, among others, the increase in capital contribution and operation and management of the affairs of Shengzhou Xinrui Wanlin.

Shengzhou Xinrui Wanlin was established in the PRC with limited liability on 18 March 2024 with an initial registered capital of RMB1.00 million and owned as to 40%, 39% and 21% by Partner A, Zhejiang Xinrui Biopharmaceutical and Partner B respectively. Pursuant to the Cooperation Agreement, the registered capital of Shengzhou Xinrui Wanlin would be increased to RMB34.00 million, and Partner A, Zhejiang Xinrui Biopharmaceutical and Partner B should make further capital contribution to Shengzhou Xinrui Wanlin in proportion to their respective shareholding. In this connection, Zhejiang Xinrui Biopharmaceutical would contribute an additional capital contribution of RMB12.87 million, and the total capital contribution to be made by Zhejiang Xinrui Biopharmaceutical would be RMB13.26 million. Partner A would contribute an additional capital contribution of RMB13.20 million, and the total capital contribution to be made by Partner A would be RMB13.60 million. Partner B would contribute an additional capital contribution of RMB6.93 million, and the total capital contribution to be made by Partner B would be RMB7.14 million. After such additional capital contribution, the shareholding of Partner A, Zhejiang Xinrui Biopharmaceutical and Partner B in Shengzhou Xinrui Wanlin would remain the same.

Shengzhou Xinrui Wanlin would engage in the project which involves the development of a healthy food industrial park ("**Industrial Park**") in Shengzhou, Zhejiang Province, the PRC. The project includes the acquisition of the land use right of a parcel of land located in Shengzhou, Zhejiang Province, the PRC with site area of approximately 26,028 m² ("**Project Land**") by public tender and the development and operation of the related facilities and buildings thereon.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Material Acquisitions or Disposals and Significant Investments *(Continued)*

Cooperation agreement and increase in capital contribution of Shengzhou Xinrui Wanlin *(Continued)*

The Industrial Park is targeted at enterprises in the healthy food industry and designed to be a multifunctional site integrating production, offices and living facilities for enterprises and their employees.

The Industrial Park is expected to participate in various aspects of the industrial chain by bringing together composite functions such as production, logistics, research and development, offices, research bases, training, business and leisure, catering and entertainment, inspection and quality control, and procurement and trade, forming a sustainable business district in Shengzhou, Zhejiang Province, the PRC.

Shengzhou Xinrui Wanlin would operate and manage the Industrial Park, and is expected to commence soliciting potential customers in 2025 for the sale and lease of the facilities and buildings in the Industrial Park. The facilities and buildings will be held by the Target Company for sale, investment (through renting out) and/or self-use, depending on the market demand for such facilities and buildings upon completion of the development. On 9 July 2024, the process of the abovementioned public tender was completed. Shengzhou Xinrui Wanlin was the successful bidder of the Project Land and the final bid price was RMB14.7 million.

The Group's investment in Shengzhou Xinrui Wanlin would be recognised as a financial asset at fair value through profit or loss of the Company.

Please refer to the announcements of the Company dated 24 May 2024 and 9 July 2024 for further details of the Cooperation Agreement.

Cornerstone investment in Jiangxi Rimag Group

On 28 May 2024, China New Rich Medicine Holding Co. Limited ("**China New Rich**") (a wholly-owned subsidiary of the Company), as investor, entered into a cornerstone investment agreement ("**Cornerstone Investment Agreement**") with Jiangxi Rimag Group, CITIC Securities (Hong Kong) Limited and CLSA Limited, pursuant to which China New Rich had agreed to subscribe for the overseas listed foreign shares in the share capital of Jiangxi Rimag Group with nominal value of RMB1.00 each ("**Jiangxi Rimag H Shares**") at the offer price of the Jiangxi Rimag H Shares to be subscribed for and traded in HK\$ and were to be listed on the Stock Exchange pursuant to the global offering of the Jiangxi Rimag H Shares, up to a maximum of HK\$12,000,000 (excluding the applicable brokerage and levies which China New Rich would pay in respect of such shares).

China New Rich, as a cornerstone investor, was allotted and issued with 801,000 Jiangxi Rimag H shares upon listing of Jiangxi Rimag. All such Jiangxi Rimag H Shares are subject to a lock-up period ending on 6 June 2025.

Please refer to the announcement of the Company dated 30 May 2024 for further details of the cornerstone investment in Jiangxi Rimag Group.

Save as disclosed above, the Group did not make any significant investments and material acquisitions or disposals during the Year and up to the date of this report.

Capital Structure

The capital of the Company comprises ordinary shares. As at 31 December 2024, the Group had shareholders' equity of approximately HK\$471.0 million (2023: approximately HK\$480.3 million).

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Rights Issue

On 9 December 2016, the Company announced to raise approximately HK\$343.6 million before expenses on the basis of three rights shares ("**Rights Shares**") for every one existing share in issue held on the record date at the subscription price of HK\$0.275 per Rights Share by way of the rights issue of 1,249,344,000 ordinary shares ("**Rights Issue**"). The subscription price of HK\$0.275 per Rights Share represented a discount of 31.25% to the closing price of HK\$0.400 per share of the Company on 9 December 2016, being the date of the underwriting agreement. The Directors considered that the Rights Issue would provide funding to the Group for financing investments which would diversify the Group's investment portfolio and bring new income source to the Group or foster a closer business relationship between the Group and the invested entities so as to enable the two groups complement each other with a view to bringing more benefits to each other. The Rights Issue was approved by the independent shareholders of the Company at the special general meeting of the Company held on 26 January 2017.

The completion of the Rights Issue took place on 6 March 2017. A total of 1,249,344,000 ordinary shares of the Company were allotted and issued pursuant to the Rights Issue and the net proceeds after deduction of expenses from the Rights Issue were approximately HK\$330.0 million. On this basis, the net issue price per Rights Share was approximately HK\$0.264 and the aggregate nominal value of the Rights Shares was HK\$62,467,200. Details of the Rights Issue are set out in the Company's announcements dated 9 December 2016, 26 January 2017, 27 January 2017 and 3 March 2017, the circular of the Company dated 10 January 2017 and the prospectus of the Company dated 10 February 2017.

The actual use of the net proceeds from the Rights Issue as at 31 December 2024 was as follows:

Intended use of proceeds

Actual use of proceeds as at 31 December 2024

Net proceeds from the Rights Issue of approximately HK\$330.0 million were intended to be used in the following manner:

- (1) approximately HK\$143.2 million for the possible acquisition of interest in HCMPS and/or other potential acquisitions of medical and healthcare related business when opportunities arise (Notes a & b)

approximately HK\$25.5 million has been utilised for the acquisition of 5% of the issued share capital of HCMPS at a consideration of HK\$25.5 million in cash

approximately HK\$117.7 million has been utilised for the partial settlement of the consideration for the acquisition of approximately 1.55% of the then total issued share capital of Town Health, the issued shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 3886) at a total consideration of HK\$144 million (excluding stamp duty and related expenses) in the open market in April 2017

- (2) approximately HK\$28.8 million for the acquisition of 11% of the issued share capital of China Biotech Services Holdings Limited ("**China Biotech**") (Note b)

approximately HK\$28.8 million has been utilised for the partial settlement of the consideration for the acquisition of approximately 11% of the issued share capital of China Biotech, the issued shares of which are listed on GEM of the Stock Exchange (Stock Code: 8037) at a total consideration of approximately HK\$33.4 million in cash

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Rights Issue *(Continued)*

Intended use of proceeds	Actual use of proceeds as at 31 December 2024
(3) approximately HK\$43.0 million for the acquisition of 12% of the issued share capital of WinHealth International	approximately HK\$53.4 million (of which HK\$10.4 million was from the Relevant Proceeds (as defined below)) has been utilised for the acquisition of 15% of the issued share capital of WinHealth International at a consideration of RMB47.25 million (equivalent to approximately HK\$53.4 million) in cash
(4) approximately HK\$17.0 million for the repayment of the Group's bank borrowings in the PRC	approximately HK\$17.0 million has been utilised for the repayment of the bank borrowing of a subsidiary of the Company in the PRC
(5) approximately HK\$40.0 million for expanding the product range of imported prescription drugs	approximately HK\$40.0 million has been utilised for the payment of the distribution right of an imported prescription tablet drug in the PRC
(6) approximately HK\$8.0 million for improving marketing, sales and promotional capabilities	approximately HK\$8.0 million has been utilised for improving marketing, sales and promotional capabilities
(7) approximately HK\$50.0 million for the acquisition of the equity interests (in part or in full) of pharmaceutical companies which are principally engaged in overseas pharmaceutical business in the PRC apart from the acquisition of 12% of the issued share capital of WinHealth International (" Relevant Proceeds ") (Note c)	approximately HK\$10.4 million has been utilised for the partial settlement of the consideration for the acquisition of 15% of the issued share capital of WinHealth International as described above

As at 31 December 2023, the total unutilised proceeds from the Rights Issue were approximately HK\$39.6 million. During the Year, the Company (i) has used approximately HK\$17.3 million of the unutilised proceeds for funding the consideration for the acquisition of 16% of the issued share capital of China Nvwa Pharmaceutical Group Limited (中國女媧醫藥集團股份有限公司) (as disclosed in "Material Acquisitions or Disposals and Significant Investments" in this report), being a group of companies which are principally engaged in domestic pharmaceutical business in the PRC; and (ii) plans to use the remaining approximately HK\$22.3 million of the unutilised proceeds as the Group's general working capital.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Rights Issue *(Continued)*

Change of use of proceeds and expected timeline

Due to the instability of the economy and the impact of the Covid-19 pandemic, the Company took a cautious approach in scouting suitable business or investments opportunities in the past. The Company has constantly assessed the market conditions and development in the PRC, and will continue to try its best endeavour to identify suitable acquisition and investment opportunities or targets for the utilisation of the remaining unutilised proceeds from the Rights Issue.

As disclosed in the annual report of the Company for the year ended 31 December 2023, in order to better seize business opportunities in the PRC domestic market that are beneficial to the growth of the Group and allocate resources more effectively for the Group's general operations as well as long term development strategy in enhancing product portfolio and distribution channels, the Company intended to expand the intended use of the unutilised proceeds from the Relevant Proceeds to include the Group's general operations and the operation of domestic pharmaceutical business (apart from overseas domestic pharmaceutical business only) in the PRC.

As at 31 December 2023, the total unutilised proceeds from the Rights Issue were approximately HK\$39.6 million. As disclosed in the annual report of the Company for the year ended 31 December 2023, the Company planned to use such unutilised proceeds of approximately HK\$39.6 million (i) for the acquisition of the equity interests (in part or in full) of pharmaceutical companies which are principally engaged in overseas and/or domestic pharmaceutical business in the PRC; and (ii) as the Group's general working capital.

As disclosed in the announcement of the Company dated 16 July 2024, the Company (i) allocated approximately HK\$17.3 million of the unutilised proceeds for funding the consideration for the acquisition of 16% of the issued share capital of China Nvwa Pharmaceutical Group Limited (中國女媧醫藥集團股份有限公司) ("**China Nvwa**") (as disclosed in the section headed "Material Acquisitions or Disposals and Significant Investments" of this report, the announcement of the Company dated 16 May 2024 and the circular of the Company dated 21 June 2024), being a group of companies which are principally engaged in domestic pharmaceutical business in the PRC; and (ii) planned to use the remaining approximately HK\$22.3 million of the unutilised proceeds as the Group's general working capital.

As at the date of this report, the Company (i) has used approximately HK\$17.3 million of the unutilised proceeds for funding the consideration for the acquisition of 16% of the issued share capital of China Nvwa; and (ii) plans to use the remaining approximately HK\$22.3 million of the unutilised proceeds as the Group's general working capital.

Based on the best estimation of the present and future business market conditions in the PRC and the business prospect of the Group, it is expected that the unutilised proceeds for the intended purpose will be fully used by 31 December 2025. Currently, the Company placed the unutilised proceeds as short term interest-bearing deposits.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Rights Issue *(Continued)*

Change of use of proceeds and expected timeline *(Continued)*

Note a: It was disclosed in the prospectus of the Company in relation to the Rights Issue dated 10 February 2017 that, among others, the Company intended to apply HK\$83.5 million for the second tranche acquisition of approximately 17% of the issued share capital of HCMPS in accordance with the sale and purchase agreement dated 18 October 2016 and the supplemental agreement dated 30 November 2016 entered into by and among Major Bright, a subsidiary of the Company, the Company and JFA Capital. As at 13 March 2017, as it was unlikely for the Company to obtain the shareholders' approval on or before the long stop date of 31 March 2017 for the second tranche acquisition and the parties could not come to a consensus as to the extension of the long stop date, the parties agreed not to proceed with the second tranche acquisition and the Board decided to apply the said HK\$83.5 million to the possible acquisition of interest in HCMPS and/or other potential acquisitions of medical and healthcare related business when opportunities arose. Details of the change of use of proceeds are disclosed in the announcement of the Company dated 13 March 2017.

Note b: It was disclosed in the prospectus of the Company in relation to the Rights Issue dated 10 February 2017 that, among others, the Company intended to apply HK\$88.5 million for the acquisition of approximately 29% of the issued share capital of China Biotech in two tranches. On 16 March 2017, approximately HK\$28.8 million of the net proceeds were used for financing the first tranche acquisition of approximately 11% of the issued share capital of China Biotech and the related professional fees. As at 27 March 2017, as it was unlikely for the Company and the vendor to obtain their respective shareholders' approvals on or before the long stop date of 30 April 2017 for the second tranche acquisition and the parties could not come to a consensus as to the extension of the long stop date, the parties agreed not to proceed with the second tranche acquisition and the Board decided to apply the remaining proceeds of HK\$59.7 million to other potential acquisitions of medical and healthcare related business when opportunities arose. Details of the change of use of proceeds are disclosed in the announcement of the Company dated 27 March 2017.

Note c: For further details in relation to the application of the net proceeds of HK\$10.4 million to finance the acquisition of an additional 3% equity interest in WinHealth International by the Group and the reasons for the acquisition of such additional interest, please refer to the announcement of the Company dated 14 March 2017.

Pledge of Assets

As at 31 December 2024, the Group had no charges on its assets.

As at 31 December 2023, the Group pledged the buildings and right-of-use assets with an aggregate carrying amount of approximately HK\$12.5 million to secure general banking facilities granted to the Group.

Future Plans for Material Investments

The Group may consider the possibility of disposing of the business or assets in respect of its non-core business currently held by the Group in the coming future.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Litigation

On 17 November 2020, the Company was served a sealed copy of a petition dated 16 November 2020 filed in the High Court of the Hong Kong Special Administrative Region ("**Court**") by the Securities and Futures Commission ("**SFC**") pursuant to section 214 of the Securities and Futures Ordinance ("**SFO**") ("**Petition**"). The Petition named three respondents. Apart from the Company, the other two parties named as respondents by the Petition are two former Directors, namely, Mr. Zhou Ling ("**1st Respondent**") and Mr. Dai Haidong ("**2nd Respondent**"). The 1st Respondent and the 2nd Respondent retired and resigned from their positions as executive Directors on 27 June 2018 and 5 November 2015 respectively.

Pursuant to the Petition, the SFC alleged that, during the period from 2015 to 2018, each of the 1st Respondent and the 2nd Respondent has been wholly or partly responsible for the business or affairs of the Company having been conducted in a manner (i) involving misfeasance or other misconduct towards it or its members or any part of its members; (ii) resulting in its members or any part of its members not having been given all the information with respect to its business or affairs that they might reasonably expect; and/or (iii) unfairly prejudicial to its members or any part of its members. In particular, the SFC alleged that, *inter alia*,

- (1) the 1st Respondent and the 2nd Respondent had breached their duties as directors of the Company in relation to the Group's acquisition of 50% interest in Saike International (details of such acquisition were disclosed in the announcements of the Company dated 14 February 2015, 20 March 2015, 26 June 2015 and 16 July 2015);
- (2) the 1st Respondent had made a secret profit in the sum of HK\$26 million out of the Group's acquisition of 15% interest in Eternal Charm International Limited (now known as WinHealth International Company Limited) (details of such acquisition were disclosed in the announcements of the Company dated 5 December 2016 and 14 March 2017); and
- (3) the 1st Respondent was responsible for misfeasance and/or misconduct which was unfairly prejudicial to the members or any part of the members of the Company, comprising various artificial transactions involving dealings in a number of pharmaceutical products.

In the Petition, the SFC applied for, *inter alia*, an order that the 1st Respondent do pay to the Company the sum of HK\$26 million with interest thereon at such rate and for such period as the Court thinks fit. No order or relief is sought against the Company in the Petition. The Petition was fixed to be heard on 11 May 2021.

On 4 May 2021, the SFC, the Company, the 1st Respondent and the 2nd Respondent made a joint application by way of consent summons ("**Consent Summons**") in respect of the vacation of the hearing date fixed for the Petition. On 5 May 2021, the Court made an order in terms of the Consent Summons as amended, among other things, that the hearing date of the Petition scheduled to be held on 11 May 2021 be vacated and leave be granted to the parties to fix a case management conference on a date in consultation with counsel's diaries. Details of the Petition are disclosed in the Company's announcements dated 18 November 2020 and 10 May 2021. The said case management conference was subsequently fixed on 24 August 2022. At the said case management conference held on 24 August 2022, it was ordered that, among other things, a second case management conference was fixed to be held on 2 December 2022. The case was subsequently heard in July 2024.

The Company was excused by the Court from the hearing. On 23 July 2024, the Court made an order to, among other things, grant leave to other parties to the proceedings to file and serve certain documents.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial Review *(Continued)*

Litigation *(Continued)*

On 13 September 2024, the Court handed down the judgment ("**Judgment**") of the Petition, pursuant to which, *inter alia*, a costs order nisi ("**Costs Order Nisi**") was made that, *inter alia*, (i) the SFC should pay the Company 75% of the costs of and occasioned by the Petition including all costs reserved, to be taxed if not agreed; and (ii) the 1st Respondent and the 2nd Respondent should pay the Company 25% of the costs of and occasioned by the Petition including all costs reserved, to be taxed if not agreed ("**Costs Awarded to the Company**"). No order was made against the Company in the Judgment.

On 27 September 2024, the 1st Respondent and the 2nd Respondent filed a summons for an application to vary the Costs Order Nisi ("**Application to Vary Costs Order Nisi**").

On 10 October 2024, the SFC filed a notice of appeal in respect of the Judgment for an order that, *inter alia*, (i) the Judgment in respect of certain transactions be set aside; and (ii) certain matters pleaded in the Petition and the reliefs relating to such matters be remitted to the Court of First Instance for retrial and/or reconsideration ("**Appeal**"). A notice of setting down an appeal in respect of the Appeal was filed by the SFC on the same day to notify the parties that the Appeal had been set down in the list of appeals.

On 20 November 2024, the Application to Vary Costs Order Nisi was heard and the Court made an order to vary the Costs Order Nisi, yet the Costs Awarded to the Company remained unchanged.

On 10 December 2024, the Petitioner filed a supplementary notice of appeal, setting forth further or alternative grounds of appeal in respect of the Appeal.

As at the date of this report, the Appeal is still ongoing.

As at 31 December 2024 and the date of this report, save as disclosed above, so far as was known to the Directors, no member of the Group was involved in any litigation, arbitration or claim of material importance and no litigation, arbitration or claim of material importance was pending or threatened against any member of the Group.

BIOGRAPHICAL DETAILS OF THE DIRECTORS AND SENIOR MANAGEMENT

Executive Directors

Ms. Wang Qiuqin (“Ms. Wang”), aged 47, is the chairman of the Board, an executive Director, the chief executive officer of the Company since 15 May 2021, 27 June 2018 and 31 July 2020 respectively. She is also the chairman of the corporate governance committee (“**Corporate Governance Committee**”) of the Board and an authorised representative of the Company for the purpose of Rule 3.05 of the Listing Rules. Ms. Wang graduated from Zhejiang University (浙江大學) majoring in Chinese language and literature in 1999 and China Medical University (中國醫科大學) majoring in pharmacy in 2016 through a distance learning program. Ms. Wang has over 19 years of experience in the pharmaceutical distribution industry in the PRC. Ms. Wang was the merchandising assistant of Zhejiang Xin Rui Pharmaceutical Co., Ltd. (浙江新銳醫藥有限公司) (“**Zhejiang Xin Rui**”), a wholly-owned subsidiary of the Company, from April 2006 to April 2008 and has been the merchandising manager of Zhejiang Xin Rui since May 2008. She is responsible for the overall business operations of the Group. She is also a director of a number of subsidiaries of the Company. Ms. Wang would serve as an executive Director for a term of two years commencing on 27 June 2024 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Mr. Chu Xueping (“Mr. Chu”), aged 53, has been an executive Director since 18 June 2021. Mr. Chu graduated from Dalian Medical University (大連醫科大學) majoring in pharmacy in 1993. Mr. Chu has over 13 years of experience in the pharmaceutical industry in the PRC. Mr. Chu was the deputy general manager of 北京品尚品醫藥科技有限公司 (Beijing Pin Shang Pin Medicine Technology Co. Ltd., the English name is for identification purpose only) from 2011 to 2015 and has been the deputy president of Hainan Noken Pharmaceutical Co., Ltd. (海南諾爾康藥業有限公司) since 2016. Mr. Chu would serve as an executive Director for a term of two years commencing on 18 June 2023 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Ms. Zhou Wan (“Ms. Zhou”), aged 35, has been appointed as an executive Director with effect from 31 March 2023. Ms. Zhou joined the Group’s marketing team in February 2012 and has been promoted to the position of the general manager and legal representative of Zhejiang Xin Rui Pharmaceutical Co., Ltd.* (浙江新銳醫藥有限公司) (“**Zhejiang Xin Rui**”), a wholly-owned subsidiary of the Company, since April 2018. Ms. Zhou graduated from Zhejiang Chinese Medical University (浙江中醫藥大學) majoring in traditional Chinese pharmacy in 2017. Ms. Zhou has more than 12 years of experience in the pharmaceutical distribution industry in the PRC. Ms. Zhou would serve as an executive Director for a term of two years commencing on 31 March 2025 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

BIOGRAPHICAL DETAILS OF THE DIRECTORS AND SENIOR MANAGEMENT

Independent Non-executive Directors

Mr. Leung Chi Kin (“**Mr. Leung**”), aged 75, has been an independent non-executive Director since 26 September 2013. He is also the chairman of the remuneration committee (“**Remuneration Committee**”) and the nomination committee (“**Nomination Committee**”) and a member of the audit committee (“**Audit Committee**”) of the Board. Mr. Leung was an elected member of the Shatin District Council in Hong Kong from 1994 to 2011. Mr. Leung was also awarded a Medal of Honour by the Government of Hong Kong. Mr. Leung was an independent non-executive director of Hanergy Thin Film Power Group Limited (formerly known as Hanergy Solar Group Limited and Apollo Solar Energy Technology Holdings Limited) (stock code: 566), the issued shares of which were no longer listed on the Main Board of the Stock Exchange since 11 June 2019, during the period from 1 May 2008 to 25 November 2009 and Silk Road Energy Services Group Limited (formerly known as China Natural Investment Company Limited) (stock code: 8250) during the period from 27 November 2009 to 26 November 2012, the issued shares of which are listed on GEM of the Stock Exchange, respectively. Mr. Leung would serve as an independent non-executive Director for a term of two years commencing on 1 October 2023 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Ms. Li Sin Ming, Ivy (“**Ms. Li**”), aged 49, has been an independent non-executive Director since 20 June 2017. She is also the chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee. She holds a Bachelor’s Degree of Business Administration (Honours) in Accounting from the Hong Kong Baptist University. Ms. Li is a Certified Public Accountant of the Hong Kong Institute of Certified Public Accountants and a fellow of the Association of Chartered Certified Accountants. Ms. Li has over 27 years of accounting and auditing experience. Ms. Li worked in various audit firms and the finance department of several companies. Ms. Li would serve as an independent non-executive Director for a term of two years commencing on 20 June 2023 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Mr. Sy Lai Yin, Sunny (“**Mr. Sy**”), aged 44, has been an independent non-executive Director since 24 September 2018. He is also a member of the Audit Committee, the Remuneration Committee, the Nomination Committee and the Corporate Governance Committee. He graduated from Washington University with a Bachelor’s Degree of Science in Business Administration. He was awarded a degree of Master of Science in Business Administration by Washington University in December 2001. He has over five years of experience in accounting and auditing with an international accountancy and professional services firm. Mr. Sy has also been a director of Bradbury Securities Limited, a corporation licensed to carry on Type 1 (dealing in securities) and Type 4 (advising on securities) regulated activities under the SFO since 2008. Mr. Sy Lai Yin, Sunny was appointed as an independent non-executive director, a member of the remuneration committee and the chairman of the audit committee of the board of directors of Chen Lin Education Group Holdings Limited (stock code: 1593) with effect from 7 July 2021. Mr. Sy would serve as an independent non-executive Director for a term of two years commencing on 24 September 2024 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Senior Management

Mr. Ng Yat Sing (“**Mr. Ng**”), aged 37, has been appointed as company secretary with effect from 11 July 2023. Mr. Ng has over 12 years of experience in the field of auditing and accounting and previously worked in the audit department of an international accounting firm in Hong Kong and in the finance department of a company listed in Hong Kong before joining the Company. He joined the Group in October 2019 and is the Financial Controller of the Group with effect from 11 July 2023. Mr. Ng is a holder of a Bachelor of Business (Accounting) degree from Australian Catholic University. He is a member of Hong Kong Institute of Certified Public Accountants.

REPORT OF THE DIRECTORS

The Directors present their annual report and the audited consolidated financial statements of the Company for the Year.

Principal Activities

The Company is an investment holding company. The Group is principally engaged in the distribution and trading of pharmaceutical products and the provision of marketing and promotion services in the PRC.

Principal Subsidiaries

Details of the principal subsidiaries as at 31 December 2024 are set out in note 34 to the consolidated financial statements respectively.

Results and Appropriations

The results of the Group for the Year are set out in the consolidated statement of profit or loss and other comprehensive income on page 66 of this report.

Dividend

The Board does not recommend the payment of a final dividend for the Year (2023: nil).

Donations

Charitable donations made by the Group during the Year amounted to approximately HK\$154,000 (2023: approximately HK\$278,000).

Property, Plant and Equipment

Details of movements in the property, plant and equipment of the Group during the Year are set out in note 14 to the consolidated financial statements.

Share Capital

There was no movement in the share capital of the Company during the Year. Details of the share capital of the Company during the Year are set out in note 26 to the consolidated financial statements and the section headed "Share Option Scheme" in this report of the Directors.

Pre-emptive Rights

There is no provision for pre-emptive rights under the bye-laws of the Company ("**Bye-laws**") and the laws of Bermuda, the jurisdiction in which the Company was incorporated, which would oblige the Company to offer new shares on a pro-rata basis to its existing shareholders.

Reserves and Distributable Reserves

Details of movements in the reserves of the Group during the Year are set out in the consolidated statement of changes in equity on page 69 of this report. As at 31 December 2024, the reserves available for distribution to the Company's shareholders were approximately HK\$340,031,000 (2023: approximately HK\$344,757,000). Further details are set out in note 27 to the consolidated financial statements.

REPORT OF THE DIRECTORS

Business Review

A fair review of the business of the Group during the Year, particulars of important events affecting the Group during the Year, an analysis of the Group's performance using financial key performance indicators, and an indication of likely future developments in the Group's business are provided in the sections headed "Chairman's Statement" and "Management Discussion and Analysis" of this report. Description of the principal risks and uncertainties faced by the Group can be found throughout this report, particularly in the sub-section headed "Principal Risks and Uncertainties" in the section headed "Management Discussion and Analysis" of this report. Also, the capital risk management of the Company can be found in note 28 to the consolidated financial statements. In addition, discussions on the Group's relationships with its key stakeholders, the Group's environmental policies and performance and the Group's compliance with laws and regulations are also provided in the sub-sections headed "Relationships with Stakeholders", "Environmental Policies and Performance" and "Compliance with Applicable Laws and Regulations which have a Significant Impact on the Group" in the section headed "Management Discussion and Analysis" of this report respectively. These discussions form part of this report of the Directors.

Directors

The Directors who held office during the Year and as at the date of this report are:

Executive Directors

Ms. Wang Qiuqin (*Chief Executive Officer*)

Mr. Huo Zhihong (resigned on 16 October 2024)

Mr. Chu Xueping

Ms. Zhou Wan

Independent Non-executive Directors

Mr. Leung Chi Kin

Ms. Li Sin Ming, Ivy

Mr. Sy Lai Yin, Sunny

Directors' Service Contracts

Each of Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan entered into a service contract with the Company for a term of two years commencing on 27 June 2024, 18 June 2023 and 31 March 2025, respectively. Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny entered into a letter of re-appointment with the Company for a term of two years commencing on 1 October 2023, 20 June 2023, and 24 September 2024 respectively. They are all subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws.

Pursuant to Bye-law 84(1) of the Bye-laws, at each annual general meeting one-third of the Directors for the time being (or, if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at least once every three years. Accordingly, Ms. Zhou Wan and Ms. Li Sin Ming, Ivy will retire from office by rotation at the annual general meeting and, being eligible, will offer themselves for re-election at the annual general meeting.

None of the Directors who is being proposed for re-election at the forthcoming annual general meeting of the Company has a service contract with the Company or any of its subsidiaries which is not determinable by the Group within one year without payment of compensation (other than statutory compensation).

Change of Directors

On 16 October 2024, Mr. Huo Zhihong ("**Mr. Huo**") tendered his resignation as an executive Director which took effect on 16 October 2024 due to his other business pursuits and commitments. Upon his resignation becoming effective on 16 October 2024, Mr. Huo also ceased to be a member of the Corporate Governance Committee.

REPORT OF THE DIRECTORS

Change of Directors *(Continued)*

Following Mr. Huo's resignation, Ms. Zhou Wan, an executive Director, was appointed as a member of the Corporate Governance Committee in place of Mr. Huo with effect from 16 October 2024. For further details, please refer to the announcement of the Company dated 16 October 2024.

Independent Non-executive Directors

The Company has received from each of the existing independent non-executive Directors an annual confirmation of his/her independence pursuant to Rule 3.13 of the Listing Rules. The Company considers that each of the independent non-executive Directors is independent.

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures

As at 31 December 2024, the interests and short positions of the Directors and the chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) ("SFO") which are required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions in which they are taken or deemed to have under such provisions of the SFO), or which are required to be recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of the Listed Issuers ("Model Code"), were as follows:

Name of Director	Capacity	Number of ordinary shares/ underlying shares (Note 2)	Position	Approximate percentage of the total issued shares (Note 1)
Wang Qiuqin	Beneficial owner	16,600,000	Long	0.99% (Note 2)
Chu Xueping	(i) Beneficial owner (ii) Interest of a controlled corporation	443,272,000	Long	26.51% (Note 3)
Zhou Wan	Beneficial owner	15,000,000	Long	0.90% (Note 2)

Note 1: The total number of 1,671,846,657 shares of the Company in issue as at 31 December 2024 has been used for the calculation of the approximate percentage.

Note 2: These interests are underlying shares of the Company in respect of share options granted by the Company on 14 June 2022 and vested on 14 June 2022 pursuant to the Scheme (as defined below) adopted by the Company on 25 October 2013. Such underlying shares of the Company had an exercise period from 14 June 2022 to 13 June 2027 with an exercise price of HK\$0.287 per share.

Note 3: (i) Chu Xueping, in his capacity as beneficial owner, is interested in 16,600,000 underlying shares of the Company in respect of share options granted by the Company on 14 June 2022 and vested on 14 June 2022 pursuant to the Scheme (as defined below) adopted by the Company on 25 October 2013. Such underlying shares of the Company had an exercise period from 14 June 2022 to 13 June 2027 with an exercise price of HK\$0.287 per share.

(ii) Chu Xueping, through a controlled corporation, is interested in 426,672,000 shares of the Company. As at 31 December 2024, Eagle Amber Holdings Limited was beneficially owned by Chu Xueping as to 50.0%. As such, Chu Xueping was deemed to be interested in the 426,672,000 shares of the Company held by Eagle Amber Holdings Limited under Part XV of the SFO.

REPORT OF THE DIRECTORS

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures *(Continued)*

Save as disclosed above, as at 31 December 2024, none of the Directors nor the chief executive of the Company had any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of SFO) which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); (b) to be recorded in the register required to be kept under Section 352 of the SFO; or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code contained in the Listing Rules.

Substantial shareholders' interests and short positions in shares and underlying shares

As at 31 December 2024, the following persons (other than the Directors and Chief Executive of the Company) had interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

(i) Substantial shareholders' interest in shares and underlying shares of the Company

Name of shareholder	Capacity	Number of ordinary shares	Position	Approximate percentage of the total issued shares (Note 1)
Eagle Amber Holdings Limited (Note 2)	Beneficial owner	426,672,000	Long	25.52%
Dai Xiaosong (Note 2)	Interest of a controlled corporation	426,672,000	Long	25.52%

(ii) Other persons' interest in shares and underlying shares of the Company

Name of shareholder	Capacity	Number of ordinary shares	Position	Approximate percentage of the total issued shares (Note 1)
Zhou Ling (Note 3)	Beneficial owner and interest of spouse	161,400,000	Long	9.65%
Yang Fang (Note 3)	Beneficial owner and interest of spouse	161,400,000	Long	9.65%
Qian Shenglei	Beneficial owner	119,752,000	Long	7.16%

Note 1: The total number of 1,671,846,657 shares of the Company in issue as at 31 December 2024 has been used for the calculation of the approximate percentage.

Note 2: As at 31 December 2024, Eagle Amber Holdings Limited was beneficially owned by Chu Xueping and Dai Xiaosong as to 50.0% and 50.0% respectively. As such, Dai Xiaosong was deemed to be interested in the 426,672,000 shares of the Company held by Eagle Amber Holdings Limited under Part XV of the SFO. Chu Xueping's interest in the Shares is set out in the paragraph headed "Directors' and Chief Executive's interests and short positions in shares, underlying shares and debentures" above.

Note 3: Mr. Zhou Ling beneficially owns 132,188,952 shares of the Company. Ms. Yang Fang beneficially owns 29,211,048 shares of the Company. Mr. Zhou Ling is the spouse of Ms. Yang Fang. Accordingly, Mr. Zhou Ling was deemed to be interested in all the 29,211,048 shares of the Company held by Ms. Yang Fang by virtue of the SFO and Ms. Yang Fang was deemed to be interested in all the 132,188,952 shares of the Company held by Mr. Zhou Ling under Part XV of the SFO.

REPORT OF THE DIRECTORS

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures *(Continued)*

Save as disclosed above, as at 31 December 2024, the Company was not aware of any other persons (not being the Directors or the chief executive of the Company) or corporations having interests or short positions in the Shares or underlying Shares of the Company which were required to be disclosed to the Company and the Stock Exchange under Divisions 2 and 3 of Part XV of the SFO or recorded in the register required to be kept under section 336 of the SFO or who were directly and/or indirectly deemed to be interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company.

Major Customers and Suppliers

For the Year, the Group's five largest customers accounted for approximately 82.9% of the Group's total revenue and the Group's largest customer accounted for approximately 43.5% of the Group's total revenue. For the Year, the Group's four largest suppliers accounted for 100% of the Group's total purchases and the Group's largest supplier accounted for more than 68% of the Group's total purchases.

None of the Directors or any of their close associates, or any shareholder of the Company (which to the knowledge of the Directors owns more than 5% of the Company's issued shares), had any interest in any of the five largest customers or suppliers of the Group for the Year.

Directors' Interest in Competing Business

None of the Directors nor their respective close associates had any interest in a business, apart from the businesses of the Group, which competes or is likely to compete, either directly or indirectly, with the businesses of the Group pursuant to Rule 8.10 of the Listing Rules during the Year.

Directors' Rights to Acquire Shares or Debentures

Save as disclosed in the section headed "Share Option Scheme" in this report of the Directors, at no time during the Year was the Company or any of its subsidiaries, a party to any arrangement to enable the Directors or the chief executive of the Company or their spouse or children under 18 years of age to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

Contracts of Significance

There were no transactions, arrangements or contracts of significance, to which the Company, or any of its subsidiaries was a party and in which any Director (including any person who at any time during the Year was a Director) or an entity connected with a Director is or was materially interested, either directly and indirectly, subsisting at the end of the Year or at any time during the Year.

No contracts concerning the management and administration of the whole or any substantial part of the business of the Group were entered into or existed during the Year.

REPORT OF THE DIRECTORS

Share Option Scheme

The Company adopted a share option scheme (the “**Scheme**”) on 25 October 2013 to provide the Company with a flexible means of giving incentive to rewarding, remunerating, compensating and/or providing benefits to the eligible persons and for such other purposes as the Board may approve from time to time. The Scheme expired in October 2023.

Pursuant to the Scheme, before its expiration, the Directors might grant share options to the eligible persons prescribed in the Scheme (including but not limited to directors, employees and consultants of each member of the Group and entity in which a member of the Group held an equity interest), to subscribe for ordinary shares in the Company for a consideration of HK\$1 for each lot of share options granted. Share options granted should be accepted within 21 days from the date of grant. The exercise price of the share options would be determined by the Directors, and should be at least the highest of (i) the closing price of the Company's ordinary shares on the date of grant; (ii) the average closing price of the Company's ordinary shares for the five business days immediately preceding the date of grant; and (iii) the nominal value of an ordinary share. The maximum number of ordinary shares which might be issued upon exercise of all outstanding options granted and yet to be exercised under the Scheme and any other share option schemes of the Company should not exceed 30% (or such higher percentage as might be allowed under the Listing Rules) of the total number of ordinary shares of the Company in issue from time to time.

The total number of ordinary shares issued and to be issued upon exercise of the options granted to each individual under the Scheme and any other option schemes of the Company (including exercised, cancelled and outstanding options) in any 12-month period should not exceed 1% of the total number of ordinary shares of the Company in issue.

The Scheme was implemented in compliance with the requirements of Chapter 17 of the Listing Rules. On 14 June 2022, the Company granted share options to three Directors and certain employees of the Group which entitled the holders thereof to subscribe for an aggregate of 143,200,000 ordinary shares of the Company at an exercise price of HK\$0.287 per share. Consideration received by the Group for the grant of the share options was HK\$1.00 paid by each grantee upon acceptance of the share options granted.

The estimated fair value of the options granted on 14 June 2022 was approximately HK\$10,393,000. The fair value of share options granted was priced using a binomial option pricing model which required the management's estimates and assumptions on significant calculation inputs, including the estimated life of share options granted, the volatility of share price and expected dividend yield. Changes in the subjective input assumptions could materially affect the fair value estimate.

Details of the grant of share options by the Company are disclosed in the announcement of the Company dated 14 June 2022.

During the year ended 31 December 2024, no share options were granted, exercised, lapsed or cancelled as the Scheme expired in October 2023.

As the Scheme expired in October 2023, the Directors could no longer grant any further options under the Scheme upon its expiry. The number of share options available for grant under the existing Scheme limit as at 1 January 2024 and 31 December 2024 was nil Shares.

Since no option was granted under the Scheme during the year ended 31 December 2024, the number of shares that might be issued in respect of options granted under the Scheme during the Year divided by the weighted average number of the Company's shares in issue for the Year was zero.

Particulars of the Scheme are set out in note 30 to the consolidated financial statements.

REPORT OF THE DIRECTORS

Senior Management’s Remuneration

The annual remuneration of the members of the senior management (other than Directors) by bands for the Year is set out below:

	Number of senior management (other than Directors)
HK\$nil to HK\$1,000,000	1

The remuneration of each of the Directors for the Year is set out in note 11 to the consolidated financial statements.

Purchase, Sale or Redemption of the Company’s Listed Securities

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company’s listed securities during the Year.

Corporate Governance

Principal corporate governance practices adopted by the Company are set out in the section headed “Corporate Governance Report” of this report.

Related Party Transactions

During the Year, the related party transactions in relation to the compensation of key management personnel who are Directors or chief executive of the Company in 2024 as disclosed in note 33(i) and 33(ii) to the consolidated financial statements respectively fell under the definition of “connected transaction” or “continuing connected transaction” (as the case may be) and they are fully exempt under Chapter 14A of the Listing Rules. The Directors confirm that the Company has complied with the disclosure requirements in accordance with Chapter 14A of the Listing Rules.

Save as disclosed above, there were no other transactions which constituted connected transaction(s) or continuing connected transaction(s) of the Company under Chapter 14A of the Listing Rules during the Year.

Subsequent Events

There were no significant events affecting the Group after 31 December 2024 and up to the date of this report.

Emolument Policy

The emolument policy of the employees of the Group is devised by the Board on the basis of the positions, duties and performance of the employees.

The emoluments of the Directors are decided by the Board, having regard to the Group’s operating results, individual performances and comparable market statistics.

Retirement Benefit Scheme

Details of the retirement benefit scheme are set out in note 31 to the consolidated financial statements.

REPORT OF THE DIRECTORS

Equity-linked Agreements

Other than the Scheme as disclosed under the section headed “Share Option Scheme” in this report of the Directors and note 30 to the consolidated financial statements, no equity-linked agreements were entered into by the Company during the Year or subsisted at the end of the Year. The disclosure in the above section and note to the consolidated financial statements forms part of this report of the Directors.

Permitted Indemnity

Subject to applicable laws, every Director shall be entitled to be indemnified out of the assets and profits of the Company against all actions, costs, charges, losses, damages and expenses which he/she may sustain or incur in the execution of his/her duties or otherwise in relation thereto pursuant to the Bye-laws. The Company has maintained appropriate directors and officers liability insurance for all the Directors. The relevant provisions in the Bye-laws and the directors and officer’s liability insurance are currently in force and were in force throughout the Year.

Sufficiency of Public Float

Based on information that is publicly available to the Company and within the knowledge of the Directors, as at the latest practicable date prior to the issue of this report, the Company maintained a sufficient prescribed public float of more than 25% of the Company’s issued shares as required under the Listing Rules.

Auditor

The Company appointed Moore CPA Limited (“**Moore**”) as the auditor of the Company for the Year. Moore will retire and, being eligible, offer itself for re-appointment at the forthcoming annual general meeting. A resolution to re-appoint Moore and to authorise the Directors to fix its remuneration will be proposed at the forthcoming annual general meeting.

Dividend Policy

Policy on declaration of dividend of the Company is in place. According to the dividend policy, when determining whether to declare any dividend in the future and the amount of dividend to be declared, the Company shall consider various factors, including but not limited to, the Group’s level of cash and retained earnings, the actual and projected financial performance, the projected level of capital expenditure and other investment plans and restrictions on payment of dividends imposed on the Group by its financing arrangement (if any). The Company does not have any pre-determined dividend distribution proportion or distribution ratio. The Board will review the dividend policy from time to time.

Review By Audit Committee

The audited consolidated financial statements of the Company for the Year have been reviewed by the Audit Committee.

On behalf of the Board

Wang Qiuqin

Chairman, Chief Executive Officer and Executive Director

25 March 2025

CORPORATE GOVERNANCE REPORT

The Board is pleased to present this Corporate Governance Report for the Year.

The Board is committed to maintaining a good corporate governance standard. The Board believes that a good corporate governance standard will provide a framework for the Group to formulate its business strategies and policies, and manage the associated risks through effective internal control procedures. It will also enhance the transparency of the Group and strengthen the accountability to its shareholders and creditors. In this regard, a corporate governance committee of the Board ("**Corporate Governance Committee**") has been established with primary responsibility of developing and reviewing the Company's policies and practices on corporate governance and making recommendations to the Board.

The Company has adopted the code provisions as set out in the Corporate Governance Code contained in Appendix C1 to the Listing Rules ("**CG Code**") as its own code of corporate governance.

During the Year, the Company had complied with the code provisions of the then prevailing CG Code for the Year with the exception of code provisions C.2.1, details of which would be explained below.

Ms. Wang Qiuqin, an executive Director and the chief executive officer of the Company ("**Chief Executive Officer**"), was also appointed as the chairman of the Board ("**Chairman**"). As Ms. Wang Qiuqin is performing both the roles of the Chairman and the Chief Executive Officer, this constitutes a deviation from Code Provision C.2.1 of the CG Code which requires that the roles of the chairman and chief executive should be separate and should not be performed by the same individual.

The Board believes that vesting both the roles of the Chairman and the Chief Executive Officer in the same person gains the benefit of ensuring consistent leadership within the Group. The balance of power and authority for such arrangement are not impaired as all major decisions are made in consultation with the Board members and the senior management of the Company. Nevertheless, the Group will review the structure from time to time in light of the prevailing circumstances and may look for suitable candidate to take up the role of the Chairman and will make announcement as and when appropriate.

Directors' Securities Transactions

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") set out in Appendix C3 to the Listing Rules as the Company's code of conduct regarding Directors' securities transactions. Having made specific enquiries of all Directors, all the Directors confirmed that they had complied with the required standard set out in the Model Code throughout the Year.

Integrity

The Group strives to maintain high standards of business ethics and corporate governance across all activities and operations of the Group. The Directors, senior management, and employee are all required to act lawfully, ethically, and responsibly. The staff handbook of the Group sets out the requires standards and norms, including the code of conduct, for all staff. Frequent training is conducted from time to time to reinforce the required standards and norms in respect of ethics and integrity. The Group also established and implemented the anti-corruption policy and the whistleblowing policy to enhance the awareness of internal corporate justice.

Commitment

The Group's strategy in business development and management is to achieve long-term, steady and sustainable growth while taking due considerations into environmental, social and governance aspects.

CORPORATE GOVERNANCE REPORT

Board of Directors

During the Year, the Board comprised the following members:

Executive Directors

Ms. Wang Qiuqin (*Chairman and Chief Executive Officer*)

Mr. Huo Zhihong (resigned on 16 October 2024)

Mr. Chu Xueping

Ms. Zhou Wan

Independent Non-Executive Directors

Mr. Leung Chi Kin

Ms. Li Sin Ming, Ivy

Mr. Sy Lai Yin, Sunny

As at the date of this report, the Board comprises six members, three of which are executive Directors, namely, Ms. Wang Qiuqin who is the Chairman and the Chief Executive Officer, Mr. Chu Xueping and Ms. Zhou Wan. Three other members are independent non-executive Directors, namely Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny. There is no relationship among the members of the Board including financial, business, family or other material/relevant relationship. The biographical details of the Directors are set out in the section headed "Biographical Details of the Directors and Senior Management" on pages 24 and 25 of this report.

All Directors are subject to retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the bye-laws of the Company as amended from time to time and the requirements of the Listing Rules.

The Board is responsible for formulating the Group's business strategies and overall policies, and monitoring the performance of the management and corporate governance functions. The executive Directors are delegated with the power to develop business strategies and to execute and implement the policies in the day-to-day business operation of the Group. The independent non-executive Directors provide their professional advice to the Group whenever necessary. The management is responsible for executing the Group's business strategies and monitoring the day-to-day business operation of the Group.

Composition of the Board, including the names of the independent non-executive Directors, is disclosed in all corporate communications to the shareholders of the Company.

All Directors have full and timely access to all the information and accounts of the Group. The Directors may seek independent professional advice in appropriate circumstances, at the expense of the Company. The Company will, upon request, provide separate independent professional advice to the Directors to assist them to discharge their duties to the Company. The Company has arranged appropriate insurance cover in respect of legal action against the Directors.

CORPORATE GOVERNANCE REPORT

Attendance of Directors at Meetings

The attendance of the Directors at various meetings held during the Year are set out below:

	Number of meetings attended/held						Corporate Governance Committee meeting
	Annual General meeting	Special General meeting	Board meetings	Audit Committee meetings	Nomination Committee meeting	Remuneration Committee meeting	
Mr. Huo Zhihong	1/1	1/1	8/8	N/A	N/A	N/A	1/1
Ms. Wang Qiuqin (<i>Chairman and Chief Executive Officer</i>)	1/1	1/1	9/9	N/A	N/A	N/A	1/1
Mr. Chu Xueping	1/1	1/1	9/9	N/A	N/A	N/A	N/A
Ms. Zhou Wan	1/1	1/1	9/9	N/A	N/A	N/A	N/A
Mr. Leung Chi Kin	1/1	1/1	9/9	2/2	1/1	1/1	N/A
Ms. Li Sin Ming, Ivy	1/1	1/1	9/9	2/2	1/1	1/1	N/A
Mr. Sy Lai Yin, Sunny	1/1	1/1	9/9	2/2	1/1	1/1	1/1

Board Meetings

Apart from the said meetings, matters requiring Board approval were also arranged by means of circulation of written resolutions of all Board members.

Directors' Continuous Professional Development

All Directors confirmed that they had complied with code provision C.1.4 of the CG Code during the Year by participating in continuous professional development. The Company has from time to time provided training materials about the latest developments in the laws, rules and regulations relating to Directors' duties and responsibilities to all Directors. All Directors had been confirmed that he/she had read the training materials. It is the Company's practice to have all Directors to participate in continuous professional development to develop and refresh their knowledge and skills. This is to ensure that their contribution to the board remains informed and relevant. The Company has been being responsible for arranging and funding suitable training, placing an appropriate emphasis on the roles, functions and duties of a director of a listed company.

Chairman and Chief Executive Officer

During the Year, Ms. Wang Qiuqin was the Chairman of the Board and the Chief Executive Officer of the Company during the Year and up to the date of this report. Such practice deviates from Code Provision C.2.1 which stipulates that the roles of the chairman and chief executive officer should be separate and should not be performed by the same individual. In view of Ms. Wang Qiuqin's extensive experience in the industry and deep understanding of the Group's businesses, the Board believes that vesting the roles of both Chairman and Chief Executive Officer upon Ms. Wang Qiuqin provides the Group with strong and consistent leadership, allows for more effective planning and execution of long-term business strategies and enhances efficiency in decision-making. As all major decisions are made in consultation with members of the Board and relevant Board committees, and there are independent non-executive Directors on the Board offering independent perspectives, the Board is of the view that there are adequate safeguards in place to ensure sufficient balance of powers within the Board.

Company Secretary

Currently, Mr. Ng Yat Sing is the company secretary of the Company. The company secretary is responsible for facilitating the Board process, including the communications among the Board members and shareholders of the Company and advising the Board on corporate governance matters. The company secretary has confirmed that he has taken not less than 15 hours of relevant professional training during the Year.

CORPORATE GOVERNANCE REPORT

Independent Non-Executive Directors

The Company has three independent non-executive Directors, one of them has appropriate professional qualification or accounting or related financial management expertise. The Company has received a written confirmation of independence from each of the existing independent non-executive Directors pursuant to the requirement of Rule 3.13 of the Listing Rules. The Company considers that each of the independent non-executive Directors is and has remained independent in accordance with the independence guidelines set out in the Listing Rules. During the Year, the Chairman held one meeting with the independent non-executive Directors without the presence of other Directors and All Directors have access to the advice and services of the Company Secretary to ensure that the Board procedures and all applicable laws, rules and regulations, are followed.

To ensure that independent views and input of the independent non-executive Directors are available to the Board, the Board and the Nomination Committee are committed to assessing the independence of the independent non-executive Directors annually by considering: (i) the character, qualifications, background, experience and other business interests as well as declaration of any conflict of interests; (ii) the contribution to the Group's growth and development through independent and constructive opinion; and (iii) the devotion of time and attention to the Group's affairs.

Term of Appointment of Non-Executive Directors

All the independent non-executive Directors have been appointed for a term of two years.

Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny entered into a letter of re-appointment with the Company for a term of two years commencing on 1 October 2023, 20 June 2023 and 24 September 2024 respectively.

Remuneration Committee

The Board has established a remuneration committee of the Board ("**Remuneration Committee**") with its role and functions set out in its specific written terms of reference in accordance with the provisions set out in the CG Code, which are published on the websites of the Stock Exchange and the Company. The principal duties of the Remuneration Committee are to formulate the Company's remuneration policy and to make recommendations on the remuneration packages of the Directors and senior management of the Company to the Board for approval. The Company's remuneration policy is based on the positions, duties and performances of the employees. The employees' remuneration varies according to their positions, which may include salary, overtime allowance, bonus, shares option and various subsidies. The Remuneration Committee is also responsible for reviewing and/or approving matters relating to share option schemes of the Company. The performance appraisal system varies according to the positions of the employees. The performance appraisal is supervised by the performance management committee.

During the Year and up to the date of this report, the Remuneration Committee comprised the following Directors:

Name of Director	Position
Mr. Leung Chi Kin (<i>Chairman</i>)	Independent non-executive Director
Ms. Li Sin Ming, Ivy	Independent non-executive Director
Mr. Sy Lai Yin, Sunny	Independent non-executive Director

During the Year, one meeting of the Remuneration Committee was held to make recommendation to the Board on the Company's policy and structure for all remuneration of the Directors and the senior management of the Company and recommend the Board on the remuneration packages of all executive Directors, non-executive Directors and the senior management of the Company. All members of the Remuneration Committee attended the meeting during the Year.

CORPORATE GOVERNANCE REPORT

Remuneration Policy

The emolument of the Group's employees is mainly determined based on (i) the prevailing market level of remuneration, (ii) the individual performance and (iii) their working experience.

The Company formulates the remuneration policy to retain and attract the executive staff to achieve the success of the Group and to encourage the executive staff to pursue appropriate growth strategies while taking into account the performance of individual staff and their job duties and responsibilities. The Group should conduct a performance review and formal assessments at least once a year to review the Group employees' overall performance, achievements, and room for improvement.

The remuneration policies of the executive Directors and senior management of the Company are determined with reference to various factors including (i) qualification, performance, and personal abilities; (ii) the position and duty of the executive; (iii) the prevailing market level of remuneration; and (iv) the financial performance of the Group. The Group should conduct an annual review in order to offer a reasonable remuneration package to attract, retain and motivate the Directors and senior management to serve the Group.

The Directors' fee of independent non-executive Directors is determined with reference to their respective duty and responsibility in the Company and is reviewed annually.

Nomination Committee

The Board has established a nomination committee of the Board ("**Nomination Committee**") with its role and functions set out in its specific written terms of reference in accordance with the provisions set out in the CG Code, which are published on the websites of the Stock Exchange and the Company.

During the Year and up to the date of this report, the Nomination Committee comprised the following Directors:

Name of Director	Position
Mr. Leung Chi Kin (<i>Chairman</i>)	Independent non-executive Director
Ms. Li Sin Ming, Ivy	Independent non-executive Director
Mr. Sy Lai Yin, Sunny	Independent non-executive Director

The major responsibilities of the Nomination Committee are to review the structure, size and composition of the Board, formulate and implement the policy for nominating candidates for election by shareholders at general meetings of the Company (either to fill a casual vacancy or as an addition to the Board) and assess the independence of independent non-executive Directors, propose the re-election of retiring Directors and the appointment or re-appointment of and succession planning for the Directors. All Directors' appointments will be based on meritocracy, having due regard for the benefits of diversity on the Board. Details of the board diversity policy are set out in the section headed "Board Diversity Policy" below. The process for the nomination of Directors is led by the Nomination Committee, which has been made on a merit basis. The Company also has a board diversity policy (the "**Board Diversity Policy**") and a nomination policy (the "**Nomination Policy**") in place. The Nomination Policy aims at applying the principles of the Board Diversity Policy and other provisions under the Listing Rules to improve transparency of the process and criteria adopted by the Nomination Committee in selecting and recommending candidates to the Board on the appointment or reappointment of Directors (including INED(s)).

CORPORATE GOVERNANCE REPORT

Nomination Committee *(Continued)*

In identifying candidates qualified to become members of the Board, the Nomination Committee will give adequate consideration to the Board Diversity Policy and the Nomination Policy. While all Board appointments will continue to be made on a merit basis, a number of factors will also be taken into account, including but not limited to age, skills, regional and industry experience, cultural and educational background, race, gender and other qualities so as to ensure that the Board boasts a balance of skills, experiences as well as a diversity of perspectives. In forming its perspective on diversity, the Nomination Committee will also take into account factors based on the Company's own business model and specific needs from time to time.

According to the bye-laws of the Company, any Director appointed by the Board as an addition to the Board or to fill a casual vacancy shall be subject to re-election by the shareholders of the Company after appointment. All Directors are subject to retirement by rotation and re-election at the annual general meeting of the Company at least once every three years.

During the Year, one meeting of the Nomination Committee was held to review the structure and composition of the Board. All members of the Nomination Committee attended the meetings during the Year.

Board Diversity Policy

The Board adopted a board diversity policy setting out the approach to achieve diversity on the Board. The Company considers that a diversity of board members can be achieved through consideration of a number of aspects, including but not limited to gender, age, cultural and educational background, professional experience, skills and knowledge. In forming its perspective on diversity, the Company will also take into account factors based on its own business model and specific needs from time to time. The Company endeavours to ensure that the Board has an appropriate balance of skills, experience and diversity of perspectives that are required to support the execution of its business strategy and in order for the Board to be effective. All Directors' appointments will be based on meritocracy and candidates will be considered against objective criteria, having due regard to the benefits of diversity on the Board.

The Nomination Committee has a primary responsibility of identifying suitably qualified candidates to become members of the Board and, in carrying out this responsibility, will give adequate consideration to this diversity policy. The Nomination Committee will review the board diversity policy, as appropriate, to ensure its effectiveness. The Nomination Committee will discuss any revisions that may be required, and recommend any such revisions to the Board for consideration and approval.

The Board considered that independent non-executive Directors can enhance the effectiveness and decision-making process of the Board by providing independent views, objective judgment and constructive challenge to the Board and management of the Group.

The Company is committed to gender equality by providing fair recruitment, training and promotion opportunities for all employees throughout the Group for the Year. The Board comprises six Directors, three of which are female Directors, namely the executive Directors, Ms. Wang Qiuqin and Ms. Zhou Wan, and the independent non-executive Director, Ms. Li Sin Ming, Ivy. During the year ended 31 December 2024, the Nomination Committee was satisfied with the diversity of the existing Board composition and did not, for the time being, set up any measurable objective regarding board diversity. The Company is committed to providing fair recruitment, training and promotion in accordance with the Nomination Policy and the Board Diversity Policy and selecting competent candidates objectively, and will continue to ensure that qualified female candidates are given equal consideration alongside male counterparts. The Company will ensure that, by placing such emphasis on gender diversity in succession planning, a diverse pipeline of candidates for appointment to the Board will be available when vacancies arise.

CORPORATE GOVERNANCE REPORT

The Company is also committed to gender diversity across the workforce. The details of the gender ratio in the workforce are disclosed in the section headed “Environmental, Social and Governance Report” of this annual report. It is the Group’s recruitment strategy to hire suitable employees regardless of gender, upholding a fair and equal talent acquisition process. Leadership roles at various departments of the Group are taken up by staff of different genders. During the year ended 31 December 2024, the Company was satisfied with the diversity of the existing workforce and did not, for the time being, set a measurable objective for achieving gender diversity at workforce level. Nonetheless, on a merit-based policy, the Company is committed to providing equal opportunities to employees in respect of recruitment, training and development, job advancement, and compensation and benefits.

Nomination Policy

In selecting and evaluating candidates for directorship of the Company, the Nomination Committee may make reference to the directors’ nomination policy of the Company which contains the directors’ nomination procedures. The directors’ nomination policy aims at applying the principles of the board diversity policy and other provisions under the Listing Rules to improve transparency of the nomination process and criteria adopted by the Nomination Committee in selecting and recommending candidates as Directors. Under the directors’ nomination policy, the Nomination Committee will review the perspectives, skills and experience of the candidate and determine:

- (a) whether (and how) the candidate can contribute his/her perspectives, skills and experience to the Board; and
- (b) whether (and how) the candidate can contribute to the diversity of the Board under the principles of the board diversity policy.

Any Director may nominate a person for appointment or election by the Board as a Director or by the Shareholders at the general meeting upon first obtaining the following information:

- (a) a written consent given by the candidate to be appointed, elected or re-elected (as the case may be) as a Director stating his/her consent for acting as a Director and the supply and disclosure of his information as required under the Listing Rules and other applicable laws and regulations;
- (b) details of the character, qualifications, background, experience and other business interests of the candidate for the purpose of Rules 3.09, 3.10 and 3.12 of the Listing Rules, together with supporting documents evidencing the same (if applicable);
- (c) (for a candidate whom may be nominated as an independent non-executive Director) details assessing the candidate’s independence under Rule 3.13 of the Listing Rules and Code Provisions B.1.6 (Recommended Best Practice) and together with supporting documents evidencing the same (if applicable);
- (d) details of the candidate’s information, together with supporting documents evidencing the same (if applicable), as required to be disclosed under Rule 13.51(2) of the Listing Rules;
- (e) (for a candidate whom may be nominated as an independent non-executive Director at a general meeting) explanation from the candidate for information required under Code Provision B.3.4 of the CG Code;
- (f) (for a candidate whom may be nominated to be appointed as a member of the Audit Committee) details assessing the candidate’s independence under Code Provision D.3.2 of the CG Code, together with supporting documents evidencing the same; and
- (g) up-to-date contact details of the candidate.

Upon the candidate’s fulfilment of the above criteria, the Nomination Committee shall convene a meeting to discuss and consider the recommendation of the candidate to the Board for appointment as a Director.

CORPORATE GOVERNANCE REPORT

Audit Committee

The Board has established an audit committee of the Board ("**Audit Committee**") with written terms of reference in accordance with the provisions set out in the CG Code, which are published on the websites of the Stock Exchange and the Company. The principal duties of the Audit Committee are to review the Company's financial statements, accounts and interim and annual results and to provide advice and comments thereon to the Board. The Audit Committee is also responsible for reviewing and supervising the Group's financial reporting, risk management and internal control procedures.

During the Year and up to the date of this report, the Audit Committee comprised the following Directors:

Name of Director	Position
Ms. Li Sin Ming, Ivy (<i>Chairperson</i>)	Independent non-executive Director
Mr. Leung Chi Kin	Independent non-executive Director
Mr. Sy Lai Yin, Sunny	Independent non-executive Director

The Audit Committee held two meetings during the Year. During the meetings, the Audit Committee reviewed the financial results of the Group for the year ended 31 December 2023 and the six months ended 30 June 2024, financial reporting, risk management and internal control systems of the Group and assessed the need to set up an internal audit function of the Company. All meetings were convened with the presence of the Company's external auditor so that the members of the Audit Committee could exchange their views and concerns on the financial reporting process of the Group with the auditor of the Company. All members of the Audit Committee attended the meetings during the Year.

Corporate Governance Committee

The Board has established the Corporate Governance Committee with written terms of reference in accordance with the provisions set out in the CG Code and Corporate Governance Report contained in the CG Code, which are published on the website of the Company.

Its primary functions are (i) to develop and review the Company's policies and practices on corporate governance and make recommendations to the Board; (ii) to review and monitor the training and continuous professional development of Directors and senior management of the Group; (iii) to review and monitor the Company's policies and practices on compliance with legal and regulatory requirements; (iv) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to the Directors and employees of the Group; (v) to review the Company's compliance with the CG Code and disclosure in the Corporate Governance Report as required under the CG Code; and (vi) to consider, review and decide other matters, as authorised by the Board.

CORPORATE GOVERNANCE REPORT

Corporate Governance Committee *(Continued)*

During the Year and up to the date of this report, the Corporate Governance Committee comprised the following Directors:

Name of Director	Position
Ms. Wang Qiuqin (<i>Chairman</i>)	Executive Director
Mr. Huo Zhihong (resigned on 16 October 2024)	Executive Director
Ms. Zhou Wan (appointed on 16 October 2024)	Executive Director
Mr. Sy Lai Yin, Sunny	Independent non-executive Director

The Corporate Governance Committee held one meeting during the Year and reviewed (i) the Company's policies and practices on corporate governance; (ii) the training and continuous professional development of Directors and senior management of the Group; (iii) the Company's policies and practices on compliance with legal and regulatory requirements; (iv) the code of conduct and compliance manual applicable to the Directors and employees of the Group; and (v) the Company's compliance with the then prevailing CG Code and disclosure in the Corporate Governance Report as required under the then prevailing CG Code and the Company's policies which provide guidance to the Directors, senior management and relevant employees of the Group in handling confidential information and monitoring information disclosure. All members of the Corporate Governance Committee attended the meeting during the Year.

Corporate Governance Functions

The Board and the Corporate Governance Committee have reviewed the Company's policies and practices on corporate governance and compliance with the CG Code applicable during the Year, reviewed and monitored the training and continuous professional development of the Directors and senior management of the Group and reviewed and monitored the Company's policies and practices on compliance with legal and regulatory requirements during the Year.

Accountability and Audit

The Directors acknowledge their responsibility for preparing the financial statements of the Group which give a true and fair view of the state of affairs of the Group and of the profit and cash flows for the Year. The Directors have prepared the financial statements of the Group on a going concern basis, and have applied appropriate accounting policies consistently, in accordance with applicable disclosure requirements under the Listing Rules and pursuant to the relevant statutory requirements.

The statement issued by the auditor of the Company, Moore CPA Limited, regarding their reporting responsibilities is set out in the section headed "Independent Auditor's Report" on pages 60 to 65 of this annual report.

CORPORATE GOVERNANCE REPORT

Internal Controls and Risk Management

The Board acknowledges its responsibility for the internal control of the Group, including risk management, and setting up appropriate policies having regard to the objectives of the Group and the review of the effectiveness of the internal control system, including risk management of the Group. The system of internal control is designed to manage rather than eliminate the risk of failure to achieve business objectives and can only provide reasonable but not absolute assurance against material misstatement or loss. Controls are monitored by management review on an on-going basis. The Group's internal control systems and risk management systems have been developed with the following features and processes: Management (1) identifies significant risks in the Group's operational environment that may impact the business of the Group; (2) evaluates the impacts of those significant risks identified and the likelihood of the significant risks occurrence; (3) determines the risk management strategies and internal control processes to mitigate the risks; (4) performs on-going monitor and review of the effectiveness of the risk management strategies and internal control processes; and (5) reports to the Board on all findings regularly. The Board (1) determines the Group's risks tolerance level; and (2) oversees the Group's overall design and implementation on risk management and internal control systems.

In order to enhance the Group's system of handling inside information and ensure that inside information is handled and disseminated properly and in accordance with the applicable laws and regulatory requirements, the Group adopts and implements an inside information policy and procedures. Certain reasonable measures have been taken from time to time to ensure that proper safeguards exist to prevent a breach of a disclosure requirement in relation to the Group, which include:

- the access of information is restricted to the Board and a limited number of employees on a need-to-know basis. Employees who are in possession of inside information understand their obligations to keep it confidential under the Group's inside information policy and procedures; and
- the Board would seek independent professional advice to ensure that the Company complies with the disclosure requirements, when appropriate.

The Board has engaged an independent professional firm to review the effectiveness and adequacy of the internal control systems of the Group, covering significant operating cycles for the Year. Such review is conducted annually. The scope of the review has been previously determined and approved by the Board and the Audit Committee. The independent professional firm has reported major findings and areas of improvement to the Board. All the recommendations have been properly followed up by the Group to ensure that they will be implemented within a reasonable period of time. The Board is of the view that the Group's current risk management and internal control systems which are reviewed annually and cover all material controls, including financial, operational and compliance controls, are adequate and effective throughout the Year. The Board, through the Audit Committee, reviewed the adequacy of resources, staff qualifications and experience, training programmes, and budget of the Group's accounting and financial reporting functions as well as those relating to the Company's environmental, social and governance performance and reporting during the Year, and considered that such systems are effective and adequate.

The Group has not established a standalone internal audit department. The Board and the Audit Committee have conducted an annual review on the need of setting up an internal audit function and having taken into account the scale of the Group, the Board and the Audit Committee have considered that the setting up of an internal audit function was not necessary for the time being and the Board might consider engaging external services provider to perform the internal audit function in future.

CORPORATE GOVERNANCE REPORT

Auditor's Remuneration

The auditor of the Company, Moore CPA Limited, provided statutory audit services and non-audit services to the Group for the Year. The Audit Committee is responsible for making recommendations to the Board on the appointment, re-appointment, removal and remuneration of the external auditor.

Fees paid or payable by the Group to the Company's auditor for the Year are set out as follows:

Type of services provided	Fees paid/payable
Audit services	HK\$1,350,000

Constitutional Documents

There had been no changes to the Bye-laws during the Year. The existing version of the Bye-laws is posted on the designated website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.newraymedicine.com).

The Board proposes to seek approval from the Shareholders at the forthcoming annual general meeting to amend the existing Bye-laws in order to (i) bring the existing Bye-laws to be in line with the latest regulatory requirements of the Listing Rules in relation to the expanded paperless listing regime and the mandatory electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules; (ii) modernise the existing Bye-laws to expressly allow the Company to convene and hold electronic meetings and/or hybrid meetings in addition to physical meetings; (iii) provide the Company with flexibility to hold treasury shares under the Bye-laws; and (iv) make other miscellaneous and housekeeping amendments, as well as update certain provisions with reference to the latest applicable laws of Bermuda and the Listing Rules. Details of such proposed amendments will be announced and published in the circular to be sent to the Shareholders.

Communication with Shareholders and Investors

Shareholders Communication Policy

The Company considers that effective communication with the shareholders of the Company and stakeholders is essential for enhancing investor relations and understanding of the Group's business, performance and strategies. The Company is committed to enhancing long-term shareholder value through regular communication with its shareholders.

The Company maintains an ongoing dialogue with the shareholders and in particular, through annual general meetings and general meetings. In respect of each matter to be considered at the annual general meeting and the general meetings. The Chairman of the Board and the representatives of the Company will be available at the annual general meeting and the general meeting to meet with the shareholders and answer their enquiries. The Company will also invite representatives of the auditor of the Company to attend the annual general meeting of the Company to answer shareholders' questions about the conduct of the audit, the preparation and content of the auditor's report and the auditing matters.

In addition, the Company provides information in relation to the Group to the shareholders of the Company and investors in a timely manner through a number of formal channels, including publication of interim and annual reports, announcements and circulars. Such published documents together with the corporate information of the Group are also available on the Company's website (www.newraymedicine.com). The Company continues to enhance communication and relationship with Shareholders and investors. Designated management of the Company maintains regular dialogue with institutional investors and analysts to keep them informed of the Group's developments.

CORPORATE GOVERNANCE REPORT

Communication with Shareholders and Investors *(Continued)*

Shareholders Communication Policy *(Continued)*

The Board has reviewed the implementation of the shareholders communication policy during the year ended 31 December 2024, and confirms the effectiveness of the same. The Board will continue to review the shareholders communication policy annually.

Subject to applicable laws and regulations, including the Listing Rules and the Bye-laws as amended from time to time, shareholders of the Company may convene a general meeting or put forward proposals in accordance with the following provisions:

1. One or more shareholders holding, at the date of deposit of the requisition, not less than one-tenth of the paid-up capital of the Company having the right of voting at general meetings can deposit a written request to convene a special general meeting at the principal place of business of the Company in Hong Kong for the attention of the Board or the Company Secretary.
2. The written request must state the name of the shareholders concerned, their respective shareholdings, the objects of the meeting, including details of the business(es) and resolutions proposed to be considered and approved at the meeting, signed by the shareholders concerned.
3. The request will be verified by the Company's Branch Share Registrar and upon their confirmation that the request is proper and in order, the Company Secretary will ask the Board to convene a special general meeting by serving sufficient notice in accordance with the statutory requirements to all the shareholders. On the contrary, if the request has been verified as not in order, the shareholders concerned will be advised of this outcome and accordingly, a special general meeting will not be convened as requested.
4. If within 21 days of such deposit of the requisition, the Board fails to proceed to convene such meeting, the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.
5. The notice period to be given to the shareholders in respect of the special general meeting varies according to the nature of the proposal. For notice of the special general meeting at which the passing of a special resolution is to be considered, such notice shall be arranged to be sent to the shareholders at least 21 clear days or 10 clear business days (whichever is longer) before such special general meeting.

Procedures for Shareholders Sending Enquiries to the Board

1. Enquiries about shareholdings

Shareholders should direct their enquiries about their shareholdings to the Company's Branch Share Registrar, Tricor Investor Services Limited, via its online holding enquiry service at www.tricoris.com, or send email to is-enquiries@hk.tricorglobal.com or go in person to its public counter at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

2. Enquiries about corporate governance or other matters to be put to the Board and the Company

The Company does not normally deal with verbal or anonymous enquiries. Shareholders of the Company may send written enquiries to the Company, for the attention of the Board or Company Secretary, by mail to Room 911B, 9th Floor, Tower 1, Silvercord, No. 30 Canton Road, Kowloon, Hong Kong. Shareholders of the Company may call the Company at (852) 2152 2030 for any assistance.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

This Environmental, Social and Governance (“**ESG**”) report of the Group aims to highlight its ESG performance during the Year.

The Group is principally engaged in the business of the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services in the PRC with headquarters in Zhejiang province in the PRC. Further information about the Group’s principal business is disclosed in the sub-section headed “Business Review” in the section headed “Management Discussion and Analysis” in this annual report.

This report covers the Group’s overall performance in two subject areas, namely, Environmental and Social aspects of its operations in the PRC, from 1 January 2024 to 31 December 2024, unless otherwise stated. The reporting scope of this report focuses on the distribution and trading of pharmaceutical and related products of the Group in the PRC, which are operated by the following subsidiaries of the Company including: China New Rich Medicine Holding Co. Limited and Zhejiang Xin Rui Pharmaceutical Co. Ltd. The Group’s operation in Hong Kong is excluded from the scope as it is identified to be insignificant to the overall Group’s operation. This report should be read in conjunction with the Corporate Governance Report on pages 34 to 45 of this annual report in order to have a full understanding on the Group’s relevant performances.

Reporting Standards

This report is prepared in accordance with the Environmental, Social and Governance Reporting Guide as set out in Appendix C2 to the Listing Rules (“**HKEx ESG Reporting Guide**”). The Company has complied with the “comply or explain” provisions set out in the HKEx ESG Reporting Guide for the year ended 31 December 2024. The Group’s management approaches, strategies, priorities and targets of environmental and social aspects are disclosed in this report.

The ESG Governance Structure

The Group manages its ESG issues by employing a top-down management approach, the Board oversees and formulates the Group’s ESG strategies. The Group has set up an ESG working team (the “**ESG team**”) that comprises staff from relevant departments. The ESG team is responsible for collecting relevant ESG data, analysing and identifying the Group’s ESG issues for the Board’s assessment and prioritisation of material ESG-related issues, and reporting to the Board for the review of the progress of ESG-related goals and targets and evaluation and subsequent implementation or revision of the Group’s ESG strategies.


The Board attaches great importance to the appropriate and effective ESG risk management and internal control. The Board reviews ESG performances and identifies related risks annually.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Stakeholder Engagement and Materiality Reporting Principles

In the preparation of this ESG report, the Group has applied the following reporting principles:

Materiality: In order to identify the most significant aspects of the Group for this report, key stakeholders including employees, suppliers, distributors and customers have been involved in regular engagement meetings to discuss and review areas of attention which help the Group meet its potential growth and be prepared for future challenges. Based on the previously identified material ESG issues, a materiality assessment was conducted during the Year by the Group’s stakeholders. The materiality matrix below shows the results of our materiality assessment process:



ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Stakeholder Engagement and Materiality *(Continued)*

Reporting Principles *(Continued)*

Environmental	Social
1 Energy	7 Employment
2 Water	8 Occupational Health and Safety
3 Air Emission	9 Development and Training
4 Waste and Effluent	10 Labour Standards
5 Other Raw Materials Consumption	11 Supply Chain Management
6 Environmental Protection Measures	12 Intellectual Property
	13 Data Protection
	14 Product Quality
	15 Anti-corruption
	16 Community Investment

Quantitative: The details of how the Group quantifies the ESG data in relation to emissions/energy consumption can be found in the respective sections below.

Consistency: Consistent methodologies are employed for a meaningful comparison, using year-on-year data.

The Group has established guidelines to ensure the efficient use of fuel and to reduce air emissions from petrol consumption in its operations, which include switching off the engine whenever the vehicle is idling; and conducting regular vehicle maintenance to ensure optimal engine performance and fuel use.

Stakeholders’ Feedback

The Group welcomes stakeholders’ feedback on our ESG approach and performance. Please give your suggestions or share your views with us via email at info@newraymedicine.com.

The Company’s Sustainability Vision

The Company aims to operate in a sustainable way and targets to become a national leading pharmaceutical distributor. To achieve this goal, the Company plans to continue: (i) expanding through obtaining new exclusive distribution rights in order to diversity its product portfolio; and (ii) enhancing and expanding its market share, local distribution network and marketing efforts in the PRC.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental and Natural Resources

Our Group recognises the importance of environmental protection and the potential impacts that may cause to the natural environment from our operation, and thus strive to minimise our impacts. While we aim to generate revenue for our shareholders and provide the best products and services to our customers, our senior management is also cautious about our environmental impact due to our operational activities, and our compliance with applicable laws and regulatory requirements in the PRC. As our operation covers a wide scope of activities, mainly the distribution and trading of pharmaceutical products in the PRC, we are cautious on identifying our attributable environmental impacts and managing environmental impacts throughout the operations and minimising these attributable impacts if possible.

We have devised an in-house environmental policy with an emphasis on our business environmental management. Whilst environmental awareness programmes have been implemented internally, our customers have been encouraged to join our efforts. Further details and examples of our environmental awareness programmes and activities can be found in the later section of this report.

To cope with the climate change challenge that the world is facing, the Group puts significant effort on environmental protection and reduction of greenhouse gas emissions. The management considered that there are no significant climate-related issues which have impacted or may impact the Group.

Emissions

Air Emissions

The Group took the initiative to examine the issue of air emissions when conducting business activities and the result indicated no significant impact could be reported. Our operations had no significant impact on the environment as our business is not associated with any combustion processes or industrial activities that could lead to direct emissions to the atmosphere, nor did we have any energy generation unit (i.e. diesel generator) in operation.

Our company vehicles generated minor emissions from petroleum consumption. A total of 0.1t of nitrogen oxides, 0.1t particulate matter and 0.1kg of sulphur oxides were produced by vehicle emissions in this reporting year. We will continue to monitor our operation and ensure our air emissions will be maintained at a reasonable level.

Carbon Emissions

Despite the fact that our operations did not contribute significant air pollutant emission, we would still focus our effort on reducing carbon emission and in particular overall carbon footprint. With no direct combustion procedure or energy generation process involved, our operation does not have direct Greenhouse gas emissions. Our Group's carbon emissions are mainly contributed by vehicle emissions and indirect emissions through electricity consumption, which is counted towards our Group's overall carbon footprint. For the delivery of goods, our Group has been collaborating closely with external logistics service providers, trying its best to enhance the efficiency of the supply chain to maintain its economic competitiveness and environmental sustainability. Reducing travelling time and distance is one of our strategic approaches. The key success to stay cost-effective and environmentally sustainable is to optimise the efficiency of the distribution network and communicate with the logistics service providers continuously. We optimise the efficiency of the distribution network and the transportation network so as to save energy and reduce carbon emissions. We estimated our carbon footprint for this reporting year based on electricity consumption and its associated emissions factor provided by our electricity providers (data on electricity consumption is available on the electricity bill from our electricity providers). Our calculation also included the unleaded petroleum consumption in our transportation freight. Consumption data were kept and managed in a database system. With this information available to us, we shall further work with both our employees and external stakeholders to better our performance and minimise our overall carbon emissions. Further information and progress will be disclosed in the subsequent section of this report.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Emissions *(Continued)*

Carbon Emissions *(Continued)*

As a summary, with our efforts to curb the carbon footprint of our Group and based on the data of our electricity consumption and unleaded petroleum consumption, the carbon footprint of our Group in the reporting year was 89.3 tCO₂e, which has increased by approximately 22.3% when compared to 2023.

Summary of our greenhouse gas (GHG) emissions is as follows:

	unit	2024	2023
Direct GHG emissions – Petrol consumption	tCO ₂ e	22.5	19.0
Indirect GHG emissions – Purchased electricity			
– Office	tCO ₂ e	19.4	18.1
– Warehouse	tCO ₂ e	35.1	24.9
Other Indirect Emission – Business air travel	tCO ₂ e	0.2	0.2
Other Indirect Emission – Paper waste disposal at landfills	tCO ₂ e	0.7	1.0
Other Indirect Emission – Electricity used for fresh water and sewage processing	tCO ₂ e	11.4	9.8
Total	tCO ₂ e	89.3	73.0
Intensity	tCO ₂ e /employee	3.1	3.2

Waste Management

As our Group's business does not involve manufacturing or production processes, we are of the view that our operation did not involve handling any hazardous waste, and thus no significant impact was recorded, and the water consumed by the Group equalled the wastewater discharge during the reporting year. The information of water consumption is described under the section headed "Emissions – Resources Conservation – Water" in this report.

Non-hazardous waste

Non-hazardous waste from the Group's operation is mainly paper waste in its general administration. Our employees are constantly reminded of the "Efficient Usage" concept to minimise paper wastage and unnecessary packaging. For example, notices are posted in different office area, reminding our staff of paper recycling, while continuing other paper saving practices among employees (such as e-documentation). We take the initiative further by driving for a paperless working environment. Our staff are encouraged to work and communicate through emails and e-format documents instead of hard copies. The paper consumption of the Group has decreased by approximately 28.6% in the reporting year when compared to 2023 during the reporting year.

The method of handling other non-hazardous waste is to first collect and categorise them, then sell the recyclable non-hazardous waste, including waste plastic materials, to the recycling station. As a result, only insignificant amounts of non-hazardous wastes were disposed of during the reporting year.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Emissions *(Continued)*

Waste Management *(Continued)*

Non-hazardous waste *(Continued)*

Summary of major non-hazardous waste disposal performances is as follows:

	unit	2024	2023
Office paper	Tonnes	0.2	0.2
Packaging materials	Tonnes	2.6	1.4
General waste	Tonnes	52.7	43.3
Total	Tonnes	55.5	44.9
Intensity	Tonnes/employee	1.9	2.0

Due to the Group's business nature, the use of packaging materials is not considered as a material ESG issue to the Group.

Use of Resources

As an environmental friendly company, our Group is actively pursuing the culture of "Efficient Usage" of natural resources, setting energy saving policies with a primary focus on electricity, water, petroleum and non-hazardous waste. The Group keeps looking for efficient and sustainable practices in its business operations for better use of resources.

Internal initiatives such as Energy Conservation and Efficiency Policy and Practices in Offices were promoted and successfully implemented throughout the reporting year. In addition, the concept of "Efficient Usage" was incorporated in different parts of our business operations and was proposed as different actionable items. Details and results will be discussed in the sections below.

Resources Conservation

Our Group adopts a cautious approach in resources conservation and introduces different policies in managing and minimising our impacts to the environment during our business operations.

Electricity

Our Group understands that one of energy generation is a heavy fossil fuel combustion process, and would result in the release of air pollutants and greenhouse gases to the atmosphere. Nevertheless, it is difficult to eliminate all energy consumption in most of our business activities. We are cautious about our electricity consumption and trying our best to minimise our impacts. Our electricity consumption is mainly incurred during its business processes to provide services to customers and in its general administration. In order to minimise its consumption of electricity during its business processes, all employees are reminded to switch off light and air-conditioners before leaving work or meeting rooms. During the Year, the Group also implemented a flexible work measure by allowing our employees to work from home. As such, it could reduce energy consumption in office. The Group is constantly encouraging employees to reduce its carbon footprints through efficient use of electricity. Electricity consumption of the Group has increased by approximately 22.5% in the reporting year when compared to 2023 mainly due to the Group having launched a product of chemical reagents for pharmaceutical in the PRC in 2024, the warehouse has consumed more electricity during the reporting year.

The energy consumption details are presented below:

	unit	2024	2023
Petrol	kWh	79.0	66.9
Electricity			
– Office	kWh	30.8	28.8
– Warehouse	kWh	55.7	39.5
Total	kWh	165.5	135.1
Intensity	kWh/employee	5.7	5.9

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Emissions (Continued)

Resources Conservation (Continued)

Water

We require water as a support to our operation. We consume water responsibly in our business processes. Our Group makes every effort to maintain the same level of water usage as in the past and carries out measures of reduction in general water consumption. The Group also educates the employees on water-saving measures. We consume water responsibly in our general administration processes. To further minimise our consumption of water during the general administration processes, all employees are reminded to conserve water resources and avoid unnecessary flushing. In addition, since our Group is not engaged in manufacturing business, we do not have any issue in sourcing water that is fit for purpose.

Summary of water consumption performance is as follows:

	unit	2024	2023
Total water consumption	m ³	812.0	700.0
Intensity	m ³ /employee	28.0	30.4

During the reporting year, the Group was not aware of any material non-compliance with laws and regulations on environmental protection that have a significant impact on the Group, including but not limited to, the Environmental Protection Law of the People's Republic of China (《中華人民共和國環境保護法》), the Prevention and Control of Environmental Pollution by Solid Waste of the People's Republic of China (《中華人民共和國固體廢物污染環境防治法》), the Water Pollution Prevention and Control Law of the People's Republic of China (《中華人民共和國水污染防治法》) and the Prevention and Control of Atmospheric Pollution of the People's Republic of China (《中華人民共和國大氣污染防治法》).

Social

Employment and Labour Practices

The backbone of the Group's business consists of our team of dedicated employees working professionally and responsibly to support our daily operations. The Group rewards their hard work by offering competitive compensation, while treating all of our staff equally and fairly, and complying with laws and regulations has always been one of our Group's guiding principles.

Our employees are entitled to social insurance, medical insurance, body check, annual leave, sick leave, marriage leave, maternity leave, compassionate leave and compensation leave. Details can be found in the Group's Attendance Management Policy. The Group also employs an "Award and Penalty System" in which employees with good performance, responsibility, discipline and act as role models are recognised and given cash bonus, while disciplinary action would be taken if an employee has committed an act of serious misconduct or deceitful behaviours.

Appraisal system is in place to assess the employees' work objectives, performance, attitude and capability. Employees will be promoted with salary adjustment based on the point-based appraisal system and salaries payment scale as written in the Group's Salary Policy.

In general, employees resigning from the Group are required to give one month's written notice stating reason for leaving to their managers. The managers are responsible for hosting a meeting to discuss with employees concerned and are required to fill in relevant documents, which will also be reviewed, discussed and signed by human resources department for final decision. Any appointment, promotion or termination of employment contract will be based on lawful grounds and internal policies. The Group strictly prohibits any kind of unfair or unreasonable dismissals. Further details can be referred to the Group's Dismissal Management Policy.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Social *(Continued)*

Employment and Labour Practices *(Continued)*

During the reporting year, the Group had no material non-compliance with applicable employment and labour related laws and regulations in relation to compensation and dismissal, recruitment and promotion, working hours and rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare that have a significant impact on our Group including Labour Law of the PRC (《中華人民共和國勞動法》) and Labour Contract Law of the PRC (《中華人民共和國勞動合同法》).

Employee Health and Safety

Safety has always been one of the priorities for our Group. We strive to maintain a safe working environment for our employees and regularly review our safety procedures to safeguard employees' well-being.

Our Group has established Safety Protocol according to the applicable laws and regulations relating to health and safety in the PRC such as the Law of the PRC on Prevention and Control of Occupational Diseases (《中華人民共和國職業病防治法》) and the Regulations on Work-Related Injury Insurance (《工傷保險條例》). Our Safety Protocol clearly states our operations maintained with high occupational safety and health standards, and our employees are required to follow our Safety Protocol throughout the operation.

Reminders and instructions in relation to workplace health and safety are also posted in the conspicuous place in office for staff's reference. Employees who violate serious safety procedures can be dismissed according to their employment contracts.

Preventive and control measures are also strictly implemented to ensure the well-being of our employees. For example, the working and resting schedule for our outdoor operations are carefully planned during summer seasons, and frequent rest periods are arranged to minimise the risk to our employees due to direct sunlight exposure under a hot environment. In addition, allowance for cold drinks will be given to employees under such working environment in accordance with Labour Law of the PRC (中華人民共和國勞動法) and Standards for Distribution of High-temperature Subsidies in Zhejiang Province《浙江省高溫補貼發放標準》.

During the reporting year, our Group had no material non-compliance with relevant laws and regulations in relation to a safe working environment and protecting employees from occupational hazards that have a significant impact on our Group. No major accidents were encountered during the Group's business operation and no material injury at workplace was recorded during the past three years including the reporting year.

Development and Training

The Group believes in people development, and our employees are crucial to the sustainable development of our business. Training is an important path to improve the overall quality and provide comprehensive development of the employees and to assure their knowledge and skillset in line with current market trends.

The Group has the vision to assist new employees in adapting to our corporate culture. Specific trainings on corporate culture, rules and regulations and necessary pre-job skills will be provided to all new-recruit. Throughout the reporting year, various training courses covering procurement management, warehouse and delivery management, product knowledge, product storage management, product recall procedure, customer service and complaint procedure, sales and marketing skill, administrative management, risk management, refrigerated products management and emergency preparedness were given to different departments. The Group also encourages employees to pursue their personal development objectives and continue to grow together with the Company.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Social *(Continued)*

Development and Training *(Continued)*

Summary of staff training information during the Year is as follows:

Employee category	Senior Management	Middle Management	Non-Management
Percentage of employees having training during the Year	100.0%	100.0%	100.0%
Average training hours completed per employee	21.3	36.7	41.2

Gender	Male	Female
Percentage of employees having training during the Year	100.0%	100.0%
Average training hours completed per employee	30.8	42.0

Labour Standards

The Group strictly prohibits all forms of child labour and forced labour, and does not hire any person under age 18. During the recruitment process, the Group will conduct background check on potential employee and verify the details concerning the identity of such candidate. The Group 's human resources department strictly abides by the Group's recruitment guidelines throughout the recruitment process. It verifies candidates' identity by checking their identity cards and relevant certificates before employment. In cases of suspected criminal offences, a report should be made to the appropriate authority. In addition, no employees of the Group will be required to work extra hours involuntarily and required to pay compulsory deposits. There was neither child nor forced labour in the Group's operations in the reporting year which was in compliance with Special Protection for Female and Juvenile Workers (女職工和未成年工特殊保護), Chapter VII, and the Labour Law of the PRC (《中華人民共和國勞動法》) and Provisions on the Prohibition against the Use of Child Labour (State Council Order No. 364)《禁止使用童工規定》(國務院令第364號).

Equal Opportunity

Equal opportunities are given to employees in respect of recruitment, training and development, job advancement, and compensation and benefits. Employees are not discriminated against or deprived of such opportunities due to their gender, ethnic background, religion, colour, sexual orientation, age, marital status, family status, retirement, disability and/or pregnancy.

At the end of 2024, the total headcount in the PRC was 23 (all full-time employees). The breakdown of the number of the Group's employees by gender and by age is shown in the table below:

Workforce by Gender	Female	Male
As at 31 December 2024	13	10
Turnover rate during the year	13.3%	–

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Social *(Continued)*

Equal Opportunity *(Continued)*

Workforce by Age Group	<30	30–50	>50
As at 31 December 2024	4	16	3
Turnover rate during the year	–	–	–

Workforce by Geographical Region	Zhejiang Province	Anhui province	Others
As at 31 December 2024	17	2	4
Turnover rate during the Year	–	33.3%	–

Operating Practices

Supplier Management

Our Group maintains good working relationships with suppliers. We look forward to improving the effectiveness and efficiency in the supply chain and reducing relevant costs by capitalising on distributors' functions for:

- marketing and promotion strategies on local markets;
- speeding up the product delivery and payment collection process; and
- improving efficiencies of customers by increasing stock turnover rate.

The Group's employees have accumulated extensive experience in the PRC pharmaceutical industry. To leverage on our knowledge in the industry, our Group has also introduced internal best practices and measures to enhance our performance working with our suppliers and further our performance.

The Group has obtained the Pharmaceutical Operation Permit (藥品經營許可證) from ZFDA in order to carry out our distribution business in the PRC.

During the Year, no material breach of laws and regulations that have a material impact on the Group's business and operations was noted by the Group.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Operating Practices *(Continued)*

Supplier Management *(Continued)*

Supply chain management

The Group sourced the best products for our customers. During the reporting year, 100% of our products were sourced from two suppliers in China. Our prolonged and extensive product sourcing process ensures the quality of our products sourced at the highest compliance standard, and continuous assessments will be performed on existing suppliers on a regular basis and on potential suppliers prior to obtaining new distribution rights of products. In addition, the management will assess the potential suppliers with reference to operation scale, reputation, manufacturing capacity and capabilities, quality of the products, financial performance and historical quality control records. As an extra precautionary measure, the Group appoints an independent search agency to conduct a background search on potential suppliers. The Group is highly attentive to the reputation and reliability of its pharmaceutical product suppliers. Although it does not have specific policy for the management of the environmental and social risks of its supply chain, it evaluates how its suppliers deal with social and environmental issues and ensures that suppliers and their business partners comply with local and international standards on pharmaceutical products. The Group also conducts an annual appraisal of the existing suppliers in order to review the performance of our suppliers and the financial performance of our suppliers.

We believe our industry expertise, strong execution capability and our persistency for the best products allow us to achieve sustainable business growth in the emerging pharmaceutical distribution industry in the PRC.

Product Responsibility

The Group partners with about 30 distributors serving customers of over 800 hospitals, clinics and pharmacies. Product quality is a key element of sustainability of the Group's business.

The Group has standard procedures for inspecting and receiving all the purchased or returned pharmaceutical products. In compliance with the laws and regulations such as The Law on the Administration of Pharmaceuticals of the PRC (《中華人民共和國藥品管理法》) and the Good Supply Practices, a system is developed to control product quality. For example, Quality Inspectors in the Quality Assurance Department must be qualified professionals with academic background related to pharmaceutical, medicine, biology or chemistry, and have attended necessary trainings and are in good health conditions.

Quality Inspectors are required to follow standards and contractual agreements to carry out quality assessment for pharmaceutical products. They must verify suppliers, product name, specifications, formulations, quantity, batch number, manufacturing date, expiry date, origin, product certificates and manufacturing factory test report. For imported products, there should be a copy of stamped Import Drug Registration Certificate or Pharmaceutical Product Registration Certificate, and Import Drug Port Inspection Report or Import Drug Clearance Receipt. Quality Inspectors are also required to check the labels, instructions, packaging, drugs' quality and hygiene.

Moreover, the Group will carry out laboratory or clinical testings on the pharmaceutical products on a sample basis to safeguard the quality of the products.

For employees in Sales and Marketing Department, the Group has policy on managing the quality of sales practices, ensuring no illegal engagement is involved and protecting the customers in terms of product quality in accordance with national laws and regulations such as The Law on the Administration of Pharmaceuticals of the PRC (《中華人民共和國藥品管理法》) etc.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Product Responsibility *(Continued)*

All the products will be stored in the temperature-controlled warehouse by product type and batch number to ensure that they are sold on a first-in-first-out basis. The Group will maintain the warehouse clean and hygienic. The warehouse staff will handle and transport the products with care to avoid causing any damages to the pharmaceutical and related products. The quality control inspectors check the temperature of the storage area twice a day. They also undertake maintenance inspection and compile a series of records including the name, the specifications, the batch number, the validity period, the sampling method and numbers, the result of the inspections of the products. Those records will be kept for one to three year(s) after the expiry date of the products. The records can be retrieved from the database system with manager's approval.

To maintain a good working condition and prevent products from contamination, the Group has established policy of the management of environmental hygiene and employees' health condition. For example:

- Employees are responsible for keeping the floor, windows, product shelves and products clean and without dust;
- There is no water leakage, spider web, ashes, insects or rats, cigarettes in the warehouse;
- Employees should ensure proper temperature and good ventilation at working place, with adjustment in different seasons.

There were no products sold or shipped subject to recalls and no complaints related to our products or services were received by the Group in 2024. The Group periodically reviews its product quality and remedial solutions to address defective products, if any. When defective products are identified, the Group implements appropriate measures, including product returns and recalls, depending on the extent and impact of the defects.

For our pharmaceutical products distribution and other related businesses, during the reporting year, no material non-compliance was noted by the Group in relation to the relevant laws and regulations of the PRC concerning health and safety, advertising, labeling and privacy matters relating to products and services provided and methods of redress, including but not limited to the Law on the Administration of Pharmaceuticals of the PRC (《中國人民共和國藥品管理法》), the Implementation Regulations of the Law on the Administration of Pharmaceuticals of the PRC (《中國人民共和國藥品管理法實施條例》), the Measures on the Administration of the Pharmaceutical Operation Permit (《藥品經營許可證管理辦法》), the Good Supply Practices for Medicine Distribution Quality (《藥品經營質量管制規範》), the Administrative Measures for the Import of Drugs (《藥品進口管理辦法》), which have a material impact on the business of the Group.

Protection of Intellectual Property and Data Confidentiality

Our Group is dedicated to protecting and enforcing its intellectual property rights. Intellectual property rights are crucial to the Group's sustainable business growth and its ability to differentiate itself from its competitors. The Group's intellectual property rights (such as trademarks) have been registered in accordance with the laws and regulations of the PRC. Our Group makes sure that the protection of its intellectual property rights through registration, maintenance and enforcement measures.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Product Responsibility *(Continued)*

Protection of Intellectual Property and Data Confidentiality *(Continued)*

Our Group is committed to abiding by the laws in relation to customer privacy, such as the Law of the PRC on the Protection of Consumer Rights and Interests (《中華人民共和國消費者權益保護法》) and other relevant laws and regulations to ensure customers' rights are strictly protected. All personal data of customers collected during the course of business are treated as confidential. The Group has adopted an internal privacy policy to ensure clients' transactions and information are protected. Through internal trainings and confidentiality agreements with its employees, the Group stresses the importance of fulfilling the duties in confidentiality and the legal consequences of violating the agreements to its employees.

Anti-corruption

The Group adopted a whistleblowing policy (舉報政策) on 15 October 2012, as revised on 18 March 2013 and 31 January 2022 which clearly states guidelines on reporting the following misconduct and malpractice:

- Dishonesty;
- Fraud;
- Corruption;
- Illegal behaviour (including theft, trafficking/taking of drugs, use of violence or threat of using violence and criminal damage to property);
- Discrimination;
- Sexual harassment;
- Breaches against the laws of the PRC or bye-laws;
- Immoral behaviour;
- Extortion;
- Other serious misconduct (including serious mismanagement, serious and significant waste or repeated violations of administrative procedures);
- Dangerous working practices;
- Failure in compliance with the Group's policy;
- Any other act which may result in financial or non-financial loss to the Group.

Under such whistleblowing policy, the employees are encouraged to report any reportable conduct (such as corruption or fraudulent behaviors) directly to the incident manager, Ms. Wang Qiuqin. No reports or related complaints were received from employees and no concluded legal cases regarding corrupt practices were brought against the Group or its employees in 2024.

The Company has from time to time provided training materials of anti-corruption to all Directors at least once annually. All Directors had confirmed that he/she had read the training materials.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Anti-corruption *(Continued)*

During the reporting year, our Group complied with the Law of the PRC on Anti-money Laundering (《中華人民共和國反洗錢法》) and the Anti-Unfair Competition Law of the PRC (《中華人民共和國反不正當競爭法》) and relevant laws and regulations regarding bribery, extortion, fraud and money laundering, which have a material impact on the business of the Group in all material respects.

Community

Our Group understands the importance of our business is to generate and bring in profit to our shareholders, and also being socially responsible to care, serve and give back to our community wherever is needed at the same time.

Community Investment

In recent years, the Group made donations supporting various community activities to fulfill social responsibilities. Together with our staff, our Group is dedicated and committed to fully supporting local charity organisations, non-governmental organisations and their volunteering activities by allocating portion of our revenue to build a better local community.

The Group donated approximately HK\$154,000 to the organisations that strive to improve the living for the poor in Hangzhou during the reporting year.

INDEPENDENT AUDITOR'S REPORT



Moore CPA Limited

1001-1010, North Tower
World Finance Centre, Harbour City
19 Canton Road, Tsim Sha Tsui
Kowloon, Hong Kong

T +852 2375 3180

F +852 2375 3828

www.moore.hk

大
華
馬
施
會
計
師
事
務
所
有
限
公
司

To the shareholders of New Ray Medicine International Holding Limited

(incorporated in Bermuda with limited liability)

Opinion

We have audited the consolidated financial statements of New Ray Medicine International Holding Limited (the “**Company**”) and its subsidiaries (collectively referred to as the “**Group**”) set out on pages 66 to 132, which comprise the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2024, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

Basis for Opinion

We conducted our audit in accordance with Hong Kong Standards on Auditing (“**HKSAs**”) issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the HKICPA’s Code of Ethics for Professional Accountants (the “**Code**”) and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INDEPENDENT AUDITOR'S REPORT

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters below to be the key audit matters to be communicated in our report.

Key audit matters

How our audit addressed the key audit matters

Assessment of loss allowance for expected credit loss ("ECL") on deposits paid to suppliers

We identified the assessment of loss allowance for ECL on deposits paid to suppliers as a key audit matter due to significant judgment exercised by the Group's management on the assessment. In determining the loss allowance for ECL on deposit paid to suppliers, a considerable amount of judgement is required in assessing the ultimate realisation of these deposits paid to suppliers, including their current creditworthiness and the risk of default. The assessment on the probability of default and loss given default is based on credit rating adjusted by future economy.

As disclosed in notes 4 and 21 to the consolidated financial statements, the carrying amount of deposits paid to suppliers is approximately HK\$131,391,000 net of impairment loss allowance of approximately HK\$8,474,000 as at 31 December 2024.

Our procedures in relation to the assessment of loss allowance for ECL on deposits paid to suppliers included:

- Understood and evaluated the key controls over the impairment assessment of the deposits paid to suppliers, which related to management's identification of events that triggered the provision for impairment of the deposits and estimation of the amount of allowance;
- Inspected the agreements entered into between the Group and the suppliers and other relevant information relating to the suppliers as assessed by the Group;
- Assessed the reasonableness of the Group's ECL model and the criteria for assessing if there has been significant increase in credit risk and so allowances for financial assets should be measured on a lifetime ECL basis; and
- Circulated auditor's confirmations and conducted interview with the suppliers on sampling basis to test the existence of the deposits paid to suppliers as at the end of the reporting period.

INDEPENDENT AUDITOR'S REPORT

Key Audit Matters *(Continued)*

Key audit matters	How our audit addressed the key audit matters
<p><i>Valuation of investments in unquoted equity instruments at fair value through other comprehensive income ("FVTOCI") and unquoted investments in financial assets at fair value through profit or loss ("FVTPL")</i></p> <p>We identified the valuation of unquoted investments in equity instruments at FVTOCI and unquoted financial assets at FVTPL as a key audit matter due to significant judgment exercised by the Group's management on the valuation.</p> <p>As disclosed in notes 4 and 18 to the consolidated financial statements, the fair values of the unquoted equity instruments at FVTOCI and unquoted financial assets at FVTPL are HK\$12,907,000 and HK\$44,138,000 respectively as at 31 December 2024. The valuation is carried out by external independent valuers (the "Valuers") engaged by the Group and/or by the management of the Group.</p> <p>In determining the fair values of the unquoted investments in equity instruments at FVTOCI and unquoted financial assets at FVTPL at the end of the reporting period, significant judgements and estimation are required, as detailed in notes 4 and 18 and 29(c)(i) to the consolidated financial statements.</p> <p>Management has concluded that the adopted methodologies and inputs used in determining the fair values of unquoted equity instruments at FVTOCI and unquoted financial assets at FVTPL are reasonable and appropriate.</p>	<p>Our procedures in relation to the valuation of unquoted investments in equity instruments at FVTOCI and unquoted financial assets at FVTPL included:</p> <ul style="list-style-type: none">• Discussed with management and the Valuers how the Group estimated the fair values of unquoted investments in equity instruments at FVTOCI and unquoted financial assets at FVTPL including the valuation model adopted and key assumptions used;• Assessed the competence, capabilities and objectivity of the Valuers performing the valuation; and• Evaluated the reasonableness of the valuation methodology and key assumptions used.

INDEPENDENT AUDITOR'S REPORT

Other Information

The directors of the Company are responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Directors and Those Charged with Governance for the Consolidated Financial Statements

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Our report is made solely to you, as a body, in accordance with Section 90 of the Bermuda Companies Act, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

INDEPENDENT AUDITOR'S REPORT

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

(Continued)

As part of an audit in accordance with HKSAAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

INDEPENDENT AUDITOR'S REPORT

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

(Continued)

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Moore CPA Limited

Certified Public Accountants

Leung Man Chung

Practising Certificate Number: P08074

Hong Kong, 25 March 2025

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended 31 December 2024

	Notes	2024 HK\$'000	2023 HK\$'000
Revenue	5	93,945	50,154
Cost of sales		(82,453)	(37,213)
		11,492	12,941
Other income, gains and losses, net	7	2,052	(1,310)
Selling and distribution expenses		(15,877)	(14,067)
Administrative expenses		(14,724)	(14,629)
Finance costs	8	(102)	(32)
Impairment loss on trade and other receivables	10	(5,712)	(4,067)
Impairment loss on inventories	10	(13,114)	(1,601)
Fair value gain on financial assets at FVTPL	10	3,925	423
Loss before taxation		(32,060)	(22,342)
Income tax credit	9	1,047	172
Loss for the year attributable to owners of the Company	10	(31,013)	(22,170)
Other comprehensive income (expense) for the year			
<i>Items that will not be reclassified subsequently to profit or loss:</i>			
Exchange difference arising on translation of functional currency to presentation currency		(8,184)	(2,656)
Fair value gain (loss) on equity instruments at FVTOCI		29,900	(20,578)
Other comprehensive income (expense) for the year		21,716	(23,234)
Total comprehensive expense for the year attributable to owners of the Company		(9,297)	(45,404)
Loss per share	13		
Basic and diluted (<i>HK cents</i>)		(1.86)	(1.33)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 31 December 2024

	Notes	2024 HK\$'000	2023 HK\$'000
Non-current assets			
Property, plant and equipment	14	10,639	12,016
Right-of-use assets	15	20,171	17,403
Prepayment for a distribution right	16	–	2,856
Intangible asset	17	–	–
Equity instruments at FVTOCI	18	102,367	43,067
Financial assets at FVTPL	18	44,138	36,608
Other prepayment	20	–	1,457
		177,315	113,407
Current assets			
Inventories	19	20,104	31,167
Trade and other receivables	20	241,456	240,219
Prepayment for a distribution right	16	2,105	2,856
Bank balances and cash	22	64,255	103,954
		327,920	378,196
Current liabilities			
Trade and other payables	23	26,167	5,267
Lease liabilities	24	1,145	288
		27,312	5,555
Net current assets		300,608	372,641
Total assets less current liabilities		477,923	486,048
Non-current liabilities			
Lease liabilities	24	2,404	–
Deferred tax liabilities	25	4,563	5,795
		6,967	5,795
		470,956	480,253

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 31 December 2024

	Notes	2024 HK\$'000	2023 HK\$'000
Capital and reserves			
Share capital	26	83,592	83,592
Share premium and reserves		387,364	396,661
Equity attributable to owners of the Company		470,956	480,253

The consolidated financial statements on pages 66 to 132 were approved and authorised for issue by the Board of Directors on 25 March 2025 and are signed on its behalf by:

WANG QIUQIN
DIRECTOR

CHU XUEPING
DIRECTOR

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2024

	Attributable to owners of the Company								Total HK\$'000
	Share capital HK\$'000	Share premium HK\$'000	Contributed surplus HK\$'000 (note a)	PRC statutory reserve HK\$'000 (note b)	FVTOCI (non-recycling) reserve HK\$'000 (note c)	Share options reserve HK\$'000 (note 30)	Translation reserve HK\$'000 (note d)	Accumulated losses HK\$'000	
At 1 January 2023	83,592	607,614	50,167	23,729	(166,093)	10,393	(19,530)	(64,215)	525,657
Loss for the year	-	-	-	-	-	-	-	(22,170)	(22,170)
Other comprehensive expense for the year	-	-	-	-	(20,578)	-	(2,656)	-	(23,234)
Total comprehensive expense for the year	-	-	-	-	(20,578)	-	(2,656)	(22,170)	(45,404)
Disposals of equity instruments at FVTOCI	-	-	-	-	1,585	-	-	(1,585)	-
Forfeited share options	-	-	-	-	-	(1,089)	-	1,089	-
At 31 December 2023	83,592	607,614	50,167	23,729	(185,086)	9,304	(22,186)	(86,881)	480,253
At 1 January 2024	83,592	607,614	50,167	23,729	(185,086)	9,304	(22,186)	(86,881)	480,253
Loss for the year	-	-	-	-	-	-	-	(31,013)	(31,013)
Other comprehensive income (expense) for the year	-	-	-	-	29,900	-	(8,184)	-	21,716
Total comprehensive income (expense) for the year	-	-	-	-	29,900	-	(8,184)	(31,013)	(9,297)
At 31 December 2024	83,592	607,614	50,167	23,729	(155,186)	9,304	(30,370)	(117,894)	470,956

Notes:

- (a) Included in contributed surplus, HK\$70,167,000 represents the difference arising from share swap pursuant to the Group's reorganisation during the year ended 31 December 2013, such amount is net off with HK\$20,000,000 dividend declaration during the year ended 31 December 2014.
- (b) For the Company's subsidiaries, 浙江新銳醫藥有限公司 (in English, for identification purpose only, Zhejiang Xin Rui Pharmaceutical Co. Ltd.) ("Zhejiang Xin Rui") and 浙江泓銳貿易有限公司 (in English, for identification purpose only, Zhejiang Hong Rui Trading Co. Ltd.) ("Hong Rui Trading"), as stipulated by the relevant laws and regulations in the People's Republic of China (the "PRC"), they are required to maintain a statutory surplus reserve fund. Appropriation to such reserve is made out on 10% of the net profit after taxation as reflected in the statutory financial statements of the PRC subsidiaries in accordance with relevant laws and regulations applicable to PRC enterprises. The statutory surplus reserve fund can be used to make up prior years' losses, if any, and can be applied in conversion into capital by means of capitalisation issue. The statutory surplus reserve can be released to the retained profits upon the dissolution or winding up of the entity.

For 泓銳(杭州)生物醫藥科技有限公司 (in English, for identification purpose only, Hong Rui (Hangzhou) Bio-medical Technology Co. Ltd.) ("Hong Rui Bio-medical"), another subsidiary of the Company, as it is a wholly foreign owned enterprise, appropriation to statutory surplus reserve fund is based on the management's discretion.
- (c) Any cumulative gains or losses arising from the revaluation of the Group's equity instruments at FVTOCI have been recognised in the FVTOCI (non-recycling reserve) in other comprehensive income. Upon disposal of the equity security, the amount accumulated in other comprehensive income is transferred directly to retained profits/accumulated losses.
- (d) Translation reserve represents exchange differences relating to the translation of the net assets of the Group from their functional currencies to the Group's presentation currency (i.e. Hong Kong dollar) which are recognised directly in other comprehensive income and accumulated in the translation reserve. Such exchange differences accumulated in the translation reserve will not be reclassified subsequently to profit or loss.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 December 2024

	Notes	2024 HK\$'000	2023 HK\$'000
OPERATING ACTIVITIES			
Loss before taxation		(32,060)	(22,342)
Adjustments for:			
Amortisation of prepayment for a distribution right	10	3,493	3,557
Depreciation of property, plant and equipment	14	1,701	3,017
Depreciation of right-of-use assets	15	1,610	1,415
Amortisation of an intangible asset	17	–	1,778
Interest expenses	8	102	32
Gain on disposal of property, plant and equipment	7	(142)	(482)
Interest income	7	(1,971)	(2,968)
Dividend income from equity instruments at FVTOCI	7	(561)	(716)
Fair value gain on financial assets at FVTPL	10	(3,925)	(423)
Impairment loss on prepayment for a distribution right	16	–	1,033
Impairment loss on intangible asset	17	–	2,795
Impairment loss on trade and other receivables	10	5,712	4,067
Impairment loss on inventories	19	13,114	1,601
Operating cash flows before movements in working capital		(12,927)	(7,636)
(Increase) decrease in inventories		(2,606)	1,984
Increase in trade and other receivables		(10,399)	(38,800)
Increase (decrease) in trade and other payables		21,166	(955)
Cash used in operations		(4,766)	(45,407)
Income tax paid		–	–
NET CASH USED IN OPERATING ACTIVITIES		(4,766)	(45,407)
INVESTING ACTIVITIES			
Interest received	7	1,971	2,968
Dividend received from equity instruments at FVTOCI		561	671
Investment in a financial asset at FVTPL		(14,320)	(10,715)
Investment in an equity instrument at FVTOCI		(29,400)	(2,865)
Proceeds from disposal of property, plant and equipment		193	592
Proceeds from disposal of equity instruments at FVTOCI		–	3,380
Proceeds from capital distribution of FVTPL		10,715	–
Acquisition of property, plant and equipment	14	(622)	(44)

CONSOLIDATED STATEMENT OF CASH FLOWS

For the year ended 31 December 2024

	Notes	2024 HK\$'000	2023 HK\$'000
NET CASH USED IN INVESTING ACTIVITIES		(30,902)	(6,013)
FINANCING ACTIVITIES			
Payment for principal portion of lease liabilities	32	(1,479)	(981)
Payment for interest portion of lease liabilities	32	(102)	(32)
NET CASH USED IN FINANCING ACTIVITIES		(1,581)	(1,013)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(37,249)	(52,433)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR		103,954	154,413
EFFECT OF FOREIGN EXCHANGE RATE CHANGES		(2,450)	1,974
CASH AND CASH EQUIVALENTS AT END OF THE YEAR			
Represented by bank balances and cash		64,255	103,954

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

1. GENERAL

New Ray Medicine International Holding Limited was incorporated on 9 August 2012 and registered as an exempted company with limited liability in Bermuda.

The shares of the Company are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the **"Stock Exchange"**). The addresses of the registered office and principal place of business in Hong Kong of the Company are disclosed in the corporate information section of this annual report.

The Company is an investment holding company. Its principal subsidiaries are principally engaged in the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services in the People's Republic of China (the **"PRC"**).

The Company's functional currency is Renminbi (**"RMB"**). However, the consolidated financial statements are presented in Hong Kong dollars (**"HK\$"**) for the convenience of shareholders as it is listed in Hong Kong.

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (**"HKFRSs"**)

Amendments to HKFRSs that are mandatorily effective for the current year

In the current year, the Group has applied the following amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountants (**"HKICPA"**) for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2024 for the preparation of the consolidated financial statements:

Amendments to HKFRS 16	Lease Liability in a Sale and Leaseback
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020)
Amendments to HKAS 1	Non-current Liabilities with Covenants
Amendments to HKAS 7 and HKFRS 7	Supplier Finance Arrangements

The application of the amendments to HKFRSs in the current year had no material impact on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

2. APPLICATION OF NEW AND AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (Continued)

New and amendments to HKFRSs in issue but not yet effective

The Group has not early applied the following new and amendments to HKFRSs that have been issued but are not yet effective:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments ³
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity ³
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ¹
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11 ³
Amendments to HKAS 21	Lack of Exchangeability ²
Amendments to HKFRS 18	Presentation and Disclosure in Financial Statements ⁴

¹ Effective for annual periods beginning on or after a date to be determined.

² Effective for annual periods beginning on or after 1 January 2025.

³ Effective for annual periods beginning on or after 1 January 2026.

⁴ Effective for annual periods beginning on or after 1 January 2027.

Except for the new and amendments to HKFRSs mentioned below, the directors of the Company anticipate that the application of all other new and amendments to HKFRSs will have no material impact on the consolidated financial statements in the foreseeable future.

HKFRS 18 Presentation and Disclosure in Financial Statements

HKFRS 18 Presentation and Disclosure in Financial Statements, which sets out requirements on presentation and disclosures in financial statements, will replace HKAS 1 Presentation of Financial Statements. This new HKFRS Accounting Standard, while carrying forward many of the requirements in HKAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss, provides disclosures on management-defined performance measures in the notes to the financial statements and improves aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some HKAS 1 paragraphs have been moved to HKAS 8 and HKFRS 7. Minor amendments to HKAS 7 Statement of Cash Flows and HKAS 33 Earnings per Share are also made.

HKFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after 1 January 2027, with early application permitted. The application of the new standard is expected to affect the presentation of the statement of profit or loss and disclosures in the future financial statements. The Group is in the process of assessing the detailed impact of HKFRS 18 on the Group’s consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION

The consolidated financial statements have been prepared in accordance with HKFRSs issued by the HKICPA. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in accounting policies set out below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of HKFRS 2 "Share-based payment", leasing transactions that are accounted for in accordance with HKFRS 16, and measurements that have some similarities to fair value but are not fair value, such as net realisable value in HKAS 2 "Inventories" or value in use in HKAS 36 "Impairment of assets".

Basis of consolidation

The consolidated financial statements incorporate the financial information of the Company and entities controlled by the Company and its subsidiaries.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Revenue from contracts with customers

The Group recognises revenue when (or as) a performance obligation is satisfied, i.e. when “control” of the goods or services underlying the particular performance obligation is transferred to the customer.

A performance obligation represents a good or service (or a bundle of goods or services) that is distinct or a series of distinct goods or services that are substantially the same.

Revenue is recognised at a point in time when the customer obtains control of the distinct good or service.

A contract liability represents the Group’s obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

A contract liability relating to the same contract are accounted for and presented on a net basis.

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods sold in the normal course of business, net of discounts and sales related taxes.

Revenue is recognised when the amount of revenue can be reliably measured; when it is probable that future economic benefits will flow to the Group and when specific criteria have been met for each of the Group’s activities, as described below.

Revenue from sales of goods is recognised when goods are received by and title have passed to the customers.

For marketing and promotion services income, the Group promotes customers’ medical products and chemical reagents, and the Group is only entitled to consideration from the customers when the ultimate users make sales order from the Group’s customers and the Group does not have inventory risk.

Refund liabilities

The Group recognises a refund liability if the Group expects to refund some or all of the consideration received from customers.

Dividend income from investments is recognised when the shareholders’ rights to receive payment have been established.

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial asset to that asset’s net carrying amount on initial recognition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Leases

Definition of a lease

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

For contracts entered into or modified on or after the date of initial application or arising from business combinations, the Group assesses whether a contract is or contains a lease based on the definition under HKFRS 16 at inception, modification date or acquisition date, as appropriate. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed. As a practical expedient, leases with similar characteristics are accounted on a portfolio basis when the Group reasonably expects that the effects on the consolidated financial statements would not differ materially from individual leases within the portfolio.

The Group as a lessee

Non-lease components are separated from lease components and are accounted for by applying other applicable standards.

Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to leases of properties that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. It also applies the recognition exemption for lease of low-value assets.

Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis or another systematic basis over the lease term.

Right-of-use assets

The cost of right-of-use asset includes:

- the amount of the initial measurement of the lease liability;
- any lease payments made at or before the commencement date, less any lease incentives received;
- any initial direct costs incurred by the Group; and
- an estimate of costs to be incurred by the Group in dismantling and removing the underlying assets, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term are depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Leases *(Continued)*

The Group as a lessee *(Continued)*

Refundable rental deposits

Refundable rental deposits paid are accounted under HKFRS 9 Financial Instruments ("**HKFRS 9**") and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets.

At the commencement date of a lease, the Group recognises and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

The lease payments include:

- fixed payments (including in-substance fixed payments) less any lease incentives receivable;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable by the Group under residual value guarantees;
- the exercise price of a purchase option if the Group is reasonably certain to exercise the option; and
- payments of penalties for terminating a lease, if the lease term reflects the Group exercising an option to terminate the lease.

After the commencement date, lease liabilities are adjusted by interest accretion and lease payments.

The Group presents lease liabilities as a separate line item on the consolidated statement of financial position.

Property, plant and equipment

Property, plant and equipment including buildings held for administrative purposes are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any.

Depreciation is recognised so as to write off the cost of assets less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal or retirement of an item of property, plant and equipment is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognised in profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Impairment on property, plant and equipment, right-of-use assets and prepayment for a distribution right

At the end of the reporting period, the Group reviews the carrying amounts of its property, plant and equipment, right-of-use assets and prepayment for a distribution right to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of property, plant and equipment, right-of-use assets and prepayment for a distribution right are estimated individually. When it is not possible to estimate the recoverable amount of an asset individually, the Group estimates the recoverable amount of the cash-generating unit to which the assets belong. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or a cash-generating unit) for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or a cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or a cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the entity's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise.

For the purposes of presenting the consolidated financial statements, the assets and liabilities of the Group's operation are translated into the presentation currency of the Group (i.e. Hong Kong dollars) using exchange rates prevailing at the end of each reporting period. Income and expenses items are translated at the average exchange rates for the year, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the date of transactions are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity under the heading of translation reserve.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Foreign currencies *(Continued)*

On the disposal of a foreign operation (that is, a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation, or a partial disposal of an interest in a joint arrangement or an associate that includes a foreign operation of which the retained interest becomes a financial asset), all of the exchange differences accumulated in equity in respect of that operation attributable to the owners of the Company are reclassified to profit or loss. For all other partial disposals (i.e. partial disposals of associates or joint arrangements that do not result in the Group losing significant influence or joint control), the proportionate share of the accumulated exchange differences is reclassified to profit or loss.

Employee benefits

Retirement benefit costs

Payments to defined contribution retirement benefit plans are recognised as an expense when employees have rendered service entitling them to the contributions.

Termination benefits

A liability for a termination benefit is recognised at the earlier of when the group entity can no longer withdraw the offer of the termination benefit and when it recognises any related restructuring costs.

Short-term employee benefits

Short-term employee benefits are recognised at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognised as an expense unless another HKFRS requires or permits the inclusion of the benefit in the cost of an asset.

A liability is recognised for benefits accruing to employees (such as wages and salaries, annual leave and sick leave) after deducting any amount already paid.

Share-based payment

Equity-settled share-based payment transactions

Share options granted to directors and employees of the Company

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in note 30 to the consolidated financial statements.

The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payments reserve). At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payments reserve. For share options that vest immediately at the date of grant, the fair value of the share options granted is expensed immediately to profit or loss.

When share options are exercised, the amount previously recognised in share-based payments reserve will be transferred to share premium. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognised in share options reserve will be transferred to retained profits.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Taxation

Income tax expense represents the sum of current and deferred income tax expense.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit (loss) before taxation because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary difference to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit and at the time of the transaction does not give rise to equal taxable and deductible temporary differences. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and interests in associates and a joint venture, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

For the purposes of measuring deferred tax for leasing transactions in which the Group recognises the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Taxation *(Continued)*

For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies HKAS 12 requirements to the lease liabilities and the related assets separately. The Group recognises a deferred tax asset related to lease liabilities to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised and a deferred tax liability for all taxable temporary differences.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied to the same taxable entity by the same taxation authority.

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

In assessing any uncertainty over income tax treatments, the Group considers whether it is probable that the relevant tax authority will accept the uncertain tax treatment used, or proposed to be used by individual group entities in their income tax filings. If it is probable, the current and deferred taxes are determined consistently with the tax treatment in the income tax filings. If it is not probable that the relevant taxation authority will accept an uncertain tax treatment, the effect of each uncertainty is reflected by using either the most likely amount or the expected value.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is calculated using the weighted average method. Net realisable value represents the estimated selling price for inventories less costs necessary to make the sale.

Financial instruments

Financial assets and financial liabilities are recognised when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis.

Financial assets and financial liabilities are initially measured at fair value except for trade receivables arising from contracts with customers which are initially measured in accordance with HKFRS 15. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognised immediately in profit or loss.

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating interest income and interest expenses over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period to the net carrying amount on initial recognition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets

Classification and subsequent measurement of financial assets

Financial assets that meet the following conditions are subsequently measured at amortised cost:

- the financial asset is held within a business model whose objective is to collect contractual cash flows; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets that meet the following conditions are subsequently measured at equity instruments at FVTOCI:

- the financial asset is held within a business model whose objective is achieved by both selling and collecting contractual cash flows and selling; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measured at FVTPL, except that at initial recognition of a financial asset the Group may irrevocably elect to present subsequent changes in fair value of an equity investment in other comprehensive income if that equity investment is neither held for trading nor contingent consideration recognised by an acquirer in a business combination to which HKFRS 3 “Business Combinations” applies.

In addition, the Group may irrevocably designate a financial asset that are required to be measured at the amortised cost or FVTOCI as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch.

(i) Amortised cost and interest income

Interest income is recognised using the effective interest method for financial assets measured subsequently at amortised cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired. For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial assets from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit impaired.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Classification and subsequent measurement of financial assets (Continued)

(ii) Equity instruments designated as at FVTOCI

Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognised in other comprehensive income and accumulated in the FVTOCI (non-recycling reserve); and are not subject to impairment assessment. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments, and will continue to be held in the FVTOCI (non-recycling reserve).

Dividends from these investments in equity instruments are recognised in profit or loss when the Group's right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment. Dividends are included in the "other income, gains and losses" in profit or loss.

(iii) Financial assets at FVTPL

Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI or designated as FVTOCI are measured at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognised in profit or loss. The net gain or loss recognised in profit or loss excludes any dividend or interest earned on the financial asset and is included in the "other income, gains and losses" line item.

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9

The Group recognises a loss allowance for ECL on financial assets which are subject to impairment assessment under HKFRS 9 (including trade and other receivables and bank balances). The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition.

Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast, 12-month ECL ("**12m ECL**") represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessment are done based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions.

The Group always recognises lifetime ECL for trade receivables. The ECL on these assets are assessed collectively using a provision matrix and, when appropriate, individually for credit-impaired or doubtful debtors.

For all other instruments, the Group measures the loss allowance equal to 12m ECL, unless there has been a significant increase in credit risk since initial recognition, in which case the Group recognises lifetime ECL. The assessment of whether lifetime ECL should be recognised is based on significant increases in the likelihood or risk of a default occurring since initial recognition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (Continued)

(i) Significant increase in credit risk

In assessing whether the credit risk has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly:

- an actual or expected significant deterioration in the financial instrument's external (if available) or internal credit rating;
- significant deterioration in external market indicators of credit risk, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor;
- existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor's ability to meet its debt obligations;
- an actual or expected significant deterioration in the operating results of the debtor; and
- an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor's ability to meet its debt obligations.

Irrespective of the outcome of the above assessment, the Group presumes that the credit risk has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise.

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

(ii) Definition of default

For internal credit risk management, the Group considers an event of default occurs when information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group).

Irrespective of the above, the Group considers that default has occurred when a financial asset is more than 365 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (Continued)

(iii) Credit-impaired financial assets

A financial asset is credit-impaired when one or more events of default that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events:

- (a) significant financial difficulty of the issuer or the borrower;
- (b) a breach of contract, such as a default or past due event;
- (c) the lender(s) of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession(s) that the lender(s) would not otherwise consider;
- (d) it is becoming probable that the borrower will enter bankruptcy or other financial reorganisation; or
- (e) the disappearance of an active market for that financial asset because of financial difficulties.

(iv) Write-off policy

The Group writes off a financial asset when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, for example, when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings, or in the case of trade receivables, when the amounts are over two years past due, whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the Group's recovery procedures, taking into account legal advice where appropriate. A write-off constitutes a derecognition event. Any subsequent recoveries are recognised in profit or loss.

(v) Measurement and recognition of ECL

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risks of default occurring as the weights. The Group uses a practical expedient in estimating ECL on trade receivables using a provision matrix taking into consideration historical credit loss experience, adjusted for forward looking information that is available without undue cost or effort.

Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (Continued)

(v) Measurement and recognition of ECL *(Continued)*

Where ECL is measured on a collective basis or cater for cases where evidence at the individual instrument level may not yet be available, the financial instruments are grouped on the following basis:

- Nature of financial instruments;
- Past-due status;
- Nature, size and industry of debtors; and
- External credit ratings where available.

The grouping is regularly reviewed by management to ensure the constituents of each Group continue to share similar credit risk characteristics.

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit impaired, in which case interest income is calculated based on amortised cost of the financial asset.

Foreign exchange gains and losses

The carrying amount of financial assets that are denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of each reporting period. Specifically:

- For financial assets measured at amortised cost that are not part of a designated hedging relationship, exchange differences are recognised in profit or loss in the 'other income gain and losses, net' line item (note 7) as part of the net exchange gains (losses);
- For debt instruments measured at FVTOCI that are not part of a designated hedging relationship, exchange differences on the amortised cost of the debt instrument are recognised in profit or loss in the 'other income gain and losses, net' line item (note 7) as part of the net exchange gains (losses). As the foreign currency element recognised in profit or loss is the same as if it was measured at amortised cost, the residual foreign currency element based on the translation of the carrying amount (at fair value) is recognised in other comprehensive income in the FVTOCI/revaluation reserve;
- For financial assets measured at FVTPL that are not part of a designated hedging relationship, exchange differences are recognised in profit or loss in the 'other income gain and losses, net' line item as part of the gain (loss) from changes in fair value of financial assets (note 7);
- For equity instruments measured at FVTOCI, exchange differences are recognised in other comprehensive income in the FVTOCI/revaluation reserve.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial assets *(Continued)*

Derecognition of financial assets

The Group derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in profit or loss.

On derecognition of an investment in equity instruments which the Group has elected on initial recognition to measure at FVTOCI, the cumulative gain or loss previously accumulated in the investments revaluation reserve is not reclassified to profit or loss, but is transferred to retained profits.

Classification as debt or equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities. Equity instruments issued by the Group are recognised at the proceeds received, net of direct issue costs.

Financial liabilities and equity instruments

Financial liabilities

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

Financial liabilities at amortised cost

Financial liabilities (including trade and other payables and lease liabilities) are subsequently measured at amortised cost, using the effective interest method.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognised on an effective interest basis.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

3. MATERIAL ACCOUNTING POLICY INFORMATION *(Continued)*

Financial instruments *(Continued)*

Financial liabilities and equity instruments *(Continued)*

Foreign exchange gains and losses

For financial liabilities that are denominated in a foreign currency and are measured at amortised cost at the end of each reporting period, the foreign exchange gains and losses are determined based on the amortised cost of the instruments. These foreign exchange gains and losses are recognised in the 'other income gain and losses, net' line item in profit or loss (note 7) as part of net exchange gains (losses) for financial liabilities that are not part of a designated hedging relationship. For those which are designated as a hedging instrument for a hedge of foreign currency risk, foreign exchange gains and losses are recognised in other comprehensive income and accumulated in a separate component of equity.

The fair value of financial liabilities denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of the reporting period. For financial liabilities that are measured as at FVTPL, the foreign exchange component forms part of the fair value gains or losses and is recognised in profit or loss for financial liabilities that are not part of a designated hedging relationship.

Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or expire. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

4. KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Group's accounting policies, which are described in note 3 to the consolidated financial statements, the directors of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Estimation of fair values of unquoted investments in equity instruments at FVTOCI and unquoted financial assets at FVTPL

The fair values of financial instruments that are not traded in active markets are determined by using discounted cash flow method, market-based valuation technique, etc. according to the nature of the financial instruments. The Group makes assumptions that are mainly based on market conditions existing at the end of each reporting period. Details of the key assumptions used, the impact of changes to these assumptions and the carrying amounts of unquoted equity instruments at FVTOCI and unquoted financial assets at FVTPL are disclosed in notes 18 and 29(c)(i).

Impairment loss on trade receivables

The policy for allowance for doubtful debts of the Group is based on the evaluation of collectability of amounts based on management's estimate. In determining whether impairment is required, the Group takes into consideration the likelihood of collection of debts on an individual basis as well as on a collective basis, including the Group's past experience of collecting payments. Specific allowance is only made for receivables that are unlikely to be collected and is recognised on the difference between the estimated future cash flow expected to receive discounted using the original interest rate and the carrying value. As at 31 December 2024, the carrying amount of trade receivables is approximately HK\$60,393,000 (2023: approximately HK\$55,052,000), net of impairment loss allowance of approximately HK\$44,311,000 (2023: approximately HK\$39,347,000). The provision of ECL is sensitive to changes in estimates. The information about the ECL and the Group's trade receivables are disclosed in note 29(b).

Impairment assessment on property, plant and equipment, right-of-use assets and prepayment for a distribution right

When there is indication that property, plant and equipment, right-of-use assets and prepayment for a distribution right may be impaired, the Group estimates the recoverable amounts of the relevant assets or the cash-generating unit to which the assets belong. When it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit in which the relevant assets are attached to, which is the higher of the value in use or fair value less costs of disposal. The value in use calculation requires the Group to estimate the future cash flows expected to arise from the cash-generating units projected with reference to the projected sales quantities, unit selling prices, unit costs, gross margins and discounted at a suitable discount rate in order to calculate the present value. The estimated uncertainty mainly includes gross margin, discount rate. Where the actual future cash flows are less than expected, or change in facts and circumstances which results in downward revision of future cash, a material impairment loss or a further impairment loss may arise.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

4. KEY SOURCES OF ESTIMATION UNCERTAINTY *(Continued)*

Estimated allowances on deposits paid to suppliers

Management regularly assess the loss allowances for ECL on deposits paid to suppliers. Allowances for these deposits are made based on evaluation of ECL for deposits paid to suppliers and involve exercise of management's judgements. A considerable amount of judgement is required in assessing the ultimate realisation of these deposits paid to suppliers, including their current creditworthiness and the risk of default. The assessment on the probability of default and loss given default is based on credit rating adjusted by future economy. As at 31 December 2024, the carrying amount of deposits paid to suppliers is approximately HK\$131,391,000 (2023: approximately HK\$133,783,000), net of impairment loss allowance of approximately HK\$8,474,000 (2023: impairment loss allowance of approximately HK\$8,818,000) as disclosed in note 21 to the consolidated financial statements. The information about the ECL and the Group's deposits paid to suppliers are disclosed in note 29(b).

Allowance for inventories

The management of the Group reviews the ageing of the inventories at the end of the reporting period, and makes allowance for obsolete and slow-moving inventory items identified that are no longer saleable in the market. The identification of obsolete inventories requires the use of estimation of the net realisable value of items of inventory and estimates on the conditions and usefulness of items of inventories. Where the expectation on the net realisable value is lower than the cost for certain items, a write-down of inventories may arise. As at 31 December 2024, the carrying amount of inventories is approximately HK\$20,104,000 (2023: approximately HK\$31,167,000).

Principal versus agent consideration

During the year ended 31 December 2024, in the opinion of the directors of the Company, it is considered that the Group acts as the principal for sales of chemical reagents as it controls the specified goods before being transferred to the customer after taking into consideration indicators such as the Group being primarily responsible for fulfilling the promise to provide the chemical reagents, being exposed to inventory risk and having discretion in establishing the prices of the chemical reagents. When the Group satisfies the performance obligation, the Group recognises revenue from sales of goods in the gross amount of consideration to which the Group expects to be entitled as specified in the contracts. During the year ended 31 December 2024, the Group recognised revenue relating to sales of chemicals reagents amounted to HK\$39.7 million (2023: nil).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

5. REVENUE

Disaggregation of revenue from contracts with customers by segments is as follows:

Revenue represents the aggregate of the net amounts received and receivable, recognised at a point in time basis, for the year. An analysis of the Group's revenue for the year is as follows:

	2024 HK\$'000	2023 HK\$'000
Distribution and trading of pharmaceutical and related products	88,708	42,852
Provision of marketing and promotion services	5,237	7,302
	93,945	50,154

The Group recognises the marketing and promotion fee from its customers at the time when the ultimate users placed orders to the Group's customers and it is highly probable that a significant reversal in the cumulative revenue recognised will not occur, this is also the time when the services were completed and the Group has the enforceable right for payment.

6. SEGMENT INFORMATION

The Group is principally engaged in the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services in the PRC and the management has organised the Group on the basis of these two types of business activities. Information reported to the chief operating decision maker (the "CODM"), being the executive directors of the Company, for the purposes of resources allocation and assessment of segment performance focuses on types of business activities.

Specifically, the Group's reportable and operating segments are as follows:

- (i) Distribution and trading of pharmaceutical and related products – distribution and trading of drugs and chemical reagents for pharmaceutical; and
- (ii) Provision of marketing and promotion services – provision of marketing and promotion services of drugs and chemical reagents for pharmaceutical.

Segment profit represents the gross profit attributable to each segment after deducting impairment loss on trade and other receivables attributable to each segment. This is the measure reported to the CODM for the purposes of resource allocation and assessment of segment performance.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

6. SEGMENT INFORMATION *(Continued)*

Segment information about these reportable and operating segments is presented below.

Year ended 31 December 2024

	Distribution and trading of pharmaceutical and related products HK\$'000	Provision of marketing and promotion services HK\$'000	Total HK\$'000
REVENUE			
External sales and segment revenue	88,708	5,237	93,945
RESULT			
Segment (loss) profit (Note)	(12,079)	4,745	(7,334)
Other income, gains and losses, net			2,052
Selling and distribution expenses			(15,877)
Administrative expenses			(14,724)
Finance cost			(102)
Fair value gain on financial assets at FVTPL			3,925
Loss before taxation			(32,060)
Included in arriving at segment (loss) profit:			
Impairment loss on trade and other receivables	(5,886)	174	(5,712)
Impairment loss on inventories	(13,114)	–	(13,114)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

6. SEGMENT INFORMATION (Continued)

Year ended 31 December 2023

	Distribution and trading of pharmaceutical and related products HK\$'000	Provision of marketing and promotion services HK\$'000	Total HK\$'000
REVENUE			
External sales and segment revenue	42,852	7,302	50,154
RESULT			
Segment profit (Note)	1,529	5,744	7,273
Other income, gains and losses, net			(1,310)
Selling and distribution expenses			(14,067)
Administrative expenses			(14,629)
Finance cost			(32)
Fair value gain on financial asset at FVTPL			423
Loss before taxation			(22,342)
Included in arriving at segment profit			
Impairment loss on trade and other receivables	(2,863)	(1,204)	(4,067)
Impairment loss on inventories	(1,601)	–	(1,601)

Note: The segment (loss) profit included the impact of impairment loss on trade and other receivables and impairment loss on inventories.

Information of assets and liabilities for operating segments is not provided to CODM for their review. Therefore, no analysis of the Group's assets and liabilities by reportable and operating segments is presented.

Geographical information

The Group's operations are located in the PRC (country of domicile). The geographical location of the Group's non-current assets is substantially situated in the PRC.

All of the Group's revenue from external customers is attributed to the Group entities' country of domicile (i.e. in the PRC).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

6. SEGMENT INFORMATION *(Continued)*

Information about major customers

Revenue from customers of the corresponding years contributing over 10% of the total revenue of the Group are as follows:

	2024 HK\$'000	2023 HK\$'000
Customer A ¹	13,327	15,125
Customer B ¹	N/A ³	11,454
Customer C ¹	13,379	N/A ³
Customer D ²	40,897	N/A ³

¹ The revenue was derived from the distribution and trading of pharmaceutical products.

² The revenue was derived from the distribution and trading of pharmaceutical related products and provision of marketing and promotion services.

³ The customer did not contribute over 10% of the total revenue of the Group in the corresponding year.

7. OTHER INCOME, GAINS AND LOSSES, NET

	2024 HK\$'000	2023 HK\$'000
Bank interest income	1,971	2,968
Penalty	–	(568)
Others	49	(510)
Dividend income from equity instruments at FVTOCI	561	716
Net exchange loss	(671)	(570)
Gain on disposal of property, plant and equipment	142	482
Impairment loss on intangible asset	–	(2,795)
Impairment loss on prepayments for a distribution right	–	(1,033)
	2,052	(1,310)

8. FINANCE COSTS

	2024 HK\$'000	2023 HK\$'000
Interest expense on lease liabilities	102	32

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

9. INCOME TAX CREDIT

	2024 HK\$'000	2023 HK\$'000
Current tax:		
PRC Enterprise Income Tax ("EIT")	73	–
Deferred tax (note 25)	(1,120)	(172)
	(1,047)	(172)

Under the Laws of the PRC on Enterprise Income Tax (the "EIT Laws") and Implementation Regulations of the EIT Laws, the tax rate of the PRC subsidiaries was 25% for the years ended 31 December 2024 and 2023.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands ("BVI"), the Group is not subject to any income tax in those jurisdictions.

The directors of the Company considered the amount involved upon implementation of the two-tiered profits tax rates regime as insignificant to the consolidated financial statements. Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profit for both years.

The tax credit for the year can be reconciled to the loss before taxation per the consolidated statement of profit or loss and other comprehensive income as follows:

	2024 HK\$'000	2023 HK\$'000
Loss before taxation	(32,060)	(22,342)
Tax at the domestic income tax rate of 25% (2023: 25%) (note (i))	(8,015)	(5,585)
Tax effect of income not taxable for tax purpose	(1,350)	(321)
Tax effect of expenses and losses not deductible for tax purposes	1,910	2,868
Tax effect of deductible temporary differences not recognised	6,625	2,117
Tax effect of utilisation of tax losses previously not recognised	(125)	(585)
Tax effect of tax loss not recognised	659	90
Tax effect of utilisation of deductible temporary differences not recognised in prior year	(107)	(123)
Effect of different tax rate of subsidiaries operating in other jurisdictions	476	1,539
Deferred tax on undistributed earnings of PRC subsidiaries and associates	(1,120)	(172)
Income tax credit for the year	(1,047)	(172)

Note:

- (i) The domestic tax rate (which is PRC EIT rate) in the jurisdiction where the operation of the Group is substantially based is used.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

10. LOSS FOR THE YEAR

	2024 HK\$'000	2023 HK\$'000
Loss for the year has been arrived at after charging (crediting):		
Directors' emoluments, including contributions to retirement benefits scheme and equity-settled share-based payment expenses (note 11(a))	3,083	3,080
Other staff's salaries, bonus and other benefits	5,105	4,490
Contributions to retirement benefits scheme, excluding directors	531	493
Total staff costs	8,719	8,063
Depreciation of property, plant and equipment	1,701	3,017
Depreciation of right-of-use assets	1,610	1,415
Amortisation of prepayment for a distribution right	3,493	3,557
Amortisation of an intangible asset	–	1,778
Auditor's remuneration	1,350	1,500
Legal and professional fees (included in administrative expenses)	2,328	2,883
Gain on disposal of property, plant and equipment	(142)	(482)
Impairment loss on trade and other receivables	5,712	4,067
Impairment loss on inventories	13,114	1,601
Fair value gain on financial assets at FVTPL	(3,925)	(423)
Cost of inventories recognised as an expense (excluded impairment loss on inventories)	82,147	36,859

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

11. DIRECTORS', CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES

(a) Directors' and chief executive's emoluments

The emoluments paid or payable to each of the Directors and the Chief Executive Officer, disclosed pursuant to the applicable Listing Rules and Hong Kong Companies Ordinance, were as follows:

	Year ended 31 December 2024							Total HK\$'000
	Executive directors				Independent non-executive directors			
	Wang Qiuqin ("Ms. Wang") HK\$'000	Huo Zhihong ("Mr. Huo") HK\$'000 (note (i))	Chu Xueping ("Mr. Chu") HK\$'000	Zhou Wan ("Ms. Zhou") HK\$'000	Leung Chi Kin HK\$'000	Li Sin Ming, Ivy HK\$'000	Sy Lai Yin, Sunny HK\$'000	
Fees	960	285	360	360	240	240	240	2,685
Salaries and other benefits	207	-	-	148	-	-	-	355
Contributions to retirement benefits scheme	21	-	-	22	-	-	-	43
Total emoluments	1,188	285	360	530	240	240	240	3,083

	Year ended 31 December 2023							
	Executive directors				Independent non-executive directors			
	Wang Qiuqin ("Ms. Wang") HK\$'000	Huo Zhihong ("Mr. Huo") HK\$'000	Chu Xueping ("Mr. Chu") HK\$'000	Zhou Wan ("Ms. Zhou") HK\$'000	Leung Chi Kin HK\$'000	Li Sin Ming, Ivy HK\$'000	Sy Lai Yin, Sunny HK\$'000	Total HK\$'000
Fees	960	360	360	270	240	240	240	2,670
Salaries and other benefits	211	–	–	158	–	–	–	369
Contributions to retirement benefits scheme	21	–	–	20	–	–	–	41
Total emoluments	1,192	360	360	448	240	240	240	3,080

Note:

(i) Mr. Huo resigned as executive director on 16 October 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

11. DIRECTORS', CHIEF EXECUTIVE'S EMOLUMENTS AND FIVE HIGHEST PAID EMPLOYEES *(Continued)*

(a) Directors' and chief executive's emoluments *(Continued)*

The executive directors' emoluments shown above were for their services in connection with the management of the affairs of the Company and the Group.

The independent non-executive directors' emoluments shown above were for their services as directors of the Company.

All of their emoluments disclosed above include those for services rendered by them in such roles.

For both 2024 and 2023, no emoluments were paid by the Group to any of the directors as an inducement to join or upon joining the Group or as compensation for loss of office. No directors waived any emoluments for both 2024 and 2023.

(b) Five highest paid employees

Of the five individuals with the highest emoluments in the Group, two (2023: two) are executive directors of the Company and the emoluments of the remaining three individuals (2023: three) were as follows:

	2024 HK\$'000	2023 HK\$'000
Salaries and other allowances	2,444	1,802
Contributions to retirement benefits scheme	56	36
	2,500	1,838

Their emoluments were within the following bands:

	Number of employees	
	2024	2023
Nil to HK\$1,000,000	2	3
HK\$1,000,001 to HK\$1,500,000	1	–
	3	3

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

12. DIVIDENDS

No dividend was paid or proposed for holders of ordinary shares of the Company during the years ended 31 December 2024 and 2023, nor has any dividend been proposed since the end of the reporting period.

13. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to the owners of the Company is based on the following data:

	2024 HK\$'000	2023 HK\$'000
Loss for the year attributable to owners of the Company for the purposes of basic and diluted loss per share	(31,013)	(22,170)
	Number of ordinary shares	
	2024 '000	2023 '000
Number of shares		
Weighted average number of ordinary shares for the purposes of basic and diluted loss per share	1,671,847	1,671,847

The computation of diluted loss per share does not assume the exercise of the Company's outstanding share options since their assumed exercise would result in decrease in loss per share for the year ended 31 December 2024 and 2023.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

14. PROPERTY, PLANT AND EQUIPMENT

	Buildings HK\$'000	Furniture, fixtures and equipment HK\$'000	Motor vehicles HK\$'000	Total HK\$'000
COST				
At 1 January 2023	10,880	7,619	12,395	30,894
Additions	–	44	–	44
Disposals	–	(37)	(947)	(984)
Exchange realignment	(155)	(107)	(170)	(432)
At 31 December 2023	10,725	7,519	11,278	29,522
Additions	–	2	620	622
Disposals	–	(8)	(1,118)	(1,126)
Exchange realignment	(230)	(157)	(222)	(609)
At 31 December 2024	10,495	7,356	10,558	28,409
ACCUMULATED DEPRECIATION				
At 1 January 2023	2,027	6,226	7,341	15,594
Provided for the year	365	1,186	1,466	3,017
Disposals	–	(34)	(840)	(874)
Exchange realignment	(32)	(95)	(104)	(231)
At 31 December 2023	2,360	7,283	7,863	17,506
Provided for the year	358	44	1,299	1,701
Disposals	–	(8)	(1,067)	(1,075)
Exchange realignment	(54)	(153)	(155)	(362)
At 31 December 2024	2,664	7,166	7,940	17,770
CARRYING VALUES				
At 31 December 2024	7,831	190	2,618	10,639
At 31 December 2023	8,365	236	3,415	12,016

The above items of property, plant and equipment are depreciated on a straight-line basis at the following rates per annum:

Buildings	Over the shorter of term of land lease and 5%
Furniture, fixtures and equipment	20% to 33%
Plant and machinery	10% to 33%
Motor vehicles	25%

As at 31 December 2024, the Group did not pledge any property, plant or equipment (2023: pledged buildings with aggregate carrying values of approximately HK\$2,184,000) to secure general banking facilities granted to the Group. During the years ended 31 December 2023 and 2024, the Group did not utilise any banking facilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

15. RIGHT-OF-USE ASSETS

	Prepaid lease payments HK\$000	Leased properties HK\$000	Total HK\$000
Carrying amount			
As at 1 January 2023	17,781	1,294	19,075
Addition	–	–	–
Depreciation charged to profit or loss during the year	(508)	(907)	(1,415)
Exchange realignment	(250)	(7)	(257)
At 31 December 2023	17,023	380	17,403
Addition	–	4,777	4,777
Depreciation charged to profit or loss during the year	(429)	(1,181)	(1,610)
Exchange realignment	(360)	(39)	(399)
At 31 December 2024	16,234	3,937	20,171

For both years, the Group holds land use rights on land and leases offices and warehouses for its operations. Lease contracts are entered into for fixed term of 2 to 5 years without any extension and termination options. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable.

As at 31 December 2024, the Group did not pledge any right-of-use assets (2023: pledged right-of-use assets with aggregate carrying values of approximately HK\$10,288,000) to secure general banking facilities granted to the Group. During the years ended 31 December 2023 and 2024, the Group did not utilise banking facilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

16. PREPAYMENT FOR A DISTRIBUTION RIGHT

The Group entered into an agreement with a third party, whereby the third party would facilitate and secure the Group to obtain an exclusive distribution right in the PRC for an injection drug for a period of 10 years starting from 1 January 2016 from the drug manufacturer, which is based in Taiwan. The third party was previously the holder of the exclusive distribution right in the PRC for the injection drug. The Group had made a prepayment of RMB32,000,000 (equivalent to HK\$38,209,000) to the third party during the year ended 31 December 2015. The prepayment is refundable if the exclusive distribution right cannot be obtained by the Group and the amount to be refunded is in proportion to the period or periods which the Group cannot obtain such right over 10 years. The prepayment is being amortised as an expense in profit or loss over a period of 10 years and the prepayment for such right for the next financial year is classified as a current asset.

During the year ended 31 December 2024, the distribution and trading of pharmaceutical and related products segment was affected by the PRC government policies and sustained operating loss of the segment, the management of the Group performed an impairment assessment on the prepayment for a distribution right, together with the intangible asset with carrying amount of HK\$2,105,000 and nil (2023: HK\$7,062,000 and HK\$2,795,000) respectively in accordance with the HKAS36 as at 31 December 2024. With the consideration about the recoverable amounts and carrying amounts, no impairment losses (2023: impairment loss of HK\$1,033,000 and HK\$2,795,000) in relation to the prepayment for a distribution right and the intangible asset respectively was recognised during the year.

The recoverable amount has been determined based on the value in use calculation which uses cash flow projections based on most recent financial budgets approved by the management covering the remaining useful lives of the intangible asset which was one year period (2023: two years period) and discount rate of 15% (2023: 15%). Other key assumptions for the value in use calculations related to the estimation of cash inflow/outflows which include expected changes in projected sales quantities, unit selling prices, unit cost and gross margin, such estimation is based on the past performance and management's expectations for the market development.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

17. INTANGIBLE ASSET

	HK\$'000
COST	
At 1 January 2023	17,912
Exchange realignment	(256)
At 31 December 2023	17,656
Exchange realignment	(378)
At 31 December 2024	17,278
ACCUMULATED AMORTISATION	
At 1 January 2023	13,285
Provided for the year	1,778
Impairment losses	2,795
Exchange realignment	(202)
At 31 December 2023	17,656
Exchange realignment	(378)
At 31 December 2024	17,278
CARRYING VALUE	
At 31 December 2024	—
At 31 December 2023	—

The cost of the intangible asset represents the cost of acquisition of the trademark of the injection drug in the PRC which was paid to the drug manufacturer based in Taiwan, who had granted to the Group the exclusive distribution right in the PRC for the injection drug.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

18. EQUITY INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME/FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

Equity instruments at FVTOCI comprise:

	2024 HK\$'000	2023 HK\$'000
Listed investments:		
– Equity securities listed in Hong Kong (note i)	89,460	43,067
Unlisted investments:		
– Equity securities (notes ii & iii)	12,907	–
Total	102,367	43,067
Analysed for reporting purposes as:		
Non-current assets	102,367	43,067

Financial assets at FVTPL comprises:

	2024 HK\$'000	2023 HK\$'000
Unlisted investments (notes iv & v)	44,138	36,608
Total	44,138	36,608
Analysed for reporting purpose as:		
Non-current assets	44,138	36,608

Notes:

- (i) Balance mainly comprises of the Group's investment in the equity securities listed on the Stock Exchange. The directors of the Company have elected to designate these investments in equity instruments at FVTOCI as they believe that this investment is held for long-term purpose and realising the performance potential in the long-run.

During the year ended 31 December 2024, fair value gain of HK\$34,273,000 (2023: loss of HK\$20,578,000) has been recognised in other comprehensive income.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

18. EQUITY INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME/FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS (Continued)

Notes: (Continued)

- (ii) The above unlisted equity investment includes investment in unlisted equity securities issued by HCMPS, a private entity incorporated in the Cayman Islands with limited liability. The Group holds 14% (2023: 14%) of the issued share capital of HCMPS as at 31 December 2024. HCMPS and its subsidiaries are principally engaged in the provision of contracted medical schemes for integrated medical and healthcare check-up services in Hong Kong. The directors of the Company have elected to designate this investment in equity instruments at FVTOCI as they believe that this investment is held for long-term purpose and realising the performance potential in the long-run. The directors adopted the discounted cash flows in arriving at the fair value. Significant assumptions used in the valuation such as budgeted sales, gross margin, other related expenses, discount rate and terminal growth rate. Details are disclosed in note 29(c) (i) to the consolidated financial statements.
- (iii) The above unlisted equity investment includes investment in unlisted equity securities issued by China Nvwa Pharmaceutical Group Limited ("**China Nvwa**"), a private entity incorporated in Hong Kong with limited liability. On 16 May 2024, the Group entered into a sale and purchase agreement with Mr. U Man long, an independent third party, to acquire 16% unlisted equity securities of China Nvwa, at the consideration of HK\$17,280,000. The acquisition was completed on 31 July 2024. The Group holds 16% of the issued share capital of China Nvwa as at 31 December 2024. China Nvwa and its subsidiaries are principally engaged in the manufacture, sales and distribution of pharmaceutical products in the PRC. The directors of the Company have elected to designate this investment in equity instruments at FVTOCI as they believe that this investment is held for long-term purpose and realising the performance potential in the long-run. The directors adopted the market-based valuation technique in arriving at the fair value. In measuring the fair value of the investment, management is required to make assumptions which involve significant judgement which include, amongst others, price to sales ("**P/S**") ratio and discount for lack of marketability ("**DLOM**"). Details are disclosed in note 29(c)(i) to the consolidated financial statements.

As at 31 December 2024, the fair value of the Group's investment in China Nvwa amounted to HK\$12,907,000. The fair value loss of HK\$4,373,000 has been recognised in other comprehensive income for the year ended 31 December 2024.

- (iv) The above unlisted investment represents investment in unlisted shares issued by Shengzhou Xinrui Wanma Industrial Co., Ltd ("**Shengzhou Xinrui Wanma**"), a private entity incorporated in Mainland China with limited liabilities in July 2022. On 11 July 2022, the Group and two partners, independent third parties, entered into a cooperation agreement. Pursuant to the cooperation agreement, the initial registered capital of Shengzhou Xinrui Wanma is RMB50 million (equivalent to approximately HK\$58.8 million) and 39% of the initial capital contribution shall be made by the Group. The amount of initial capital contribution of the Group is RMB19.5 million (equivalent to approximately HK\$22.9 million). Further capital contribution of RMB2.5 million (equivalent to approximately HK\$2.6 million) paid by the Group in December 2022. On 16 January 2023, China New Rich and the two partners entered into a supplemental agreement, pursuant to which the registered capital of Shengzhou Xinrui Wanma would be increased from RMB50.0 million to RMB56.3 million and the capital contribution to the initial registered capital of the Target Company by each of the parties should be adjusted accordingly. China New Rich would contribute an initial capital contribution of RMB22.0 million (equivalent to approximately HK\$25.5 million). Shengzhou Xinrui Wanma is to engage in the project which involves the investment and construction of a healthcare industrial park in Shengzhou, Zhejiang Province, the PRC, and the project includes the acquisition of the land use right of the project land which is a parcel of land with site area of approximately 100,000 sq.m. by public tender and the construction, development and operation of the related facilities and buildings thereon. On 22 December 2022, the Shengzhou Xinrui Wanma successfully acquired land use right of the project land located in Shengzhou, Zhejiang Province by public tender.

The directors of the Company are of the opinion that the Group does not have significant influence over the Shengzhou Xinrui Wanma and recognised the investment as financial assets at FVTPL, and the aforesaid investment is classified as non-current asset as the management expects to realise this financial asset after twelve months after the reporting period. The directors adopted the discounted cash flows in arriving at the fair value. Significant assumptions used in the valuation such as budgeted sales, gross margin, other related expenses and discount rate. Details are disclosed in note 29(c) (i) to the consolidated financial statements.

As at 31 December 2024, the fair value of the Group's investment in Shengzhou Xinrui Wanma amounted to HK\$29,874,000 (2023: HK\$36,608,000). The fair value gain of HK\$3,980,000 (2023: gain of HK\$423,000) has been recognised in profit or loss for the year ended 31 December 2024. In addition, a capital distribution of HK\$10,715,000 was paid to the Group during the year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

18. EQUITY INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME/FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS *(Continued)*

Notes: *(Continued)*

- (v) The above unlisted investment represents investment in unlisted shares issued by Shengzhou Xinrui Wanlin Enterprise Management Co., Ltd ("**Shengzhou Xinrui Wanlin**"), a private entity incorporated in Mainland China with limited liabilities in March 2024. On 24 May 2024, the Group and two partners, independent third parties, entered into a cooperation agreement. Pursuant to the cooperation agreement, the initial registered capital of Shengzhou Xinrui Wanlin is RMB1 million (equivalent to approximately HK\$1.1 million) and 39% of the initial capital contribution shall be made by the Group. The amount of initial capital contribution of the Group is RMB0.39 million (equivalent to approximately HK\$0.43 million). Further capital contribution of RMB12.87 million (equivalent to approximately HK\$14.16 million) was paid by the Group in June 2024. Shengzhou Xinrui Wanlin is to engage in the project which involves the development of a healthy food industrial park in Shengzhou, Zhejiang Province, the PRC. The project includes the acquisition of the land use right of a parcel of land located in Shengzhou, Zhejiang Province, the PRC with site area of approximately 26,028 sq.m. by public tender and the development and operation of the related facilities and buildings thereon. On 9 July 2024, the Shengzhou Xinrui Wanlin successfully acquired land use right of the project land located in Shengzhou, Zhejiang Province by public tender.

The directors of the Company are of the opinion that the Group does not have significant influence over the Shengzhou Xinrui Wanlin and recognised the investment as financial assets at FVTPL, and the aforesaid investment is classified as non-current asset as the management expects to realise this financial asset after twelve months after the reporting period. The directors adopted the adjusted net asset value in arriving at the fair value.

As at 31 December 2024, the fair value of the Group's investment in Shengzhou Xinrui Wanlin amounted to HK\$14,264,000. The fair value loss of HK\$55,000 has been recognised in profit or loss for the year ended 31 December 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

19. INVENTORIES

	2024 HK\$'000	2023 HK\$'000
Finished goods	20,104	31,167

During the year, an impairment loss of HK\$13,114,000 (2023: HK\$1,601,000) on inventories was recognised due to slow-moving inventories.

20. TRADE AND OTHER RECEIVABLES

	2024 HK\$'000	2023 HK\$'000
Trade receivables	104,704	94,399
Less: allowance for credit loss	(44,311)	(39,347)
Trade receivables (net of allowance for credit loss)	60,393	55,052
Other prepayments	1,600	3,087
Other deposits	247	144
Prepayments to a supplier	42,547	43,477
Deposits paid to suppliers (net of allowance for credit loss) (note 21)	131,391	133,783
Value-added tax recoverable	5,143	5,831
Others	135	302
	241,456	241,676
Current portion	241,456	240,219
Non-current portion	–	1,457
	241,456	241,676

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

20. TRADE AND OTHER RECEIVABLES *(Continued)*

The Group allows a credit period ranging from 0 to 365 days to its trade customers. The following is an ageing analysis of trade receivables net of allowance for credit losses presented based on the dates of goods delivery notes, which approximated the respective revenue recognition dates, at the end of the reporting period.

	2024 HK\$'000	2023 HK\$'000
Trade receivables:		
0–30 days	24,550	26,740
31–60 days	7,253	427
61–90 days	1,474	62
91–180 days	1,274	2,094
181–365 days	4,200	6,772
Over 365 days	21,642	18,957
	60,393	55,052

Before accepting any new customers, the Group assesses the potential customer's credit quality and defines credit limits by the customer. Credit limits attributed to customers are reviewed periodically. Majority of the trade receivables that are neither past due nor impaired have no default payment history.

The Group has provided for impairment loss of approximately HK\$5,869,000 (2023: impairment loss of HK\$3,205,000) during the year ended 31 December 2024 based on the provision matrix. The Group does not hold any collateral over these balances.

Credit terms granted to customers mainly range from 30 to 365 days (2023: 30 to 365 days) depending on customers relationship with the Group, their creditworthiness and past settlement record.

Details of credit policy impairment assessment of trade receivable for the years ended 31 December 2024 and 2023 are set out in note 29(b).

Prepayments and deposits paid to suppliers represent the prepayments and deposits paid to its suppliers as a condition of acquiring the distribution rights of specific products and as securing for purchase of products. The Group was required to make prepayments and deposits to certain suppliers to secure regular supply of products. The amount of prepayments to suppliers varied with the terms of supplier contracts entered into with different suppliers, which was determined based on the amount of goods purchased from the suppliers. The amounts of deposits required vary on a case by case basis. The deposits paid will be refunded upon expiry of contracts.

The Group has recognised reversal of impairment loss of approximately HK\$157,000 (2023: impairment loss of approximately HK\$862,000) on deposits paid to suppliers during the year ended 31 December 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

21. DEPOSITS PAID TO SUPPLIERS

From time to time, the Group is required to make deposit payments to its suppliers as a condition of acquiring the distribution rights of specific products and as security for purchase of products. The deposits will be collected back from suppliers at the end of the distribution agreements.

During the year ended 31 December 2024 and 2023, the Group has agreed with the suppliers that, even if the minimum purchase requirement is not met, the deposit will still be refunded to the Group (i.e. no forfeiture).

As at 31 December 2024 and 2023, all deposits were classified as current assets because the amount is expected to be refunded in 2025 and 2024 respectively.

The movements of the deposits paid to suppliers are as follows:

	2024 HK\$'000	2023 HK\$'000
At 1 January	133,783	114,686
Deposits paid	–	43,845
Deposits refunded	–	(22,215)
Reversal of (allowance for) credit loss	157	(862)
Exchange realignment	(2,549)	(1,671)
At 31 December	131,391	133,783
Classified as:		
Current assets (included in trade and other receivables)	131,391	133,783

The Group's exposure to credit risk and ECL for deposits paid to suppliers is stated in note 29(b) to the consolidated financial statements.

22. BANK BALANCES AND CASH

Bank balances and cash comprise cash held by the Group and short-term bank deposits with an original maturity of three months or less. The deposits carry interest at market rates which range from 0.10% to 0.25% (2023: 0.2% to 0.75%) per annum, for the year ended 31 December 2024.

As at 31 December 2024, deposits of HK\$203,000 (2023: HK\$1,565,000) were placed with the securities brokers for trading securities in Hong Kong. The amounts were unrestricted and withdrawable on demand.

The Group's bank balances and cash that are denominated in currencies other than the functional currencies of the relevant group entities are set out below:

	2024 HK\$'000	2023 HK\$'000
HK\$	8,768	6,581

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

23. TRADE AND OTHER PAYABLES

	2024 HK\$'000	2023 HK\$'000
Trade payables (note (i))	21,613	342
Deposits received from customers	637	872
Contract liabilities (note (ii))	30	50
Accruals	3,887	4,003
	26,167	5,267

Note:

- (i) An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date or issue date is as follows:

	2024 HK\$'000	2023 HK\$'000
Trade payables:		
0–30 days	10,286	342
31–60 days	4,114	–
61–90 days	5,431	–
Over 90 days	1,782	–
	21,613	342

The trade payables are non-interest-bearing. The trade payables are normally settled on terms of 180 days upon receipt of suppliers' invoices.

- (ii) All contract liabilities, that are expected to be settled within the Group's normal operating cycle which is within 12 months after the end of the reporting period, are classified as current liabilities based on the Group's earliest obligation to transfer goods or services to the customers. The receipts in advance from customers for the years ended 31 December 2024 and 31 December 2023 were classified to contract liabilities. Movement of contract liabilities during the years ended 31 December 2024 and 31 December 2023 are as follows:

	2024 HK\$'000	2023 HK\$'000
At 1 January	50	999
Decrease in contract liabilities as a result of recognition of revenue during the year that was included in the contract liabilities at the beginning of the year	(19)	(948)
Exchange realignment	(1)	(1)
At 31 December	30	50

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

24. LEASE LIABILITIES

	2024 HK\$'000	2023 HK\$'000
As at 1 January	288	1,278
Addition	4,777	–
Payments	(1,581)	(1,013)
Interest expense on lease liabilities	102	32
Exchange realignment	(37)	(9)
At 31 December	3,549	288
Lease liabilities payable		
Within 1 year	1,145	288
After 1 year but within 5 years	2,404	–
	3,549	288

No lease obligations that are denominated in currencies other than the functional currencies of the relevant group entities as at 31 December 2024 and 2023.

25. DEFERRED TAX LIABILITIES

The deferred tax liabilities recognised by the Group and movements thereon during the reporting periods are as follows:

	Withholding tax on undistributed earnings of the PRC subsidiaries and associates HK\$'000
At 1 January 2023	6,052
Credit to profit or loss	(172)
Exchange realignment	(85)
At 31 December 2023	5,795
Credit to profit or loss	(1,120)
Exchange realignment	(112)
At 31 December 2024	4,563

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

25. DEFERRED TAX LIABILITIES (Continued)

Under the EIT Law of the PRC, a 10% withholding tax is imposed on dividends declared to foreign investors in respect of profits earned by PRC subsidiaries from 1 January 2008 onwards.

Pursuant to an approval from the relevant PRC government obtained by the Group in December 2012, the Group is entitled to a withholding tax at the rate of 5% for dividend payments from the Group's PRC subsidiaries.

The Group has unused tax losses of approximately HK\$6,507,000 (2023: HK\$11,813,000) for the year ended 31 December 2024, available for offset against future profits. No deferred tax asset has been recognised in respect of the unutilised tax losses due to the unpredictability of future profits stream. Included in unrecognised tax losses as at 31 December 2024 are losses of HK\$923,000, HK\$262,000, HK\$80,000, HK\$358,000 and HK\$2,635,000 that will expire in 2025, 2026, 2027, 2028 and 2029 respectively.

At the end of the reporting period, the Group has deductible temporary difference of HK\$6,625,000 (2023: HK\$2,117,000). No deferred tax asset has been recognised in relation to such deductible difference as it is not probable that taxable profit will be available against which the deductible temporary difference can be utilised.

26. SHARE CAPITAL OF THE COMPANY

The movements of share capital of the Company are as follows:

	Number of shares '000	Amount HK\$'000
Ordinary shares		
Authorised:		
At 1 January 2023, 31 December 2023, 1 January 2024 and 31 December 2024	3,000,000	150,000
Issued and full paid:		
At 1 January 2023, 31 December 2023, 1 January 2024 and 31 December 2024	1,671,847	83,592

All ordinary shares issued during the years ended 31 December 2024 and 2023 rank *pari passu* with the then existing ordinary shares in all respects.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

27. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY

Information about the statement of financial position of the Company at the end of the reporting periods are as follows:

	Notes	2024 HK\$'000	2023 HK\$'000
Non-current assets			
Investments in subsidiaries		109,591	93,074
Amounts due from subsidiaries		312,870	334,218
		422,461	427,292
Current assets			
Other receivables		1,514	1,514
Bank balances and cash		594	544
		2,108	2,058
Current liabilities			
Other payables		946	1,001
Net current assets		1,162	1,057
Total assets less current liabilities		423,623	428,349
Capital and reserves			
Share capital	26	83,592	83,592
Reserves	27(a)	340,031	344,757
Equity attributable to owners of the Company		423,623	428,349

The financial statements were approved and authorised for issue by the Board of Directors on 25 March 2025 and are signed on its behalf by:

WANG QIUQIN
DIRECTOR

CHU XUEPING
DIRECTOR

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

27. STATEMENT OF FINANCIAL POSITION AND RESERVES OF THE COMPANY

(Continued)

Note:

(a) Movement in the Company's reserves

	Share premium HK\$'000	Share option reserve HK\$'000	Contributed surplus HK\$'000	Translation reserve HK\$'000	Accumulated losses HK\$'000	Total HK\$'000
At 1 January 2023	607,614	10,393	50,167	(927)	(248,313)	418,934
Total comprehensive expense for the year	–	–	–	(257)	(73,920)	(74,177)
Forfeited share options	–	(1,089)	–	–	1,089	–
At 31 December 2023	607,614	9,304	50,167	(1,184)	(321,144)	344,757
Total comprehensive expense for the year	–	–	–	–	(4,726)	(4,726)
At 31 December 2024	607,614	9,304	50,167	(1,184)	(325,870)	340,031

28. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders through the optimisation of the debt and equity balance. The Group's overall strategy remained unchanged from prior year.

The capital structure of the Group consists of cash and cash equivalents and equity attributable to owners of the Company, comprising share capital, various reserves and retained profits.

The directors of the Company review the capital structure periodically. As part of this review, the directors consider the cost of capital and the risks associated with each class of capital. Based on the recommendations of the directors, the Group will balance its overall capital structure through the new share issues as well as the issue of new debt or the redemption of existing debt.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS

(a) Categories of financial instruments

	2024 HK\$'000	2023 HK\$'000
Financial assets		
Equity instruments at FVTOCI	102,367	43,067
Financial assets at FVTPL	44,138	36,608
Financial assets at amortised cost (including cash and cash equivalents)	256,039	292,789
	402,544	372,464
Financial liabilities		
Amortised cost	29,041	4,633

(b) Financial risk management objectives and policies

The management of the Group monitors and manages the financial risks relating to the operations of the Group through internal risk reports which analyse exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risks), credit risk and liquidity risk.

There has been no change to the types of the Group's exposure in respect of financial instruments or the manner in which it manages and measures the risks.

Market risk

(i) Interest rate risk management

The Group is exposed to cash flow interest rate risk in relation to bank deposits and bank borrowing at floating interest rates. The Group cash flow interest rate risk is mainly concentrated on the fluctuation of interest rates on bank balances and Loan Prime Rate arising from the Group's RMB denominated borrowing. The Group aims at keeping borrowing at variable rates.

The Group manages its interest rate exposures by assessing the potential impact arising from any interest rate movements based on interest rate level and outlook. The management will review the proportion of borrowing in floating rates and ensure they are within reasonable range.

The directors consider the Group's exposure of the bank balances to cash flow interest rate risk is insignificant as interest bearing bank balances are within a short maturity period. Besides, as the fluctuation of the market interest rate on bank balances is not expected to be significant, no sensitivity analysis for the bank balances is prepared.

The Group currently does not have any interest rate hedging policy in relation to cash flow interest rate risks. The directors monitor the Group's exposure on an ongoing basis and will consider hedging the interest rate should the need arise.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Market risk *(Continued)*

(ii) Other price risks

The Group is exposed to equity price risk through its investments in listed equity securities. The management manages this exposure by maintaining a portfolio of investments with different risks. The Group's equity price risk is concentrated on equity securities quoted on the Stock Exchange.

The Group has concentration of equity price risk on its equity instruments at FVTOCI listed in Hong Kong as 100% (2023: 100%) of its equity interests held by the Group are issued by six (2023: five) issuers. The management of the Group considers that the equity price risk on the equity instruments at FVTOCI in the equity interests held is limited as they were issued by six (2023: five) companies whose shares are listed on the Stock Exchange.

The Group has concentration of equity price risk on its unlisted equity instruments at FVTOCI as 100% (2023: 100%) of its equity interests held by the Group are issued by two (2023: one) issuers. The management of the Group considers that the equity price risk of the unlisted equity instruments at FVTOCI in equity interests held is limited as the directors of the Company took into consideration of the discounted cash flow method and market-based valuation technique of the investments and considered that they could recover fully the carrying value of the investments.

Equity price sensitivity analysis

The sensitivity analyses below have been determined based on the exposure to equity price risk, excluding the listed securities under suspension and unlisted investments, at the end of the reporting period. Sensitivity analyses for unquoted equity securities with fair value measurement categorized within level 3 were disclosed in Note 29 (c).

If the prices of the respective equity instruments at FVTOCI had been 10% (2023: 10%) lower/higher:

- Loss after tax for the year ended 31 December 2024 and 2023 would have no impact as a result of the changes in fair value; and
- FVTOCI (non-recycling reserve) would increase/decrease by HK\$10,237,000 (2023: HK\$4,307,000) for the Group as a result of the changes in fair value of equity instruments at FVTOCI.

The Group's sensitivity to equity instruments at FVTOCI has not changed significantly from the prior year.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Credit risk and impairment assessment

As at 31 December 2024 and 2023, the Group's maximum exposure to credit risk which will cause a financial loss to the Group due to failure to discharge an obligation by the counterparties is arising from the carrying amount of the respective recognised financial assets as stated in the consolidated statement of financial position.

The Group's credit risk arising from its financial assets is primarily attributable to its trade receivables and deposits paid to suppliers. In order to minimise the credit risk arising from its trade receivables and deposits paid to suppliers, the management of the Group has delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual trade debt and each deposit paid to supplier at the end of the reporting period to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, the directors of the Company consider that the Group's credit risk is significantly reduced.

The Group has concentration of credit risk on bank balances as 92% (2023: 15%) of balances are placed with four (2023: four) banks of which three (2023: three) is located in the PRC and one (2023: one) are located in Hong Kong as at 31 December 2024.

The credit risk on liquid funds is limited because the counterparties are banks with good reputation.

The Group has concentration of credit risks on its outstanding trade receivables as 60% (2023: 74%) of its trade receivables were due from three (2023: three) customers as at 31 December 2024. These three (2023: three) customers are distributors which are private enterprises engaged in trading and wholesaling of drugs and related products in Jiangsu, Hubei and Zhejiang in the PRC as at 31 December 2024 (2023: Jiangsu, Hubei and Hunan in the PRC). In addition, the Group also has concentration of credit risks on its deposits paid to suppliers as 100% (2023: 100%) of its deposits paid to suppliers were paid to three (2023: three) suppliers in aggregate as at 31 December 2024. Such suppliers are also private enterprises principally engaged in pharmaceutical trading and distribution in the PRC. In the opinion of the directors of the Company, indicators that there is no reasonable expectation of recovery include the failure of debtors to make ongoing settlement with the Group and the failure of debtors to make contractual payments on certain debts that are more than 365 days past due. The management of the Group has delegated a team responsible for determination of credit limits and monitoring procedures to ensure that follow-up action to recover overdue debts and to monitor credit risk on customers and suppliers.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Credit risk and impairment assessment *(Continued)*

The Group's internal credit risk grading assessment comprises the following categories:

Internal credit rating	Description	Trade receivables/ deposits paid to suppliers	Other financial assets/other items
Low risk	The counterparty has a low risk of default and does not have any past-due amounts	Lifetime ECL – not credit-impaired	12m ECL
Watch list	Debtor frequently repays after due dates in full.	Lifetime ECL – not credit-impaired	12m ECL
Doubtful	There have been significant increases in credit risk since initial recognition through information developed internally or external resources	Lifetime ECL – not credit-impaired	Lifetime ECL – not credit-impaired
Loss	There is evidence indicating the asset is credit-impaired	Lifetime ECL – credit-impaired	Lifetime ECL – credit-impaired
Write-off	There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery	Amount is written off	Amount is written off

The tables below detail the credit risk exposures of the Group's financial assets, which are subject to ECL assessment:

		External credit rating	Internal credit rating	Gross carrying amount	
Notes				2024 HK\$'000	2023 HK\$'000
Bank balances and cash	22	AA+	N/A	64,255	103,954
Trade receivables	20	N/A	(note ii)	104,704	94,399
Deposits paid to suppliers	21	N/A	Low risk (note iii)	139,865	142,601
				308,824	340,954

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Credit risk and impairment assessment *(Continued)*

Notes:

- i. For the purposes of internal credit risk management, the Group uses past due information to assess whether credit risk has increased significantly since initial recognition.
- ii. For trade receivables, the Group has applied the simplified approach in HKFRS 9 to measure the loss allowance at lifetime ECL.

The Group measures loss allowance for trade receivables at an amount equal to lifetime ECLs, which is calculated using a provision matrix or assessed individually. For the remaining customers, as the Group's historical credit loss experience does not indicate significant different loss patterns for different customer segments, the loss allowance based on past due status is not further distinguished between the Group's different customer bases.

The following table provides information about the exposure to credit risk for trade receivables which are assessed on a collective basis by using provision matrix within lifetime ECL.

For the year ended 31 December 2024	Expected loss rate %	Gross carrying amount HK\$'000	Loss allowance HK\$'000	Net carrying amount HK\$'000
Current (not past due)	3%	36,379	1,172	35,207
1–365 days past due	37%	11,361	4,226	7,135
Over 365 days past due	68%	56,964	38,913	18,051
		104,704	44,311	60,393

For the year ended 31 December 2023	Expected loss rate %	Gross carrying amount HK\$'000	Loss allowance HK\$'000	Net carrying amount HK\$'000
Current (not past due)	1%	33,891	393	33,498
1–365 days past due	38%	10,837	4,161	6,676
Over 365 days past due	70%	49,671	34,793	14,878
		94,399	39,347	55,052

ECL rates are based on actual loss experience over the past 12 months. These rates are adjusted to reflect differences between economic conditions during the period over which the historic data has been collected, current conditions and the Group's view of economic conditions over the expected lives of the receivables.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Credit risk and impairment assessment *(Continued)*

Notes: *(Continued)*

ii. *(Continued)*

The following table shows the movement in lifetime ECL that has been recognised for trade receivables under the simplified approach:

	Lifetime ECL (not credit- impaired) HK\$'000	Lifetime ECL (credit- impaired) HK\$'000	Total HK\$'000
As at 1 January 2023	15,097	21,592	36,689
Impairment loss recognised	2,387	818	3,205
Exchange realignment	(232)	(315)	(547)
As at 1 January 2024	17,252	22,095	39,347
Impairment loss (reversal of impairment loss) recognised	7,131	(1,262)	5,869
Exchange realignment	(445)	(460)	(905)
As at 31 December 2024	23,938	20,373	44,311

The directors of the Company are of the opinion that certain customers who did not share the same credit risk characteristics were in delinquency of payments and their respective trade receivable balances amounting to approximately HK\$20,373,000 (2023: HK\$22,095,000) were fully impaired. ECL are also estimated by grouping the remaining trade receivables balances based on shared credit risk characteristics and collectively assessed for likelihood of recovery, taking into account its ageing category and applying the ECL rates to the respective gross carrying amounts of these trade receivables and forecast of future economic conditions. Therefore, the ECL of the trade receivables recognised in profit or loss for the year ended 31 December 2024 was approximately HK\$5,869,000 (2023: recognised HK\$3,205,000).

iii. At the end of the reporting period, the directors of the Company have performed impairment assessment, and concluded that there has been no significant increase in credit risk. No loss allowance was recognised as at 31 December 2024 in accordance with HKFRS 9 as the amount is immaterial.

	Gross carrying amount HK\$'000	Loss allowance HK\$'000	Net carrying amount HK\$'000
Deposits paid to suppliers At 31 December 2024	139,865	8,474	131,391
At 31 December 2023	142,601	8,818	133,783

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Credit risk and impairment assessment *(Continued)*

Notes: *(Continued)*

iii. *(Continued)*

The following table shows the movement in lifetime ECL that has been recognised for deposits paid for suppliers under the simplified approach:

	Lifetime ECL (not credit- impaired) HK\$'000
As at 1 January 2023	8,078
Impairment loss recognised	862
Exchange realignment	(122)
As at 1 January 2024	8,818
Reversal of impairment loss recognised	(157)
Exchange realignment	(187)
As at 31 December 2024	8,474

The directors of the Company are of the opinion that the deposits paid to suppliers are assessed as low risk because these deposits paid has yet been past due. The calculation of ECL based on the probability weighted outcome, time value of money, reasonable and supportable information that is available at the reporting date about current conditions and forecast of future economic conditions. The Group has concluded that reversal of impairment loss on deposits paid to suppliers recognised for the year ended 31 December 2024 was approximately HK\$157,000 (2023: impairment loss HK\$862,000).

Other than the above, the Group does not have other significant concentration of credit risk.

Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the Board of Directors, which has built an appropriate liquidity risk management framework to meet the Group's short, medium and long-term funding and liquidity management requirements. The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(b) Financial risk management objectives and policies *(Continued)*

Liquidity risk management *(Continued)*

Liquidity tables

The following table details the Group's remaining contractual maturity for its non-derivative financial liabilities. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. The maturity dates for other non-derivative financial liabilities are based on the agreed repayment dates.

The table includes both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate curve at the end of the reporting period.

	Weighted average interest rate %	On demand or less than 1 year HK\$'000	Between 1 year and 5 years HK\$'000	Total undiscounted cash flows HK\$'000	Carrying amount HK\$'000
At 31 December 2024					
Non-derivative financial liabilities					
Trade payables	–	21,613	–	21,613	21,613
Other payables	–	3,879	–	3,879	3,879
Lease liabilities	4.9%	1,322	2,385	3,707	3,549
		26,814	2,385	29,199	29,041

At 31 December 2023

Non-derivative financial liabilities

Trade payables	–	342	–	342	342
Other payables	–	4,003	–	4,003	4,003
Lease liabilities	4.9%	290	–	290	288
		4,635	–	4,635	4,633

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS (Continued)

(c) Fair value measurements of financial instruments

(i) Fair value of financial assets that are measured at fair value on a recurring basis

Some of the Group's financial assets are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets are determined (in particular, the valuation technique(s) and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categorised (levels 1 to 3) based on the degree to which the inputs to the fair value measurements are observable.

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active market for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Financial assets	Fair value as at		Fair value hierarchy	Valuation technique(s)	Significant unobservable input(s)	Range (weighted average)	Relationship of unobservable inputs for fair value
	31 December 2024 HK\$'000	31 December 2023 HK\$'000					
Equity instruments at FVTOCI listed in Hong Kong	89,460	43,067	Level 1	Quoted bid prices in an active market	N/A	N/A	N/A
Equity instrument at FVTOCI for unlisted investment	–	–	Level 3	Discounted cash flow method	Discount rate	12.11% (2023: 12.11%)	note (i)(a)
					Terminal growth rate	2.31% (2023: 2.31%)	note (i)(a)
					Discount for lack of marketability	15.80% (2023: 15.80%)	note (i)(a)
Equity instrument at FVTOCI for unlisted investment	12,907	–	Level 3	Market-based valuation technique	*P/S ratio	2.81	note (i)(b)
					Discount for lack of marketability	58%	note (i)(b)
Financial asset at FVTPL for unlisted investment	29,874	36,608	Level 3	Discounted cash flow method	Discount rate	14.68% (2023: 17.84%)	note (i)(c)
					Discount for lack of marketability	15% (2023: 15%)	note (i)(c)
Financial assets at FVTPL for unlisted investment	14,264	–	Level 3	Adjusted net asset value	The fair value of net assets of the investee	N/A	note (i)(d)

* P/S ratio stands for the Price to Sales ratio.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(c) Fair value measurements of financial instruments *(Continued)*

(i) Fair value of financial assets that are measured at fair value on a recurring basis *(Continued)*

Notes:

- a. An increase in the discount rate used in isolation would result in a decrease in the fair value measurement of the equity instruments at FVTOCI for unlisted investment and vice versa. A 10% increase/decrease in the discount rate holding all other variables constant would decrease/increase the carrying amount of the equity instruments at FVTOCI for unlisted investment by nil/nil (2023: nil/nil).

A decrease in the terminal growth rate used in isolation would result in a decrease in the fair value measurement of the equity instruments at FVTOCI for unlisted investment and vice versa. A 10% increase/decrease in the terminal growth rate holding all other variables constant would increase/decrease the carrying amount of the equity instruments at FVTOCI for unlisted investment by nil/nil (2023: nil/nil).

An increase in the discounts for lack of marketability used in isolation would result in a decrease in the fair value measurement of the equity instruments at FVTOCI for unlisted investment and vice versa. A 10% increase/decrease in the discounts for lack of marketability holding all other variables constant would decrease/increase the carrying amount of the equity instruments at FVTOCI for unlisted investment by nil/nil (2023: nil/nil).

- b. An increase in P/S ratio used in isolation would result in an increase in the fair value measurement of the equity instruments at FVTOCI for unlisted investment and vice versa. A 5% increase/decrease in the P/S ratio holding all other variables constant would increase/decrease the carrying amount of the equity instruments at FVTOCI for unlisted investment by HK\$645,000/HK\$645,000.

An increase in discounts for lack of marketability used in isolation would result in an increase in the fair value measurement of the equity instruments at FVTOCI for unlisted investment and vice versa. A 5% increase/decrease in the discounts for lack of marketability holding all other variables constant would decrease/increase the carrying amount of the equity instruments at FVTOCI for unlisted investment by HK\$882,000/HK\$882,000.

- c. An increase in the discount rate used in isolation would result in a decrease in the fair value measurement of the financial assets at FVTPL for unlisted investment and vice versa. A 10% increase/decrease in the discount rate holding all other variables constant would decrease/increase the carrying amount of the financial assets at FVTPL for unlisted investment by HK\$214,000/HK\$224,000 (2023: HK\$179,000/HK\$192,000).

An increase in the discounts for lack of marketability used in isolation would result in a decrease in the fair value measurement of the financial assets at FVTPL for unlisted investment and vice versa. A 10% increase/decrease in the discounts for lack of marketability holding all other variables constant would decrease/increase the carrying amount of the financial assets at FVTPL for unlisted investment by HK\$527,000/HK\$527,000 (2023: HK\$646,000/HK\$646,000).

- d. An increase in the fair value of net assets would result in increase in the fair value measurement of the financial asset at FVTPL for unlisted investment and vice versa. A 1% increase/decrease in the fair value of net assets would increase/decrease the fair value of the financial asset at FVTPL for unlisted investment by HK\$143,000/HK\$143,000.

The quantitative information of significant unobservable inputs used in arriving at the level 3 fair value measurement are set out above.

During the year ended 31 December 2024, there were no (2023: no) transfers between level 1 and level 2. There is no (2023: no transferred into and no transferred out) transfers of Level 3 fair value measurements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

29. FINANCIAL INSTRUMENTS *(Continued)*

(c) Fair value measurements of financial instruments *(Continued)*

(i) Fair value of financial assets that are measured at fair value on a recurring basis *(Continued)*

Reconciliation of fair value measurements categorised within Level 3 of the fair value hierarchy

	Financial assets at FVTPL for unlisted investments HK\$'000	Equity instruments at FVTOCI for unlisted investments HK\$'000	Total HK\$'000
Carrying amount as at 1 January 2023	25,470	15,540	41,010
Addition	10,715	–	10,715
Fair value change recognised in other comprehensive income	–	(15,540)	(15,540)
Fair value change recognised in profit or loss	423	–	423
Carrying amount as at 31 December 2023	36,608	–	36,608
Addition	14,320	17,280	31,600
Capital distribution	(10,715)	–	(10,715)
Fair value change recognised in other comprehensive income	–	(4,373)	(4,373)
Fair value change recognised in profit or loss	3,925	–	3,925
Carrying amount as at 31 December 2024	44,138	12,907	57,045

(ii) Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis

The fair value of other financial assets and financial liabilities is determined in accordance with generally accepted pricing models based on discounted cash flow analysis.

The directors of the Company consider that the carrying amounts of financial assets and liabilities recorded at amortised cost in the consolidated financial statements approximate their fair values.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

30. SHARE OPTION SCHEME

Pursuant to the resolution passed at the special general meeting held on 26 September 2013, the Company adopted a share option scheme (the “**Scheme**”). The Scheme expired in October 2023. The Company operated the Scheme for the purpose of providing the Company with a flexible means of giving incentive to, rewarding, remunerating, compensating and/or providing benefits to the eligible participants and for such other purposes as the board of directors may approve from time to time. The eligible participants of the Scheme included any director or employee of the Company or its subsidiaries (together the “**Group**” and an entity of which any member of the Group held any equity interest (“**Invested Entity**”)), and any consultants, professional and other advisers, any suppliers, customers, service providers, business or joint venture partners, contractors of the Group or any Invested Entity, any chief executives of substantial shareholders of the Company, and any other persons whom the board of directors considered, at its absolute discretion, would contribute or had contributed to the Group.

The grant of share options should be accepted within the period from the date on which an offer of the grant of an option is made to a participant to such date as the board of directors might determine, at a consideration of HK\$1, being payable by the grantee upon the acceptance of grant. The options may be exercised at any time within the period commencing from the date of grant of the options and expiring on the date determined by the directors, but in any event such exercise period shall not exceed a period of ten years commencing on the date the relevant option is deemed to be granted.

The exercise price of the share options was determinable by the directors, but was not able to be less than the higher of (i) the closing price of the shares as stated in the Stock Exchange’s daily quotations sheet on the date of grant, which must be a business day; (ii) the average closing price of the shares as stated in the Stock Exchange’s daily quotation sheet for the five business days immediately preceding the date of grant; and (iii) the nominal value of the Company’s share.

Pursuant to the Scheme, before its expiration, the maximum number of shares in the Company in respect of which options might be granted when aggregated with any other share option scheme of the Company was not permitted to exceed 10% of the total number of shares in issue as at the date of adoption of the Scheme. Subject to the issue of a circular and the approval of the shareholders of the Company in a general meeting and/or such other requirements prescribed under the Listing Rules from time to time, the board might refresh the limit at any time to 10% of the total number of shares in issue as at the date of approval by the shareholders of the Company in a general meeting. As the Scheme expired in October 2023, the directors of the Company could no longer grant any further options under the Scheme upon its expiry. As at 31 December 2024 and the date of this report, the number of ordinary shares of the Company which could be issued upon exercise of all outstanding options granted under the Scheme is 128,200,000 ordinary shares of HK\$0.05 each, representing approximately 7.67% of the issued share capital of the Company. Notwithstanding the foregoing, the shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Scheme and any other share option schemes of the Company at any time shall not exceed 30% of the shares in issue from time to time.

No option might be granted to any person if the total number of shares of the Company already issued and issuable to him under all the options granted to him in any 12-month period up to and including the date of grant would exceed 1% of total number of shares in issue as at the date of grant. Any further grant of options in excess of this 1% limit should be subject to the issue of a circular by the Company and the approval of the shareholders in a general meeting. Such participant and his associates (as defined in the Listing Rules) should abstain from voting and/or other requirements prescribed under the Listing Rules from time to time. Options granted to substantial shareholders or independent non-executive directors in excess of 0.1% of the Company’s share capital or with a value in excess of HK\$5,000,000 should be approved in advance by the Company’s shareholders in a general meeting.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

30. SHARE OPTION SCHEME (Continued)

The Scheme was valid and effective for a period of 10 years commencing on its adoption date. The Scheme expired in October 2023.

During the year ended 31 December 2022, share options of 143,200,000 were granted by the Company to directors and employees under the Scheme on 14 June 2022 and all the share options were vested on the same day. The exercisable period is from 14 June 2022 to 13 June 2027. The estimated fair values of the options granted on that date is HK\$10,393,000.

These fair values were calculated using the Binomial model. The inputs into the model were as follows:

Weighted average share price	HK\$0.287
Exercise price	HK\$0.287
Expected volatility (note)	38.795%
Expected life	5 years
Risk-free rate	2.987%
Expected dividend yield	0%

Note: Expected volatility was determined by using the historical volatility of the comparable companies' share prices over the previous five years since trading in shares of the Company was suspended in previous years. The expected life used in the model has been adjusted, based on the management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

The number and weighted average exercise prices of share options scheme for the year are as follows:

Type of grantee	Date of grant	Exercisable period	Exercise price HKD	Outstanding number of options		
				Balance at 1 January 2024 '000	Forfeited during the year '000	Balance at 31 December 2024 '000
Key Management						
Mr. Chu Xueping	14 June 2022	14 June 2022 to 13 June 2027	0.287	16,600	–	16,600
Ms. Wang Qiuqin	14 June 2022	14 June 2022 to 13 June 2027	0.287	16,600	–	16,600
Ms. Zhou Wan	14 June 2022	14 June 2022 to 13 June 2027	0.287	15,000	–	15,000
				48,200	–	48,200
Employees						
In aggregate	14 June 2022	14 June 2022 to 13 June 2027	0.287	80,000	–	80,000
				80,000	–	80,000
				128,200	–	128,200

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

30. SHARE OPTION SCHEME (Continued)

Type of grantee	Date of grant	Exercisable period	Exercise price HKD	Outstanding number of options		
				Balance at 1 January 2023	Forfeited during the year	Balance at 31 December 2023
				'000	'000	'000
Key Management						
Mr. Chu Xueping	14 June 2022	14 June 2022 to 13 June 2027	0.287	16,600	–	16,600
Ms. Wang Qiuqin	14 June 2022	14 June 2022 to 13 June 2027	0.287	16,600	–	16,600
Ms. Zhou Wan	14 June 2022	14 June 2022 to 13 June 2027	0.287	15,000	–	15,000
				48,200	–	48,200
Employees						
In aggregate	14 June 2022	14 June 2022 to 13 June 2027	0.287	95,000	(15,000)	80,000
				95,000	(15,000)	80,000
				143,200	(15,000)	128,200

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

31. RETIREMENT BENEFIT PLANS

The employees employed in the PRC are members of the state-managed retirement benefit schemes operated by the PRC government. The PRC subsidiaries are required to contribute a certain percentage of their payroll to the retirement benefit schemes to fund the benefits. The only obligation of the Group with respect to the retirement benefit schemes is to make the required contributions under the schemes.

The Group also operates a Mandatory Provident Fund Scheme for all its qualifying employees in Hong Kong. The assets of the schemes are held separately from those of the Group, in funds under the control of trustees. The Group contributes 5% or HK\$1,500 per month in maximum of relevant payroll costs to the scheme, which contribution is matched by employees.

At 31 December 2024 and 2023, there were no significant forfeited contributions which arose upon employees leaving the schemes before they are fully vested in the contributions and which are available to reduce the contributions payable by the Group in the future.

The total cost of HK\$531,000 (2023: HK\$493,000) for the year ended 31 December 2024 charged to the consolidated statement of profit or loss and other comprehensive income represents contribution paid or payable to the above retirement benefit plans by the Group.

At the end of the reporting periods, the Group had no significant obligation apart from the contribution as stated above.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

32. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Group's consolidated statement of cash flows as cash flows from financing activities.

	Lease liabilities HK\$'000
At 1 January 2023	1,278
Changes from financing cash flows:	
Payment for principal portion of lease liabilities	(981)
Payment for interest expenses	(32)
Total changes from financing cash flows	(1,013)
Exchange adjustments	(9)
Other changes:	
Interest expenses	32
Total other changes	32
At 31 December 2023	288
Changes from financing cash flows:	
Payment for principal portion of lease liabilities	(1,479)
Payment for interest expenses	(102)
Total changes from financing cash flows	(1,581)
Exchange adjustments	(37)
Other changes:	
Addition to lease liabilities	4,777
Interest expenses	102
Total other changes	4,879
At 31 December 2024	3,549

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

33. RELATED PARTY DISCLOSURES

(i) Related party transactions

Other than as disclosed elsewhere in these consolidated financial statements, the Group has no transactions and balances with related parties.

(ii) Compensation of key management personnel

	2024 HK\$'000	2023 HK\$'000
Short term benefits	4,241	3,638
Post employment benefits	60	49
	4,301	3,687

The remuneration of directors and key executives is determined having regard to the position, duties and performance of the individuals.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the year ended 31 December 2024

34. PARTICULARS OF THE SUBSIDIARIES

Particulars of the subsidiaries directly and indirectly held by the Company at the end of each reporting period.

Name of subsidiaries	Place and date of incorporation/ establishment/ operation	Equity interest attributable to the Group		Issued and fully paid share capital/ registered capital	Principal activities
		2024	2023		
Direct					
Max Goodrich International Limited (note (i))	the BVI 21 September 2007	100%	100%	HK\$163,800	Investment holding
Indirect					
China New Rich Medicine Holding Company Limited (note (i))	Hong Kong 7 February 2005	100%	100%	HK\$1	Trading of pharmaceutical products and investment holding
Major Bright Holdings Limited (note (i))	the BVI 9 May 2014	100%	100%	HK\$1	Investment holding
Brilliant Dream Holding Limited (note (i))	the BVI 7 July 2014	100%	100%	HK\$1	Inactive
Hong Rui Bio-medical 泓銳(杭州)生物醫藥科技有限公司(note (ii))	the PRC 8 July 2008	100%	100%	HK\$5,000,000	Investment holding
Zhejiang Xin Rui 浙江新銳醫藥有限公司 (note (ii))	the PRC 26 April 2006	100%	100%	RMB10,000,000	Distribution and trading of pharmaceutical products and provision of marketing and promotion services
Hong Rui Trading 浙江泓銳貿易有限公司 (note (ii))	the PRC 6 September 2005	100%	100%	RMB5,000,000	Inactive
Zhejiang Xinrui Biopharmaceutical 浙江新銳生物藥業有限公司 (notes (ii) and (iii))	the PRC 14 November 2023	100%	100%	RMB90,000,000	Investment holding

Notes:

- (i) A company incorporated with limited liability.
- (ii) A domestic company established in the PRC with limited liability.
- (iii) The company incorporated during the year ended 31 December 2023.

All of the above subsidiaries adopt 31 December as the financial year end date. None of the subsidiaries had issued any debt securities at the end of the reporting period.